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Abstract 
Dry powder inhalers (DPIs) are easier to use, more stable and efficient systems with better 
lung delivery than nebulizers/ metered dose inhalers (MDIs) and gained significant attention 
of researchers in the field of pulmonary drug delivery. Present-day research in this area is 
predominantly directed towards designing controlled release DPI formulations using 
polymeric micro- or nanoparticles. Nanoparticulate systems can escape mucociliary 
clearance and phagocytic removal that favour a prolonged residence of the delivered 
formulation in the lungs for drug release.  The natural polymer chitosan has been found 
highly promising as a matrix for fabricating micro-/ nanoparticle based controlled release 
DPI formulations. Analogous to conventional DPIs, the major challenge with formulation of a 
controlled release DPI is cohesive agglomeration and consequent poor aerosolization of 
micronized particles. Recent research has shown that addition of L-leucine to a chitosan-
based DPI formulation greatly enhances its dispersibility. This observation encouraged to 
undertake this work aimed at investigation of the impact of chemical conjugation of               
L-leucine to chitosan on dispersibility of particles from a DPI system. The major focus of this 
work was to synthesize an L-leucine conjugate of chitosan and prepare controlled release 
nanoparticulate DPI formulations thereof in order to compare their aerosolization and drug 
release. Diltiazem hydrochloride (DH), an antihypertensive agent, was chosen as the model 
drug for this study. The oral administration of this drug suffers from high degree of hepatic 
first-pass metabolism and poor bioavailability that make it a good candidate for designing 
controlled release DPI formulation. An attempt was also made to investigate in vitro the 
safety of chitosan, its L-leucine conjugate and their nanoparticles for respiratory delivery 
using a non-malignant bronchial epithelial cell line, BEAS-2B. 
 
The first part of this work involved selective conjugation of L-leucine to the C-2 of chitosan 
by reacting with Boc-L-leucine succinimide (Boc-leu-OSu). A protection-deprotection 
strategy was adopted with phthalic anhydride and trityl chloride as the protecting groups at 
C-2 and C-6 for ensuring regional selectivity. Hydrazine hydrate was used for removal of 
phthaloyl protection while trityl and Boc (in Boc-leu-OSu) groups were deprotected 
simultaneously by 4M HCl in 1, 4-dioxane. The product was adequately characterized by 
Fourier Transform Infrared (FT-IR), 1H, 13C and 2D 1H-13C HSQC Nuclear Magnetic Resonance 
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(NMR) spectroscopy, Elemental Analysis and X-ray Photoelectron Spectroscopy (XPS). The 
results of the analyses confirmed conjugation of L-leucine to chitosan.  
 
The second part of this work involved preparation of nanoparticle formulation of chitosan 
and its L-leucine conjugate and comparison of their aerosolization and drug release 
characteristics. Nanoparticles were prepared by two different approaches based on      
water-in-oil (W/O) emulsification of aqueous polymeric solution in heavy mineral oil, viz. 
W/O emulsion-solvent evaporation and W/O emulsion-glutaradehyde cross-linking. Loading 
of the model drug, DH, into the nanoparticles was successfully done by glutaraldehyde 
cross-linking technique, but the drug could not be loaded into particles by solvent 
evaporation technique. The nanoparticles were characterized for size, shape and surface 
morphology by scanning electron microscopy (SEM) and Malvern Zetasizer Nano-S. The drug 
loading and entrapment efficiency were estimated by an indirect method based on 
quantification of drug lost in the external oil phase by UV spectrophotometry. The 
aerosolization of nanoparticles was studied by a Twin Stage Impinger (TSI) with a Rotahaler 
at an airflow rate of 65±5 L/min. Drug release study was conducted in phosphate buffered 
saline (PBS, pH 7.3±0.2) at 37 °C with gentle stirring and the samples withdrawn at intervals 
were quantified by UV spectrophotometry. The drug loading and entrapment efficiency of 
conjugate nanoparticles were significantly (p<0.05) higher than those of chitosan 
nanoparticles (drug loading: 20±1% vs. 16±1%; entrapment efficiency: 46±1% vs. 38±1%). 
The aerosolization study with glutaraldehyde cross-linked particles showed significantly 
(p<0.05) higher Fine Particle Fraction (FPF) for both the blank and drug-loaded conjugate 
nanoparticles compared to corresponding chitosan nanoparticles (blank nanoparticles: 
24±0.8% vs. 19±1.01%; drug-loaded nanoparticles: 21±0.7% vs. 15±1.5%). The conjugate 
nanoparticles also showed twice as much higher and more prolonged drug release as 
chitosan nanoparticles (52%, 16 days vs. 23%, 8 days). 
 
The third part of this work studied in vitro the effect of chitosan, its L-leucine conjugate and 
their nanoparticles on the cell viability, trans-epithelial permeability and chemokine (IL-8) 
release by MTT assay, sodium fluorescein transport assay and enzyme-linked 
immunosorbent assay (ELISA), respectively using the in vitro cell model, BEAS-2B. For MTT 
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assay, a series of concentrations (between 0.125 and 16 mg/mL) of the test samples were 
applied to 24-hour old cultures of the cell for a period of 12, 24 and 48 hours.  Based on the 
MTT assay results, 4 concentrations (0.5, 1, 2 and 4 mg/mL) were chosen to perform sodium 
fluorescein transport assay and ELISA. These were the highest concentrations at which, for 
most of the test samples, the % survival of treated cells was above 50% and beyond which 
the % survival was found to fall abruptly.  For sodium fluorescein transport assay, confluent 
cell monolayers grown on transwell inserts were apically treated by test samples mixed with 
sodium fluorescein and aliquots of medium withdrawn from the basolateral chambers at 
various time intervals (0.5-48 h) were analysed by spectrofluorometry. ELISA for IL-8 was 
performed on culture supernatants harvested after exposure of the cell cultures to the 
samples for 24 h period.  The results of MTT assay showed that all the 4 samples had a 
concentration- and time-dependent effect on cell viability. Chitosan was found to have low 
toxicity with IC50 values of 48, 24 and 17 mg/mL for 12, 24 and 48 h treatment durations, 
respectively. Other 3 samples were more toxic, but still showed a low toxicity with IC50 
values being in the range of 2-7 mg/mL. In general, the rank order of their cytotoxic effect 
was: chitosan nanoparticles < conjugate < conjugate nanoparticles.  According to the results 
of sodium fluorescein transport assay, chitosan and its nanoparticles did not cause any 
significant change in transepithelial permeability (p>0.05). The conjugate produced a mild, 
but significant increase in the permeability (p<0.05) up to a concentration of 2 mg/mL. 
Paradoxically, cell monolayers treated with conjugate nanoparticles showed lower 
permeability than that of control. However, there was a concentration-depended gradual 
increase in the permeability, with the highest concentration of 4 mg/mL exhibiting a 
permeability close to that of control.  According to ELISA performed on cell culture 
supernatants, all the 4 samples significantly induced IL-8 release (p<0.05). The rank order of 
IL-8 induction of the 4 samples were conjugate < chitosan = chitosan nanoparticles 
<conjugate nanoparticles. 
 
To conclude, the body of work presented in this dissertation showed successful conjugation 
of L-leucine to chitosan. The nanoparticle formulation prepared from the L-leucine 
conjugate was found to be more dispersible from a DPI than that prepared from the parent 
chitosan corroborating the hypothesis previously made in this connection.  The conjugate 
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was also found to hold a strong promise in controlling drug release. However, nanoparticles 
made of the conjugate appeared to be relatively more toxic, but still within an acceptable 
limit (IC50 of 2 mg/mL after 48 h exposure). So, the product could be considered to have a 
good prospect for controlled release pulmonary drug delivery. 
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1.1 Background 
Pulmonary route is receiving increasing acceptance as a convenient, non-invasive way of 
drug delivery to the lung tissue and/or the systemic circulation. The route has successfully 
been exploited for targeting drugs to the lung in the treatment of asthma and chronic 
obstructive pulmonary disease (COPD) and quite a few drugs, such as salbutamol sulfate, 
terbutaline sulfate, budesonide etc., are already available for administration through this 
route. Because of the unique features of the lung, such as its large surface area, high 
permeability and wide blood supply, the route appears to be of great potential for systemic 
delivery of poorly absorbable drugs too. Considerable efforts have been made during the 
last few decades for developing appropriate formulations for pulmonary delivery of many 
therapeutic agents such as insulin, calcitonin, interferons, parathyroid hormone, leuprolide 
etc. for systemic action (Agu et al., 2001; Damms & Bains, 1995; Okamoto et al., 2011; 
Patton, 1997; Patton, 2000; Shahiwala & Misra, 2005).  
 
The three most common types of devices available for pulmonary drug delivery include dry 
powder inhaler (DPI), pressurized metered dose inhaler (pMDI) and nebulizer. pMDIs can 
deliver more consistently a predetermined dose of drug (Leach, 2007), but these devices 
need synchronization of actuation and inhalation, failing which a significant proportion of 
the delivered dose is wasted as oropharyngeal deposition (Newman, 2005). Besides, these 
devices require a chemical propellant (e.g. CFC or HFA) to dispense the inhaled 
formulations. Nebulizers aerosolize drug from an aqueous solution or suspension and 
require a jet of gas or ultrasonic wave as the dispersing force. In general, nebulizers are not 
very portable. They are more often used in hospital settings for emergency treatment of 
acute pulmonary conditions. DPI is superior to the two other common pulmonary drug 
delivery systems in terms of not requiring any propellant or actuation-inhalation 
coordination (Li et al., 2005). Moreover, it is easy to use and portable. With the FDA 
approval and advent of first inhaled insulin dry powder aerosol, Exubera (Pfizer) in the 
market in 2006 (albeit withdrawn later for some unknown reason), dry powder inhaler drug 
delivery has become a subject of tremendous interest and there has been an increased drive 
in research for developing new systems for delivering therapeutic agents by inhalation for 
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systemic action (Chougule et al., 2007; Hickey, 2013; Kandasamy & Chandrasekaran, 2013; 
Taneja et al., 2012). In addition to insulin, drug molecules that have already been 
investigated for delivery by a DPI for systemic action include: anti-malarial vaccine (Edwards 
et al., 2005), human growth hormone (Blizzard et al., 2003), morphine (Dershwitz et al., 
2000), meglumine complexes of amphotericin B and mycoheptine (Ekzemplyarov et al., 
1977), heparin (Bai et al., 2010) etc. 
 
An important drawback of many currently available pulmonary therapies is their short 
duration of action and need for administration 3-4 times a day. For instance, the effect of 
inhaled salbutamol sulfate, one of the most popular bronchodilators used in the treatment 
of asthma and COPD, lasts only several hours, requiring repeated administration every 4 to 
6 h to sustain a bronchodilator response (Jantikar et al., 2007).  To overcome the problem, 
an increasing trend is seen for designing these therapies in controlled release forms suitable 
for pulmonary delivery (Salama et al., 2009a).  Controlled pulmonary therapy could be 
particularly beneficial for enhancing systemic bioavailability of drugs, like diltiazem or 
morphine, which undergo extensive hepatic first-pass metabolism following oral delivery. 
Although there is a continued effort in this direction, no controlled release inhalation 
system has yet found its way to the market.  
 
Micro- and nanoparticles of biodegradable polymers have drawn much attention for 
pulmonary delivery of drugs in controlled release form (Fiegel et al., 2004; Fu et al., 2002; 
Salama et al., 2009a; Sivadas et al., 2008). These systems could be widely varied in size, 
shape and other characteristics to control drug release and target the deeper regions of 
lungs and obviate the need for removal because they ultimately degrade and are 
metabolised by the body. Nanoparticulate systems have two important advantages over 
microparticles: first, they can escape mucociliary clearance and second, they can bypass 
phagocytic recognition by alveolar macrophages (Ahsan et al., 2002; Grenha et al., 2005). 
These attributes can significantly contribute to enhancing residence of these systems in the 
lungs for extended drug release. Chitosan, a widely available natural biopolymer, has gained 
special attention as matrix for designing controlled release micro- and nanoparticles. This 
polymer has been reported to have low toxicity, biocompatibility and biodegradability (Tong 
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et al., 2009). It has also been reported to have some additional attractive features like 
mucoadhesiveness and trans-epithelial permeability enhancement (Amidi et al., 2008b; 
Learoyd et al., 2009; Naikwade & Bajaj, 2009). Moreover, chitosan has also been shown to 
enhance aerosolization and lung deposition of a DPI formulation (Li & Birchall, 2006). 
 
One important challenge associated with a DPI formulation is cohesive aggregation of 
micronized particles that affects the aerosolization and subsequent lung deposition of the 
delivered drug. It has been reported that addition of the amino acid, L-leucine to chitosan-
based DPI formulations significantly enhance aerosolization of chitosan particles in vitro 
presumably by migration of L-leucine to the particle surface owing to its surfactant-like 
structure; this gives the particles a pitted appearance and in turn reduces inter-particle 
interaction (Learoyd et al., 2008a, 2009; Rabbani & Seville, 2005; Seville & Learoyd, 2007). It 
can be intriguing to investigate the effect of chemical conjugation of L-leucine to chitosan on 
aerosolization and lung deposition of such a system.  
 
For any system to be administered by inhalation, it is important to assess their safety in the 
respiratory system. The pulmonary epithelium serves as the barrier to the permeation of 
any inhaled substance into the lungs (Patton et al., 2004). In addition, it also responds to 
toxic substances by releasing various inflammatory mediators (Ghio et al., 2002). Thus, it is 
customary to explore in vitro the effect of products intended for inhalation on the 
pulmonary epithelium as a primary approach to investigate their safety for the respiratory 
administration. Many tests have been reported in the literature to this end, of which three 
commonly used tests are MTT assay to assess the effect on the cell viability (Zhang et al., 
2009), sodium fluorescein (Na Flu) transport assay to assess any untoward effect on       
trans-epithelial permeability (Grenha et al., 2007)  and induction of the inflammatory 
mediators such as the chemokine interleukin-8 (IL-8) which is often observed in lung 
inflammation (Sivadas et al., 2008). 
 
Based on these considerations, this study attempted to synthesize an L-leucine conjugate of                
chitosan and assess the impact of such conjugation on dispersibility and drug release profile 
of a nanoparticulate DPI formulation. Diltiazem hydrochloride (DH), an antihypertensive 
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agent, was chosen as a model drug for the formulations considering its high degree of 
hepatic first-pass metabolism giving poor bioavailability (~40%) following oral 
administration. The biosafety of the particles was also assessed in vitro in terms of cell 
viability, transepithelial permeability and inflammatory chemokine (IL-8) release using a 
bronchial epithelial cell line, BEAS-2B. This is a non-malignant cell line and has not been 
used before for studying the safety of chitosan or any of its derivatives. So, this study is 
expected to complement previous reports in this line on various malignant epithelial cell 
lines like calu-3 and A-549. 
 
1.2 Hypothesis 
Because of the surfactant-like property of L-leucine (Matubayasi et al., 2002; Watry & 
Richmond, 2002), upon conjugation to chitosan, it will enhance the dispersibility of the 
nanoparticles (made of conjugated chitosan) from a DPI formulation. In addition, the 
leucinization of chitosan could also be expected to increase the hydrophilicity of the 
polymer and in turn increase the loading of a water-soluble drug, which in consequence 
might provide a more prolonged release. 
 
 
 
 
O
HO
O
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Figure 1- 1: Hypothesized Inter-particle Interaction Following Conjugation of L-leucine to 
Chitosan 
Hydrophobic 
Side-chain 
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The essence of the first part of the hypothesis is enhanced dispersion and lung deposition of 
the L-leucine conjugated chitosan particles from a DPI (in comparison to unconjugated 
chitosan particles). This is based on the concept that, being surfactant in nature (Matubayasi 
et al., 2002; Watry & Richmond, 2002), L-leucine conjugated to chitosan will give an 
amphiphilic environment around the chitosan backbone where its hydrophobic domain 
would be projected outward giving a pitted appearance to the particle surface and so 
reduced inter-particle interaction (Fig. 1-1). This concept stems from the very basic 
principles of surfactant chemistry (Sinko, 2006) and has also been supported by 
observations of other investigators regarding orientation of L-leucine (Raula et al., 2010) and 
its analogue tri-leucine (Lechuga-Ballesteros et al., 2008) at a particle-air interface. The 
deposition of L-leucine (added to a particle formulation) onto the surface of the drying 
particle giving it a pitted appearance, in turn reducing inter-particle interaction and 
enhancing particle dispersion has also been well-documented in the literature (Columbano 
et al., 2003; Learoyd et al., 2008a, 2009; Rabbani & Seville, 2005; Seville et al., 2007). The 
second part of the hypothesis was concerned with the expected release of the model drug, 
DH from L-leucine conjugated chitosan particles compared to those made from chitosan 
itself. This is also based on the expected amphiphilic environment created by L-leucine 
around the chitosan backbone where its hydrophilic domain is supposed to be associated 
with the surrounding media in an aqueous environment, increasing its hydrophilicity and in 
turn facilitating increased loading of a water-soluble drug and consequently a more 
prolonged release. An elaborate discussion of these aspects making the background of the 
hypothesis  has been presented in the Paragraph 2 of the Section 2.5 [p. 17] and the 
Paragraph 3 of the Section 2.9 [p. 27-29] and associated diagrams [Fig. 2-8, Fig. 2-13 (a-d) 
and Fig. 2-14 (a-b)] in the Chapter 2.   
1.3 Aims of the Project 
1.3.1 Generic Aim 
Considering the high potential of the natural, biodegradable polymer chitosan as a release 
modifier, postulated benefits of conjugating L-leucine to chitosan and probable advantages 
of delivering the antihypertensive drug, diltiazem hydrochloride (DH) through the 
pulmonary route, this work was aimed at performing research  in order to achieve 
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controlled release DPI formulations of DH using drug-loaded nanoparticles of chitosan and 
its L-leucine conjugate for the management of systemic hypertension. The generic aim of 
this study was to gain a better understanding of the mechanism of dispersion and drug 
release of a polymer based DPI formulation. 
 
1.3.2 Specific Aims 
The following specific aims were set forth in order to address the hypothesis proposed for 
this research: 
(a) To synthesize L-leucine conjugated chitosan 
(b) To prepare drug-loaded polymeric nanoparticulate DPI formulation using chitosan and 
its L-leucine conjugate 
(c) To study the physicochemical properties of polymeric nanoparticulate DPI formulation 
prepared from chitosan and its L-leucine conjugate 
(d) To investigate in vitro the influence of chemical conjugation of L-leucine with chitosan on 
aerosolization, lung deposition, and release-retarding features of a  nanoparticle based 
DPI formulation 
(e) To evaluate in vitro the potential toxicity of the prepared DPI formulation on a            
non-malignant bronchial epithelial cell line, BEAS-2B. 
 
The aims (a), (b) and (c) were directed towards chemical conjugation of L-leucine with 
chitosan and preparation of the nanoparticulate DPI formulations of chitosan and its            
L-leucine conjugate that were prerequisites for performing the experiments relating the aim 
(d). The aim (d) was set to test the hypotheses, viz. (a) enhanced dispersibility of 
nanoparticles made of conjugated chitosan and (b) increased hydrophilicity of the 
conjugated chitosan leading to increased loading and consequent more prolonged release 
of a water-soluble drug. The experimental results, as discussed in the Chapter 6, Sections 
6.2.3-6.2.5 and 6.3.3-6.3.5, supported the hypotheses. The 5th aim (e) addressed the safety 
issues considering that the formulations are meant for administering as a DPI through the 
pulmonary route. 
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2.1 The Architecture of the Respiratory Airways 
Anatomically, the respiratory system may be divided into two regions: 1. conducting zone 
and    2. respiratory zone. The conducting airways consist of the air-transmitting passages of 
the nose, nasopharynx, larynx, trachea, bronchi and bronchioles (Gray, 2000; Itoh et al., 
2004). The last three form the tracheo-bronchial region of the lung (generations 1–16 in the 
bifurcating airway model) (Fig. 2-2). The primary function of the conducting airways is to act 
as conduit for air movement. Additionally, this region provides filtration, warming and 
humidification of inhaled air. 
 
 
Mouth/Nose     Trachea     Bronchioles   Alveoli 
 
Figure 2- 1: Human Respiratory System 
[Reproduced from (Fishbein)] 
 
 
The actual exchange of gases (oxygen and CO2) occurs across the distal lung respiratory 
epithelium comprised of the alveolar ducts and saccules (the alveoli, generations 17–23 in 
the bifurcating airway model) (Fig.2-2). 
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Figure 2-  2 : Structure of the Respiratory Airways according to the Model of Weibel 
 [adapted from: Weibel (1963)] 
2.2 The Respiratory Tract as a Portal for Drug Delivery 
The concept of administering drugs via the lung is not new. It has been used for centuries to 
deliver many drugs conveniently and effectively for medical and recreational purposes. 
Smoking of tobacco products is one of the most common examples, and before the advent 
of modern inhalers, some asthma medications were administered in the form of cigarettes 
(Sanjar & Matthews, 2001). But, inhaled medications did not reach the status of being safe, 
effective, and convenient enough for widespread public use until 1956 when 3M Riker 
(Northridge, CA) scientists invented the metered dose inhaler (MDI) (Leach, 2007). Since 
then there has been an enormous effort for using this route for delivery of drugs and, by 
this time, inhalation of aerosolized drugs  (e.g. β2-agonists, corticosteroids, and mucolytics) 
has become a well-established and preferred means of treating localized disease states 
within the lung such as asthma and COPD (Learoyd et al., 2008a).  The main reason lying 
behind this is the fact that local targeting of drugs into the lungs quickens the effect, 
reduces the dose required and systemic exposure and, in turn, results in reduced systemic 
side effects (Sahib et al., 2012; Shaikh et al., 2010). One can easily envisage the difference 
by comparing the 100-200 µg inhalation dose of the anti-asthmatic drug, salbutamol sulfate 
to the usual oral dose of 2-4 mg which is larger by about 20 times. 
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More recently, it has been demonstrated that the lung may also be an ideal site for the   
non-invasive delivery of therapeutic molecules, including peptides and proteins, to the 
systemic circulation (Agu et al., 2001; Damms & Bains, 1995; Okamoto et al., 2011; Patton, 
1997; Patton, 2000; Shahiwala & Misra, 2005). In fact, as a non-invasive route of medication, 
pulmonary delivery is drawing greater attention of scientists day by day, because it has 
many attractive features including an enormous surface area (almost 140 m2), thin (0.1-0.5 
μm) alveolar epithelial membrane, extensive vasculature, low extracellular and intracellular 
enzymatic activity and absence of first-pass metabolism, and thus permits rapid absorption 
and onset of action (Agu et al., 2001). These features, in addition, may necessitate a 
relatively lower dose resulting in reduced systemic side effects compared to other            
non-injection routes of administration (Bi et al., 2009). Small molecules deposited in the 
lungs are very rapidly absorbed into the systemic circulation, with the fastest uptake of any 
route of delivery other than the intravenous route (Patton et al., 2004). Examples of rapidly 
absorbed inhaled drugs include nicotine (Burch et al., 1989), rizatriptan (Rabinowitz et al., 
2004), morphine (Dershwitz et al., 2000) and fentanyl (Mather et al., 1998). The use of the 
lungs for the delivery of macromolecules like peptides and proteins, which otherwise must 
be injected, is one of the most exciting new areas in pulmonary delivery. For reasons that 
are not completely understood, the lungs provide higher bioavailability for peptides and 
proteins than any other non-invasive route of drug delivery (Patton, 1996; Patton et al., 
1998). However, unlike the situation with small molecules, for which lung metabolism is 
minimal, enzymatic hydrolysis of small natural peptides (less than 30 amino acids) can be 
very high unless they are chemically engineered (blocked) to inhibit peptidases (Patton et 
al., 1998). Exubera, a fast-acting inhaled insulin was the first ever macromolecular inhalable 
product to hit the market in January 2006 (Freemantle & Strack, 2006). The product had 
glycemic control comparable to subcutaneous insulin (Patton & Byron, 2007),  but in less 
than 2 years after its introduction the product was withdrawn from the market because of 
disappointing sales. Other peptides and proteins investigated for pulmonary delivery include 
growth hormone (Bosquillon et al., 2004), parathyroid hormone (Codrons et al., 2004), 
erythropoietin (Dumont et al., 2005) and quite a few others (Patton & Byron, 2007). 
 
 
Chapter 2 Literature Review 
 
10 
 
Although promising, delivery of therapeutics to the lungs faces several anatomical and 
physiological challenges (Patton, 1996). To deposit in the lungs, drugs must traverse a 
complex lung structure that is heterogeneous in geometry and environment from patient to 
patient. Once deposited, natural clearance mechanisms, including the ‘‘mucociliary 
escalator’’, work to expel particles from the upper airways (Amidi et al., 2008b; Koushik & 
Kompella, 2004), while alveolar macrophages rapidly (often within minutes) engulf particles 
between 1 and 5 μm that reach the deep lungs (Koushik & Kompella, 2004). Additional drug 
loss may occur in the inhaler device due to inefficient aerosolization, or in the mouth, 
throat, and upper airways due to sub-optimal aerosol characteristics or improper 
coordination of aerosol activation and breathing (Edwards et al., 1998). Consequently, 
optimized formulation can play vital role to maximize delivery efficiency and eliminate 
irreproducibility that can limit the practicality of new pulmonary therapies. 
2.3 Different Types of Devices for Respiratory Drug Delivery 
There are three main categories of devices in common use for pulmonary drug delivery, viz. 
nebulizers,  pressurized metered dose inhalers (pMDIs) and dry powder inhalers (DPIs).  
 
Nebulizers (Fig. 2-3) are probably one of the oldest forms of pulmonary drug delivery 
devices (Dolovich et al., 2005). These devices aerosolize the drug from an aqueous 
solution/suspension. The device requires a dispersing force (either a jet of gas or ultrasonic 
waves) for aerosolization (O'Riordan, 2002). In terms of drug delivery, nebulizers are less 
efficient and more time-consuming compared to DPIs (Le Brun et al., 2000). They are not 
portable and so their use is limited to the treatment of hospitalized patients (Islam & 
Rahman, 2008). However, nebulizers can be designed to make the best use of a patient’s 
breathing pattern, by using the so-called ‘breath-assisted nebulizers’ (O'Callaghan & Barry, 
1997). Further, with jet nebulizers, adjustments in drug dosing are easier to achieve (Rau, 
2002). Thus, Nebulizers may be best suited for inhaling high-dose drugs in hospital settings 
with little patient co-ordination/skill. 
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Figure 2- 3: Nebulizer 
 
pMDIs (also called MDIs) spray a pre-determined dose of drug, dissolved/suspended in 
liquefied propellant(s), from a pressurized canister (Fig. 2-4). Since their introduction in 
1956 by 3M Riker (Northridge, CA), pMDIs have been the mainstay of the treatment of 
asthma for >40 years (Smyth & Hickey, 2005). These devices can more consistently deliver 
doses per inhalation (Leach, 2007). But, they require synchronization of actuation and 
inhalation to achieve successful lung deposition and, therefore, a large number of drug 
particles may deposit onto the oropharyngeal areas due to a lack of co-ordination between 
actuation and inhalation. Besides, liquefied chlorofluorocarbons (CFC), the propellants 
originally used in pMDI formulations, are believed to have adverse effects on the 
stratospheric ozone layer (Sivasakthivel & Reddy, 2011) and have been banned by an 
international agreement — The Montreal Protocol (1987)  (Smyth & Hickey, 2005). 
However, CFCs have since gradually been replaced in MDIs by environment friendly 
propellants, hydrofluoroalkanes (HFAs). 
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Figure 2- 4: Metered Dose Inhaler (MDI) 
 
The latest addition to the respiratory drug delivery technology is Dry Powder Inhalers (DPIs) 
(Fig. 2-6). Since its introduction in 1967 (Altounyan, 1967), there has been a continuously 
growing interest in this new technology, especially after the signing of the Montreal Protocol 
banning CFCs ― the major propellants used in MDIs (Leach, 2007). Basically, DPI 
formulations can be categorized into two types; one consists of loose agglomerates of 
micronized drug particles (<5 μm) having controlled flow properties, and the other is carrier-
based interactive mixtures that consist of micronized (<5 μm) drug particles mixed with 
larger particles of  a   carrier      (e.g. lactose)    (Hersey, 1975)  (Fig. 2-5). The  formulation  is 
contained within a device, that upon inhalation provides sufficient de-agglomeration forces 
to de-aggregate micronized drug particles or separate them from the carrier and, in turn, 
results in dispersion and respiratory deposition of a therapeutic dose of micronized drug 
particles (Young et al., 2008) (Fig. 2-6). In carrier based DPIs, drug particles (<5 μm) are 
blended with a suitable larger carrier in order to improve flow properties and dose 
uniformity (French et al., 1996).  
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A. Loose Agglomerate of Micronized Drug Particles   B. Carrier-based Interactive Mixtures 
Figure 2- 5: Dry Powder Inhaler (DPI) formulation 
 
In recent years, DPIs represent the most rapidly expanding field in pulmonary drug delivery, 
largely as a result of the perceived limitations in pMDIs and nebulisers. Unlike pMDIs, DPIs 
avoid problems inherent in the use of propellant gases and the need for coordination of 
inhalation and actuation (Hickey et al., 1994). DPIs are also very portable, patient friendly 
and easy to use (Geller, 2005). Moreover, since drugs are kept in DPIs in solid state, they 
exhibit high physicochemical stability, particularly for proteins and peptides (Manning et al., 
1989). 
 
 
 
Figure 2- 6: Dry Powder Inhaler (DPI) 
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2.4 Formulation Challenges of Successful Drug Delivery from a DPI 
For efficient delivery of drugs to the deep lungs, aerosol particles should be small enough to 
pass through the mouth, throat, and conducting airways and deposit in the deep lung. The 
site of particle deposition within the lungs is clearly demarcated based on particle size. The 
upper airways (nose, mouth, larynx, and pharynx) and the branched anatomy of the 
tracheobronchial tree act as a series of filters for inhaled particles (Byron et al., 1986). Thus, 
aerosol particles with mass median aerodynamic diameter (MMAD) > 100 μm are trapped in 
the naso/oropharynx and generally do not enter the respiratory tract. Particles with MMAD 
> 10 μm come into contact with the upper respiratory tract (above trachea) and are 
eliminated quickly by mucociliary clearance. Particles with MMAD in the size range of 5 to 
10 μm are deposited in the large ciliated airways, and only particles having an MMAD 1-5 
μm reach the alveolar space (Schlesinger, 1985). Although it is generally accepted that the 
particles must be in the range of 1-5 µm for effective delivery to the deep lung, an increase 
in deep lung deposition is observed as the particle size is reduced still further into the 
nanometer range and an efficient particle deposition in the alveoli can also be achieved with 
nanoparticles of the size <100 nm (Jain, 2008; Pirooznia et al., 2012; Rogueda & Traini, 2007; 
Todoroff & Vanbever, 2011).  
 
From the above discussion it is evident that, for application of drugs to the deeper parts of 
the lungs, a micronization process has to be employed to produce particles of 1-5 μm or of 
further smaller diameters in the nano range. Unfortunately, such micronization produces 
particles of high surface area, resulting in a highly cohesive system where the particles show 
a strong tendency of adhering to each other. The flowability and dispersion properties of 
these systems are poor, causing manufacturing problems, dose variability and poor 
aerosolization/ lung deposition (Malcolmson & Embleton, 1998) (Fig. 2-7).  
 
The most common formulation approach employed to solve the ensuing problem is to blend 
the drug with a larger inert carrier, such as α-lactose monohydrate (lactose), giving a drug- 
carrier binary mixture (Fig. 2-5). This ordered mixing process aims to reduce the high 
cohesion forces present between micronized drug particles, improve powder flow and allow 
accurate metering  (Hersey, 1975).  During  the  inhalation  manoeuvre,  energy  supplied  to  
the   dry  powder  inhaler  (DPI)  by  the  patient’s  inspiration  must  overcome  the adhesive 
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Figure 2- 7: Problems Ensuing in a DPI due to Micronization of Particles 
 
forces between drug and carrier, allowing liberation of drug from the device and dispersion 
of the drug particles into the deep lung. Thus, a balance between the cohesive (drug-drug) 
and adhesive (drug-excipient) forces is critically important for optimum fluidization of a 
carrier-based DPI formulation. In one hand, excessive adhesive forces may prevent 
detachment of the respirable particles from the carrier surfaces, resulting in their deposition 
together with carrier particles in the upper airways. On the other hand, strong cohesive 
forces may enhance segregation and agglomeration, which could also directly affect the 
fluidization and dispersion properties of the formulation (Byron, 1986; Hickey et al., 1994). 
To further complicate the issue, the cohesion-adhesion balance in a carrier-based 
interactive mixture can additionally be influenced by the drug concentration in the 
formulation. Due to differences in the dose size of various drugs, a large variation is 
observed in the drug content in commercially available DPI formulations; however, for a 
carrier-based interactive mixture the drug content typically ranges from 0.1 to 4% 
(Grasmeijer et al., 2013). Interactive mixing of drug and carrier involves a dynamic process 
of ordered mixing (drug-carrier association) and randomization (drug-carrier dissociation) 
that ultimately determines the overall outcome of the blending process (Staniforth, 1981). 
With an increase in drug content, the equilibrium is shifted towards randomization (Hersey, 
1975; Staniforth, 1981; Staniforth, 1987) resulting in less homogeneous mixtures that are 
more prone to segregation of drug and carrier particles during handling (e.g. filling, storage 
and transportation) (Bryan et al., 1979). The upside is that this apparent adverse effect may 
come along with better detachment of drug from carrier particles when the mixture is 
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subjected to detachment forces (Kulvanich & Stewart, 1987). However, there are mixed 
reports in the literature regarding the effect of the drug content on the aerosolization 
performance of DPI formulations containing lactose as the carrier. While Steckel et al. 
(2004) reported an improvement in fine particle fraction (FPF) of salbutamol sulfate upon 
increasing the drug content from 0.25% to 2.8% in a lactose-based interactive mixture, 
other studies showed unfavorable effects with increased drug contents (Le et al., 2012; 
Steckel & Mueller, 1997).   
 
In an attempt to address the problem of poor dipersion of drug from a DPI formulation, a 
wide variety of approaches, to engineer the drug or carrier, have been investigated by 
formulation scientists. In general, the researchers have primarily focussed on the influence 
of the physicochemical properties of the carrier (Steckel et al., 2004; Young et al., 2005) or 
the addition of ternary components  to the drug/carrier mixture (Begat et al., 2005; Louey et 
al., 2003). Many researchers have also focussed on producing particles with increased 
stability and reduced interparticulate adhesion with diameters conducive to respiratory 
therapy by employing such techniques as supercritical fluid extraction (Jung & Perrut, 2001), 
high gravity precipitation (Chiou et al., 2007) and sonication (Kaerger & Price, 2004). In 
addition, controlled spray drying, with or without excipients, has also shown promise for 
producing drug particles with specific morphology (such as Nektars PulmoSphere) (Duddu et 
al., 2002) and density parameters (such as large porous particles) (Edwards et al., 1997). In 
spite of these multifarious approaches, the respirable fraction from currently available DPI 
formulations still remains not more than 40% (Lavorini, 2013; Shah & Misra, 2004; Tronde et 
al., 2008).  So, it is evident that a lot of work is yet to be done to optimize delivery of drug 
from a DPI. 
2.5  Use of Aerosolization Enhancers for Maximizing Drug Delivery from a DPI 
One of the well-characterized approaches attempted by formulation scientists to increase 
aerosolization from DPIs involves the addition of a co-excipient as a ternary component to 
binary drug-lactose mixes in order to impart modified surface properties to the primary 
excipient particles (Labiris & Dolovich, 2003). Many compounds have been shown to 
increase dispersibility of dry powders when employed in this fashion. Among these 
compounds, the amino acid, L-leucine and its analogues appeared very promising in 
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enhancing aerosolization & lung deposition and have drawn a lot of attention of researchers 
in this area (Alhusban & Seville, 2009; Learoyd et al., 2009). Other compounds used for this 
purposes include: phenylalanine (Li et al., 2005), arginine (Li et al., 2005), cyclodextrins (Li et 
al., 2005; Srichana et al., 2001), polyethylene glycols (Ely et al., 2007; Gilani et al., 2004),   
Mg stearate (Begat et al., 2009; Begat et al., 2005) and phospholipids (Begat et al., 2009; 
Staniforth et al., 2004). These compounds act as lubricants/antiadherents between surfaces, 
thus reducing cohesion forces and improving deagglomeration and flowability that in turn 
results in increased dispersibility of powders (Najafabadi et al., 2004; Staniforth & Morton, 
2002). 
 
 
 
 
 
Figure 2- 8: L-Leucine Coating and Inter-particle Interaction 
 
In the spray-drying process, because of its predominantly hydrophobic nature (Black & 
Mould, 1991) and surfactant-like properties (Glinski et al., 2000),  L-leucine migrates to the 
surface of the drying droplet and hence influences the surface characteristics of the 
resultant particle (Columbano et al., 2003; Rabbani & Seville, 2005), and in turn generates 
highly dispersible particles with optimal aerosolization properties (Learoyd et al., 2008a). It 
has been observed that accumulation of L-leucine on the spray-dried particle surface 
imparts a pitted/wrinkled appearance to the surface that reduces inter-particulate contact 
Hydrophobic Hydrophilic 
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points for aggregation resulting in a reduction of surface forces, which in turn improves 
flowability and dispersibility (Learoyd et al., 2009; Seville et al., 2007) (Fig. 2-8). Apart from 
changing the surface morphology, L-leucine-induced reduction in the surface free energy 
may also contribute to reduced inter-particulate interaction leading to an enhanced 
aerosolization of the particles. A number of studies have demonstrated L-leucine’s ability to 
reduce the surface free energy, however no direct correlation was observed between 
aerosolization performances of particles and dispersive surface energies; the key factor 
contributing to enhanced aerosolization appeared to be the change in the surface 
morphology, leading to reduced inter-particle contact  (Chew et al., 2005; Paajanen et al., 
2009; Raula et al., 2010). Some researchers have also shown concentration-dependent 
gradation in the effect of L-leucine on the enhancement of aerosolization of particles from a 
dry powder inhaler. For instance, Seville et al. (2007) reported in their study a progressive 
increase in the FPF of spray-dried powders for inhalation with an increase in L-leucine 
content from 5 to 20% using salbutamol sulphate as a model drug and lactose as a bulking 
agent. On the contrary, however, Chew et al. (2005) did not find any correlation between    
L-leucine concentration and dispersive surface free energy of disodium chromoglycate 
powders co-spray dried with L-leucine. 
 
Recently, Raula et al. (2008) investigated the effect of direct coating of drug particles with                     
L-leucine vapours by a novel one-step, aerosol flow reactor-based method. They found that, 
upon deposition, L-leucine formed a discrete crystalline surface layer around individual 
particles. This coated powder was found to flow and disperse well and appeared promising 
for use in dry powder inhaler formulations even without the addition of a coarse lactose 
carrier. When dispersed from a DPI at 60 L/min air flow without any added carrier, the fine 
particle fraction (FPF) of the coated salbutamol sulfate powder was found to be 35-48% and, 
upon blending with lactose carriers, the FPF reached as high as 90%.  
2.6 Controlled Release Dry Powder Inhalers — Current status, Challenges 
and Future Prospect 
Controlled release delivery (Fig. 2-9) is one of the most advanced and widely acclaimed 
therapeutic strategies in the present day medicinal and pharmaceutical arena. These 
systems have a number of overwhelming advantages over conventional treatment 
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modalities including extended duration of action, reduction in dosing frequency, improved 
management of therapy, improved compliance, reduction in side effects (Hardy & Chadwick, 
2000), together with potential cost savings in the long run (Saks & Gardner, 1997).  
 
 
Figure 2- 9: Ideal Release Profile of a Controlled Release Dosage Form 
 
Controlled drug release to the lung is an emerging research field that may offer new 
opportunities for enhanced clinical responses for both local and systemic treatments. 
However, due to the efficiency of lung clearance mechanisms, our ability to control release 
of drug within the lung is considered one of the major challenges in pulmonary drug delivery 
(Martonen Ted et al., 2005; Smyth & Hickey, 2005).  As a consequence of these powerful 
clearance mechanisms (as already noted in the section 2.2), researchers are very limited in 
their capacity to control drug release in the lung environment. However, by utilizing the 
current understanding of lung–particle interactions, some strategies evolved to overcome 
these limitations. For instance, pulmonary controlled release can be achieved by using 
formulation approaches like liposomes (Wong et al., 2003), polymeric micro-/nanoparticles 
(Florea et al., 2006; Jaspart et al., 2007; Yamamoto et al., 2005), swellable microgels (El-
Sherbiny & Smyth, 2012), large/low-density porous particle or aerodynamically light particle 
(Edwards et al., 1997), complexation (Aguiar et al., 2004), and drug conjugates (Williams & 
Taylor, 1992). However, although a significant amount of research has been directed 
towards delivery of drug in controlled release form to the respiratory tract, no product has 
yet found its way into the market.  
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2.7 The Role of Biodegradable Polymers in Designing a Controlled Release DPI 
The use of biodegradable polymers is an exciting approach to achieve controlled pulmonary 
delivery. Polymers can be tailored into micro- or nanoparticulate systems to deliver precise 
amount of drugs over a prolonged period of time (Kim & Pack, 2006). In the perspective of 
pulmonary delivery, apart from providing controlled drug release, they also offer other 
advantages such as increased drug penetration to the distal parts of the lung, prolonged 
residence time of the drug in situ, and improved in vivo drug stability (Sivadas, 2010). 
Attempts have been made for controlled pulmonary therapy for both local respiratory 
disorders and some systemic diseases using polymeric micro-/ nanoparticles. These included 
the topical treatment of asthma (Beck-Broichsitter et al., 2010), local infectious diseases 
(Suarez et al., 2001), pulmonary hypertension (Kimura et al., 2009), and the systemic use of 
insulin (Aguiar et al., 2004), low molecular weight heparin (Patel et al., 2012) and calcitonin 
(Yamamoto et al., 2005). A wide range of natural and synthetic polymers have so far been 
investigated as carrier materials for sustained pulmonary delivery with encouraging results. 
Examples include: chitosan(Learoyd et al., 2009; Naikwade & Bajaj, 2009), poly(dl-lactide-co-
glycolide) (PLGA) (Sung et al., 2009; Ungaro et al., 2006), sodium hyaluronate (Sivadas et al., 
2008), polyvinyl alcohol (PVA)(Salama et al., 2008), poly(ether-anhydride)(Fiegel et al., 
2004), poly lactic acid (PLA) (Coowanitwong et al., 2007), albumin (Li et al., 2001), etc.  
2.8 Chitosan ― a Promising Natural Biodegradable Polymer for Sustained 
Release DPI Formulation 
Chitosan (Fig. 2-10) is an amino-polysaccharide produced by alkaline N-deacetylation of the 
naturally occurring polymer chitin  which is a major component of the shells of 
crustaceans like crabs and shrimps and the second most abundant biopolymer after 
cellulose in the world. It is a copolymer of (β1→4)-linked D-glucosamine with a smaller 
amount of N-acetyl-D-glucosamine from incomplete deacetylation (Armiji & Patel, 1994; 
Choi et al., 2004). The glucosamine residue of chitosan has a pKa value of 6-7, resulting in 
protonation of the amino groups in acidic condition. As a consequence, chitosan dissolves in 
acidic solutions; but, due to suppression of ionization of the amino groups, it does not 
dissolve in neutral to alkaline solutions (Agnihotri & Aminabhavi, 2004; Amidi et al., 2008b; 
Asada et al., 2004; Germershaus et al., 2008; Learoyd et al., 2009); the rigid crystalline 
structure of chitosan (Saito et al., 1981; Saito et al., 1987) and extensive intra- and inter-
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chain hydrogen bonding (Liu et al., 2004; Nishimura et al., 1991) have also been reported to 
make important contribution to this intractability of the polymer. These chemical properties 
allow chitosan to play an effective role in controlling drug delivery. It can be processed in 
acidic conditions where it is soluble; by contrast, as products made of chitosan are insoluble 
in neutral or alkaline pH, it behaves as a sustained release delivery system under such 
conditions (Onishi & Machida, 2006). It would be relevant to note here that, though 
chitosan is typically insoluble in water, it could be prepared in some water-soluble forms 
(the so-called ‘water-soluble chitosan — WSC) by controlling its degree of deacetylation 
(DDA) and/or molecular weight (MW). Thus, chitosan with a DDA of about 50% is water 
soluble and can be obtained from chitin by hydrolysis with alkali (Kurita et al., 1977) or from 
chitosan by N-acetylation with acetic anhydride (Kurita et al., 1989). Similarly, low molecular 
weight water-soluble forms can be prepared by chemical or enzymatic depolymerisation of 
insoluble chitosan (Qin et al., 2002; Vikhoreva et al., 1999).  
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Figure 2- 10: The Structure of Chitosan 
 
Because of multifarious industrial sources and preparation methods and conditions, 
chitosan widely varies in its physicochemical properties (Kumirska et al., 2009). Commercial 
chitosan is characterized by a DDA between 70 and 95% and a MW between 50 and 2,000 
kDa (Sun et al., 2009). A knowledge of DDA and MW is important for its applications and, by 
far, the MW is the most important factor that control its properties (Yaghobi, 2012). Based 
on the MW, chitosan is divided into three categories, namely low molecular weight (LMW), 
medium molecular weight (MMW) and high molecular weight (HMW), but these categories 
are rather arbitrary — there are no well-recognized boundaries between them. Thus, 
various researchers reported different and sometimes overlapping values for the three 
categories.  For example, when some investigators termed 50-190 kDa as low-, 190-310 kDa 
as medium-, and 310-375 kDa as high-molecular-weight chitosan (Shuai et al., 2013), others 
used the values <10 kDa, 20-50 kDa, and  1,000 kDa, respectively, for indicating the same 
categories (Lee et al., 2005). In spite of this ambiguity, the classification has been widely 
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used in the literature and served as a useful tool for describing differences observed in 
physicochemical properties with a change in the molecular weight of the polymer. In 
general, it has been shown that solubilization of chitosan gets increasingly difficult with an 
increase in MW (El-Hefian et al., 2009; Pillai et al., 2009), making chitosan LMW easier to 
process for drug delivery applications compared with MMW or HMW ones (Kumirska et al., 
2011), but lower molecular weights of the polymer offer relatively less drug encapsulation 
efficiency and poorer control over drug release (Kumirska et al., 2011; Learoyd et al., 
2008a). These shortcomings, however, might be compensated by adequately crosslinking 
the polymer with an appropriate agent (such as glutaraldehyde) (Bansal et al., 2011).    
 
Chitosan has been shown to be both biocompatible and biodegradable (Dodane & Vilivalam, 
1998; Grenha et al., 2007). The 16 g/kg oral LD50 of the polymer for mice indicates a very 
low toxicity potential for this product (De Jesus Valle et al., 2008; Huang et al., 2005). 
Furthermore, its degradation products are also considered to be non-toxic and                  
non-immunogenic (Muzzarelli, 1993) — the degradation products being oligosaccharides of 
variable length (Dumitriu, 2002).  Because of its cationic nature, It can also bind to mucosal 
surfaces, which leads to bioadhesion, and in turn reduces mucociliary clearance, thereby 
providing a longer contact time for drugs (Davis, 1999). In addition, it has also been found to 
improve the drug absorption by opening the intercellular tight junctions of the lung 
epithelium (Yamamoto et al., 2005). Moreover, in a recent study, it has been shown that 
chitosan can also be employed as a ‘dispersibilty enhancer’  in dry powder inhaler 
formulations (Li & Birchall, 2006). 
 
Chitosan has widely been used as sustained release carrier systems in several 
pharmaceutical formulations  such as beads (Aiedeh & Taha, 2001; Srinatha et al., 2008), 
gels (Patel & Amiji, 1996; Ruel-Gariepy et al., 2000), films (Ji et al., 2009; Puttipipatkhachorn 
et al., 2001), sponges (Oungbho & Muller, 1997; Phaechamud & Charoenteeraboon, 2008) 
and micro- and nanoparticles (Barakat & Almurshedi, 2011; Saha et al., 2010) for its unique 
properties like low toxicity, biocompatibility, biodegradability and mucoadhesion. Given that 
chitosan not only acts as a drug release modifier (Learoyd et al., 2008a), but also has 
mucoadhesive properties (Sigurdsson et al., 2006) and potential for enhancing 
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aerosolization (Li & Birchall, 2006), it can be regarded as a highly promising carrier for 
preparing sustained release formulations for pulmonary drug delivery. 
 
Of various formulation strategies, micro- and nano-particulate systems have attracted much 
attention as systems for drug inclusion for controlled delivery of drugs (Agnihotri et al., 
2004; Mitra & Dey, 2011). Micro- and nanoparticles can be prepared in a variety of  size, 
shape, and porosity by varying the process parameters (DeLuca et al., 1993). By 
appropriately controlling the properties, particles can be designed to provide a steady 
release of encapsulated drugs over prolonged periods of time to local tissues or the 
systemic circulation (Chow et al., 2007). In addition to controlling drug release, they can also 
offer protection to the encapsulated drug from enzymatic degradation (Abd El-Hameed & 
Kellaway, 1997; Sadeghi et al., 2008). Most importantly, such systems can potentially be 
designed for deposition of drugs to the targeted regions of lungs (Fu et al., 2002; Madlova et 
al., 2009). Finally, being biodegradable, the particles ultimately degrade and are 
metabolized by the body obviating need for removal (Budhian et al., 2005; Fu et al., 2004b). 
 
Nanoparticles have widely been studied in drug delivery research for site-specific targeting 
and controlled release (Swami et al., 2012). They have been proposed as valuable vehicles 
for efficient drug transport to the lungs (Sham et al., 2004). By controlling particle 
dispersion, breathing and particle size, 90% of an inhaled nanoparticle dose can specifically 
be deposited to lower regions of lungs (Madlova et al., 2009). Moreover, nanoparticles 
exhibit some characteristics that make them ideal candidates for pulmonary drug delivery. 
Studies have shown that nanoparticles can escape mucociliary clearance and recognition by 
alveolar macrophages (Ahsan et al., 2002; Grenha et al., 2005; Mao et al., 2009). However, 
exploitation of this system in therapeutic setting could not yet be done to its potential 
because of technological limitation of producing stable, non-aggregating nanoparticle 
formulations (Madlova et al., 2009). 
 
Chitosan micro- and nano-particles have been formulated by a variety of techniques 
including spray drying (Khan & Vishakante, 2013; Learoyd et al., 2009), ionotropic gelation 
(Boonyo et al., 2008; Liu & Gao, 2009), emulsion-solvent evaporation (Panos et al., 2008), 
emulsion-crosslinking (Dhawan & Singla, 2003; Xu et al., 2012), coacervation (Gupta & 
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Jabrail, 2007a; Tavares et al., 2012), etc. The release of drug from the particles is controlled 
by three different mechanisms: (a) release from the surface of microspheres, (b) diffusion 
through a swollen rubbery matrix and (c) erosion (Fig. 2-11). In most cases, the release may 
involve more than one mechanism. Release from the surface layer of the matrix gives an 
initial burst effect; this effect can be reduced by cross-linking. The diffusion of the drug 
through the gel diffusion layer caused by polymer swelling takes place slowly over a 
prolonged period of time and results in a sustained drug release effect. Three steps are 
involved in the diffusion of drug out of the matrix: first, penetration of water into the matrix 
causing swelling; secondly, transition from glassy to rubbery polymer, and finally, the 
diffusion of drug out of the swollen rubbery matrix. Thus, the release follows a typical 
hydrogel release profile (Agnihotri et al., 2004; Learoyd et al., 2008a).  
 
The molecular weight of chitosan, the ratio of polymer to drug, solubility of the 
encapsulated molecule in the release media and extent of cross-linking — all these factors 
play their role in controlling the release of the loaded drug from the particle. Due to the 
cationic nature of the polymer, the pH of the release media also influences the drug release 
profile. 
 
An increase in chitosan molecular weight has been found to increase duration of drug 
release. For example, Learoyd et al. (2009) have shown for chitosan-lactose based 
formulations that chitosan LMW (low molecular weight: <190 kDa) took 2.5 h of time to 
release 100% BDP (beclometasone dipropionate) from spray-dried microspheres, whereas 
time required by chitosan MMW (medium molecular weight: 190–310 kDa) and chitosan 
HMW (high molecular weight: >310 kDa) were 5 h and 12 h, respectively.  Increasing the 
amount of chitosan in the particle increases the thickness of the diffusion layer, resulting in 
slower release of drug. Martinac et al. (2005) studied the drug release profile of loratadine-
loaded spray-dried chitosan microspheres in two different drug:polymer ratios (1:6 and 1:8). 
The result showed that 50% drug release from the two samples took 45 and 80 minutes, 
respectively. The solubility of the encapsulated drug is another factor that has a marked 
effect on drug release.  Drugs with low solubility in water are most slowly released.  
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Figure 2- 11: Mechanism of Drug Release from Chitosan Micro- and Nanoparticles 
 
In vitro release study of terbutaline sulfate (TS) and beclometasone dipropionate (BDP) in 
phosphate  buffer  solution   (PBS, pH 6.8)  from  spray-dried  chitosan microspheres showed 
that the release of BDP was much slower than TS (Learoyd et al., 2009). The investigators 
attributed it to partial solubility of BDP in PBS unlike TS which is freely soluble in this 
medium. Cross-linking with an agent like glutaraldehyde (GL) can greatly increase the 
duration of drug release. Ventura et al. (2008) studied the in vitro release of moxifloxacin 
from spray-dried glutaraldehyde-crosslinked chitosan microspheres in phosphate buffer 
solution (PBS, pH 7.4). The results showed that cross-linked microspheres gave a burst effect 
followed by a prolonged moxifloxacin (MXF) release. About 60%, 40% and 25% (w/w) of 
MXF was released within the first hour for the systems prepared in the presence of 4, 2 and 
0.5 mL of GL, respectively, while a further release of only 10% (w/w), 22% (w/w) and 32% 
(w/w) of loaded MXF, respectively, took place in 4 days. On the other hand, the entire drug 
loaded into the un-crosslinked microspheres was released within 24 h. Since chitosan is 
more soluble in acidic pH than alkaline one, drug release in the acidic environment occurs 
more quickly. A study on theophylline-loaded chitosan/β-cyclodextrin (1:3:1) microspheres 
showed that the release of the drug was more than 61% in the first hour and attained 74% 
within 8 h at pH 1.2, while the drug release was only 39% and 60%, respectively at pH 6.8 
(Zhang et al., 2008b).  
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2.9 Conjugation of L-Leucine with Chitosan ― a Novel Approach for 
Maximizing Drug Delivery from a Controlled Release DPI 
As mentioned in the section 2.5, L-leucine (Fig. 2-12) ― a predominantly hydrophobic amino 
acid with surfactant like property ― has been found to be a very efficient aerosolization 
enhancer when added to a DPI formulation by blending, spray drying or even by direct 
coating on drug particles by physical vapour deposition (PVD). In recent years, some 
researchers attempted to combine the potential of chitosan as a release modifier with the 
aerosolization enhancing ability of L-leucine and found it to be very effective (Learoyd et al., 
2008a, 2009; Seville & Learoyd, 2007). Learoyd et al. (2008a)  reported that spray-drying 
30% v/v aqueous ethanol formulations, containing terbutaline sulfate as a model drug, 
chitosan as a drug release modifier, L-leucine as an aerosolization enhancer and lactose as a 
bulking agent, produced highly dispersible sustained release powder for pulmonary delivery 
with emitted doses of over 90% and FPFs of up to 82% of the total loaded dose. In another 
study, these investigators demonstrated that combining L-leucine and chitosan together in a 
spray-dried lactose-based formulation of beclomethasone dipropionate could give 64% FPF 
with 2 hour dissolution time for low MW (<190 kDa) chitosan and 54% FPF with 12 hour 
dissolution time for high MW (>310 kDa) chitosan (Learoyd et al., 2008b). In a subsequent 
study, Learoyd et al. (2009) reported over 90% of emitted doses and up to 76% FPF of the 
loaded dose from a spray-dried powder containing both the hydrophilic drug, terbutaline 
sulfate and the hydrophobic drug, beclomethsone dipropionate along with chitosan,              
L-leucine and lactose. The formulation showed sustained release profiles for both drugs in 
dissolution tests. 
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Figure 2- 12: The Structure of L-Leucine 
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It is evident that these workers concentrated their attention mainly on physically combining 
chitosan and L-leucine in a DPI formulation. No attempt has so far been made to chemically 
conjugate chitosan with L-leucine in order to investigate its impact on aerosolization and 
lung deposition from a DPI formulation. It can be an interesting question to explore if 
chemical conjugation of chitosan with L-leucine can still maintain this effect on dispersibility 
of chitosan from a DPI which is a very likely possibility in view of the structural features of   
L-leucine that could be expected to orient the molecule around the chitosan backbone with 
its hydrophobic part being projected outward. There is good possibility that this will in turn 
reduce the inter-particle cohesion and may even add further to dispersiblity enhancing 
property of L-leucine found with simple physical addition. In addition to this possible effect 
on the surface morphology, the ability of L-leucine to reduce the surface tension, as detailed 
in the section 2.5 of this chapter, could also be expected to play a positive role in enhancing 
the dispersion of particles. 
 
It would be relevant here to shed some more light on the probable interfacial orientation of 
the hydrophilic (─NH2─COOH) and hydrophobic (─CH2─CH(CH3)2) domains of L-leucine 
conjugated to chitosan.   As shown in the Fig. 2-13 (a) and (b), as a general rule, the 
hydrophobic   domain   of   an   amphiphilic   agent  is  projected  towards  air  at  a  water-air 
interface or towards the oil phase at a water-oil interface, while the hydrophilic domain is 
associated with the aqueous phase (Sinko, 2006). Because of this tendency of the two 
different domains to get associated with two different phases, when this type of molecules 
are added to a liquid they are oriented at the interface rather than the bulk. However, as 
the concentration is increased, the interface becomes saturated at a certain point (called 
critical micelle concentration, CMC) and the molecules begin to form in the bulk of liquid 
special type of aggregates called micelles where the domain liked by the surrounding 
medium is organized at the periphery in association with it but the one disliked by the 
medium is oriented towards the core of the micelle in order to keep itself away from the 
surrounding medium ((Fig. 2-13 (c) and (d)) (Sinko, 2006). So, it is obvious that in an aerial 
environment (for example, when aerosolized from a DPI), the polymer chitosan — being 
hydrophilic in nature (Wen & Park, 2011) — would behave as the hydrophilic phase and so 
the hydrophobic domain of L-leucine conjugated to it would be projected towards the air 
(Fig. 2-14(a)).  This  is  in  conformity  with  the  observations  of  other  investigators  for the   
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Figure 2- 13: (a) & (b) Orientation of a surfactant molecule at oil-water and air-water 
interfaces respectively, (c) & (d) Micellar orientation of a surfactant molecule in water and 
non-polar solvents respectively [adapted from Sinko (2006)] 
 
 
Figure 2- 14: Probable orientation of hydrophilic and hydrophobic domains of L-leucine 
conjugated to chitosan in particle-air (a) and particle-water (b) interfaces. 
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orientation of L-leucine (Raula et al., 2010) and its tri-leucine analogue (Lechuga-Ballesteros 
et al., 2008) at a particle-air interface. On the other hand, although hydrophilic in nature 
(Wen & Park, 2011),  the polymer chitosan is poorly soluble in water due to its rigid 
crystalline structure (Saito et al., 1981; Saito et al., 1987) and extensive intra- and inter-
chain hydrogen bonding (Liu et al., 2004; Nishimura et al., 1991). So, in an aqueous 
environment (for example, in the lung fluid or in vitro release medium), the polymer would 
behave as a hydrophobic pahse in relation to the surrounding water and the orientation of 
the hydrophobic and hydrophilic domains of L-leucine would be just opposite to what is 
seen in a particle-air interface (that is, the hydrophilic domain would be associated with the 
surrounding aqueous medium and the hydrophobic domain would tend to burry itself into 
the polymer backbone within the particle) (Fig. 2-14(b)).  It would be worth noting here that 
lung fluid — the in vivo release medium (as well as PBS used as in vitro release medium in 
this study)— has a pH of 7.3  that is slightly higher than pure water (pH 7.0) and may also 
contain substances like enzymes, but a pH variation or presence of enzymes (which are 
protein in nature and so water-soluble macromolecules) does not bring any change to the 
hydrophilic nature of the aqueous phase and so its interfacial interaction with the 
suspended polymer particles in terms of hydrophilicity/ hydrophobicity remains all the 
same. However, at a pH of 7.3 the ionization of the amino group of L-leucine may be 
suppressed causing it to be less associated with the surrounding medium, but the carboxylic 
acid group would be ionized and so well associated with the the medium. The pulmonary 
route is considered to be free from the drawback of first-pass metabolism (Agu et al., 2001)  
and so there should not be any significant enzymatic degradation of the administered 
particles in the lung fluid until they are engulfed by macrophages. However, for the sake of 
argument, even if the particles are assumed to be ezymatically metablized to give chitosan 
monomers or oligomers, it would rather increase their hydrophilicity.  
 
2.10 The Human Bronchial Epithelial Cell Line, BEAS-2B for the Assessment 
of the Toxicity and Inflammatory Activity of the DPI formulation 
As already noted, pulmonary route of drug delivery has drawn immense attention of 
formulation scientists for its interesting and attractive features, and polymer-based drug 
delivery to the respiratory system for local or systemic action is an exciting area of present 
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day research. However, it is important to ensure in the first place that the formulation/ 
system intended for inhalation does not have any adverse reaction to the respiratory 
airways. The safety of inhaled formulations is best evaluated in vitro by using a variety of 
toxicological tests on respiratory epithelial cell lines to provide complementary information. 
Literature reports suggest many different toxicological tests for the assessment of the safety 
of polymeric nanoparticles in respiratory epithelial cell lines. Three most commonly used 
and well-characterised tests in this series are MTT cell viability assay, sodium fluorescein 
transport assay and release of proinflammatory mediators.  
 
2.10.1 MTT Cell Viability Assay  
The determination of cell viability is a common method for in vitro evaluation of the 
cytotoxicity of biomaterials (Wu et al., 2008). In vitro assays based on cultured cells are 
often used to screen potential drugs and excipients for any adverse biological effects 
towards body cells and tissues before in vivo testing to reduce untoward use of research 
animals. Researchers have widely used cell viability assays to evaluate the safety of inhaled 
materials (Amidi et al., 2006; Bivas-Benita et al., 2004; Forbes et al., 2000; Grenha et al., 
2007; Stone et al., 1998; Westmoreland et al., 1999). Traditionally, a number of in vitro 
cytotoxicity assays have been used to this end. These assays are based on assessing 
membrane integrity (e.g., neutral red, calcein AM) or cell metabolism (e.g. MTT, alamar 
Blue) by using colorimetric or fluorescent dyes as marker (Monteiro-Riviere et al., 2009).  
The predictive value of these tests is based on the concept that toxic chemicals affect the 
basic functions of cells and so the toxicity can be measured by assessing cellular damage 
(Mao et al., 2005). The changes in metabolic activity has been shown to be superior 
indicators of early cell injury, because disruption of membrane integrity reflects more 
serious damage leading to cell death (Davila et al., 1990).  
 
MTT cell proliferation assay, originally developed by Tim Mosmann in 1983 (Mosmann, 
1983), is a quick effective method for testing mitochondrial impairment and correlates well 
with cell proliferation (Muzzarelli et al., 2005), and therefore is often performed for 
evaluation of the cytotoxicity of polymers (Mosmann, 1983).  The assay integrates both the 
number of cells and mitochondrial activity per cell (Wan et al., 1994). Central to this assay is 
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a water-soluble, yellow tetrazole dye, 3-(4,5 dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium 
bromide (MTT), that is metabolically reduced by living cells to water insoluble, purple MTT-
formazan (Fig. 2-15) (Mosmann, 1983). Damaged or dead cells show reduced or no 
dehydrogenase activity and thus fail to reduce MTT to formazan (Florea et al., 2006). The 
MTT formazan is extracted from cells with an organic solvent (e.g. DMSO, 1-propanol etc.) 
and its concentration is determined by measuring the absorbance with a 
spectrophotometer at ~550 nm. In general, the absorbance is a linear function of the 
number of metabolically active cells (Monteiro-Riviere et al., 2009; Zhang et al., 2011). 
Decreased absorbance reflects reduced mitochondrial activity, and, by inference, decreased 
cell health.  
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Figure 2- 15: Conversion of MTT to Formazan 
 
Referring to an article of Slater et al. (1963), some authors incorrectly attributed the 
reduction process to the mitochondrial enzyme, succinate dehydrogenase (Denizot & Lang, 
1986). But, based on cell homogenates and isolated mitochondria, two coupling points have 
been found between MTT reduction and the mitochondrial respiratory chain — coenzyme 
Q: cytochrome c (Liu et al., 1997; Marshall et al., 1995; Slater et al., 1963). In addition, there 
has been increasing evidence that denies exclusive role of mitochondria and suggests for an 
even more important role of NADH- and NADPH-dependent mechanisms (Berridge & Tan, 
1993; Liu et al., 1997; Vistica et al., 1991). Considering these facts, the MTT assay can be 
regarded as a quantitative measure of a combination of cellular proliferation and an 
integrated set of enzyme activities that are related to cell metabolism in various ways 
(Berridge et al., 2005). In addition, its rapidity, precision and lack of requirement of any 
radioisotope are important advantages of this test (Mosmann, 1983). 
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There have been quite a few studies on the safety and biocompatibility of chitosan and its 
derivatives in pulmonary drug delivery systems both in neat and particulate forms. In light of 
these studies, chitosan has generally been recognised as a biocompatible and biodegradable 
polysaccharide with low toxicity (Dornish et al., 1997; Grenha et al., 2007; Hirano et al., 
1988; Huang et al., 2004; Mansouri et al., 2004; Mi et al., 2001; Nordtveit et al., 1996; Wang 
et al., 2007). Chitosan in solution has been reported to exhibit low or no toxicity in 
respiratory cell lines like A-549 and 16HBE14o- (Florea et al., 2006; Grenha et al., 2007; 
Huang et al., 2004; Lim et al., 2001; Smith et al., 2004; Smith et al., 2005). A high 
concentration of chitosan has, however, been reported to exert some degree of cytotoxic 
effect. For instance, chitosan solution at a concentration of 15 mg/mL has been reported to 
reduce Calu-3 cell viability to approximately 70% (Florea et al., 2006). Contradictory reports 
are seen in the literature about the compatibility of particulate chitosan with the respiratory 
system. Chitosan nanoparticles, prepared by an ionic gelation method, were shown to 
reduce the viability of A-549 cells by approximately 70% at a concentration of about 
1 mg/mL (Huang et al., 2004). Another report from this group noted that chitosan 
microparticles induced pro-inflammatory responses in rat lungs (Huang et al., 2005). In 
contrast, other studies reported a low toxicity of chitosan nanoparticles in respiratory cell 
lines (Grenha et al., 2007; Smith et al., 2005).  Grenha et al. (2007) found <50% reduction in 
Calu-3 or A-549 cell viability with chitosan nanoparticles. Further, Vllasaliu et al. (2010) 
observed the effect of chitosan nanoparticles on Calu-3 cell viability to be slightly lower 
compared to chitosan solution. While in some cases this difference did not reach a statistical 
significance, in other cases the discrepancy was clearly apparent (Vllasaliu et al., 2010). In 
another report, the authors noted that chitosan/cyclodextrin (‘hybrid’) nanoparticles 
exhibited a significantly lower cytotoxicity than those based on chitosan only (Teijeiro-
Osorio et al., 2009a, 2009b), with  the IC50 values for chitosan/cyclodextrin-containing 
nanoparticles being 3-fold higher compared to the chitosan-only nanoparticles. However, it 
should be emphasized here that direct comparisons between these studies are difficult 
because of differences in experimental parameters including different MWs and DDAs of 
chitosan, different chitosan formulations and finally different cytotoxicity assays and cell 
lines. 
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One of the best characterized derivatives of chitosan is TMC (trimethyl chitosan chloride) — 
a compound obtained by quaternization of the –NH2 group at C-2. The outstanding 
biocompatibility of unmodified chitosan is accompanied by its low solubility at physiological 
pH.  Quaternization improves solubility (Thanou et al., 2002), but on the other hand 
significantly increases its cytotoxicity (Godbey et al., 2001; Mao et al., 2005). In general, 
polycations are considered to be cytotoxic (Morgan et al., 1989). It is suggested that TMC, 
like most cationic macromolecules such as protamine and polylysine, produces cytotoxic 
effects by interacting with anionic components (sialic acid) of the glycoproteins on the 
surface of epithelial cells (Choksakulnimitr et al., 1995; Fischer et al., 2003; Mao et al., 
2005). There have been extensive studies with TMC and it was found that the toxicity varies 
with various factors like molecular weight, degree of quaternization, duration and dose etc. 
(Mao et al., 2005; Mourya & Inamdar, 2009). Some investigators, however, found TMC to be 
low or non-toxic in the forms and assay conditions they applied (Mao et al., 2005; Mourya & 
Inamdar, 2009). PEGylation was found to considerably decrease the cytotoxicity of TMC.  
PEG is considered to shield a proportion of the positive charges present on TMC (Mao et al., 
2005). A similar effect was found upon complexation of TMC with insulin. This is again 
attributable to the electrostatic interaction between TMC and insulin, which decreased the 
interaction of the cationic amino groups of TMC with the anionic components of the cell 
membrane, leading to higher cell viability (Mao et al., 2005). 
 
2.10.2 Sodium Fluorescein Transport Assay 
Apart from the effect on the cell viability, one important indicator of adverse effects of an 
inhaled material on pulmonary epithelium is any detrimental change in the epithelial barrier 
function, because the epithelium serves as the protective barrier against inhaled particles 
and acts as a major determinant of the interaction of the particles with other body 
compartments (Hermans & Bernard, 1999; Strengert & Knaus, 2011). Permeation of a 
substance across an epithelial barrier can occur through two different routes, viz.                  
1) transcellular transport across the cell, passing through both the apical and basolateral 
membranes, and  2) paracellular transport through intercellular junctions (Krug et al., 2009). 
In functional epithelial tissues, the paracellular route is regulated mainly by tight-junctional 
complexes, which confer a virtually impermeable barrier (Florea et al., 2006) to 
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macromolecules larger than 1000 Da (Illum, 2000; Stolnik & Shakesheff, 2009). In vitro, the 
tightness of this intercellular barrier can be determined by measuring the transepithelial 
electrical resistance (TEER) and the paracellular apparent permeability (Papp) of a fluid phase 
marker (Florea et al., 2006) like fluorescein isothiocyanate (FITC)-dextran (FD)  (Vllasaliu et 
al., 2010), [14C]-mannitol (Thanou et al., 2000a; van der Merwe et al., 2004), [14C]-PEG4000 
(van der Merwe et al., 2004) or sodium fluorescein (Na Flu) (Sivadas et al., 2008) which are 
normally unable to permeate through tight junctions. 
 
It is worth noting here that a mild, transient enhancement of trans-epithelial permeability 
can rather be used to the benefit of increasing drug permeability. From this perspective, 
chitosan and its derivatives have long been studied for their ability to enhance epithelial 
permeability to investigate their potential as a possible carrier or excipient capable of 
enhancing drug absorption (Boonyo et al., 2007; Florea et al., 2006; Hamman et al., 2002; 
Illum, 1998; Illum et al., 1994; Illum et al., 2001; Kotze et al., 1997a; Kotze et al., 1998b; 
Thanou et al., 2001a; Thanou et al., 2000b; Thanou et al., 2001b; van der Merwe et al., 
2004; Vllasaliu et al., 2010). Many of these studies demonstrated that chitosan can improve 
paracellular permeability of drugs or fluid phase markers through polarized pulmonary 
epithelial cell line, Calu-3 (Bonferoni et al., 2008; Florea et al., 2006; Vllasaliu et al., 2010). 
Vllasaliu et al. (2010) also reported a significant bronchoepithelial permeation enhancement 
of FD4 and FD10 with chitosan nanoparticles at a concentration of 0.003% (w/v) (the 
permeability of FD4 was enhanced 7.6-fold while there was a 6.5-fold increase in the 
permeability of FD10). However, they found chitosan solution to be more efficient in 
improving the permeability of both FD4 and FD10, with a 10.1-fold improvement in 
permeability across the cells observed for both FITC-dextrans, relative to their respective 
controls. Some investigators, however, observed that although particulate chitosan caused 
an increase in permeability, it was not significant (Grenha et al., 2007; Sivadas et al., 2008). 
When chitosan dissolves in an aqueous medium, its amino groups are protonated giving 
positive charges (Illum et al., 2001). The opening of tight junctions by chitosan results from 
its interaction with negative charges on cell membrane, which causes a redistribution in 
cytoskeletal F-actin, thereby resulting in a structural reorganization of tight junction 
associated proteins like ZO-1 (Illum, 1998; Schipper et al., 1997). In addition, Smith and co-
workers (2005) have also shown that chitosan causes a loss of tight junction integrity 
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through inactivation of a protein kinase C (PKC). But, chitosan is soluble only at a pH below 
5.6, limiting its use in body compartments (Yadav et al., 2011). It has been found that, at pH 
7.4 (the more commonly found pH in body compartments) chitosan is ineffective as 
permeability enhancer (Borchard et al., 1996; Kotze et al., 1998a). Evidently, at lower pH 
values a higher charge density, in combination with a better solubility, provides a better 
environment for intimate contact with the epithelial membrane (Artursson et al., 1994). 
Experiments with TMC — which is more soluble than chitosan, especially at neutral and 
basic pH values (Kotze et al., 1997b)― demonstrated strong permeation enhancement 
effect for small hydrophilic compounds such as [14C]-mannitol, large molecules such as [14C]-
PEG4000, and peptide drugs, buserelin and octreotide, across the cell monolayers (Kotze et 
al., 1997a; Thanou et al., 2000a; van der Merwe et al., 2004).  
 
2.10.3 Release of Proinflammatory Mediators 
Epithelial cells of the respiratory tract provide an excellent structural barrier to inhaled 
agents, but they also play a crucial role in the lung function, partly through production of 
various pro-inflammatory mediators such as tumour necrosis factor-α (TNF-α), interleukin 
(IL)-1, and IL-8  (Ghio et al., 2002; Rahman & MacNee, 2000). These mediators are basically 
released as a protective response of the host to destroy and remove injurious agents and in 
turn promote tissue repair. But, when these crucial and normally beneficial agents are 
generated in excessive amounts or at inappropriate times or places, they can cause 
untoward damage to the host tissue and exacerbate or perpetuate the injury and may even 
lead to chronic inflammation (Laskin et al., 2007; Rahman & MacNee, 2000).  
 
Many studies have emphasised the ability of inhaled particles to induce inflammation and 
other toxicity in the lung (Borm, 2002; Churg & Brauer, 2000; Oberdorster, 2001). 
Interactions with particles can induce various types of lung cells, including lung 
monocytes/macrophages and pulmonary epithelial cells, to increase their release of 
inflammatory mediators (Becher et al., 2001; Driscoll et al., 1997; Hetland et al., 2004; 
Mazzarella et al., 2012; Monn & Becker, 1999; Takizawa et al., 2000; Tal et al., 2010; Tsukue 
et al., 2010; Vanhee et al., 1995). Increased levels of proinflammatory mediators, such as 
interleukin-8 (IL-8)/macrophage inflammatory protein-2 (MIP-2) and interleukin-6 (IL-6), 
have also been demonstrated in both animal and human bronchoalveolar lavage fluid (BALF) 
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after particle exposure (Becher et al., 2001; Ulrich et al., 2002; Vanhee et al., 1995). Thus, it 
is imperative to ascertain for any particulate matter intended for delivery through 
pulmonary route that it would not induce undue inflammatory response. This can be 
accomplished by checking the release of inflammatory mediators like IL-8 or IL-6 by an 
immunological technique like enzyme-linked immunosorbent assay (ELISA) (Saedisomeolia 
et al., 2009; Sivadas et al., 2008).   
 
There have been a limited number of works on inflammatory activity of chitosan, both neat 
and particulate, on the lung and pulmonary epithelial cell lines (Choi et al., 2010; Florea et 
al., 2006; Huang et al., 2005; Sivadas et al., 2008; Witschi & Mrsny, 1999).  Florea et al. 
(2006) performed in vivo studies by administering chitosan and its derivative, TMC, into rat 
lungs. Histopathological analysis of lung tissue showed that chitosan elicited neutrophil 
infiltration and structural damage to the lung parenchyma; the effects were relatively milder 
with TMC. In another study, Huang et al. (2005) have shown that inhaled chitosan 
microparticles at a dose of 2-10 mg/kg induced dose-dependent proinflammatory effects in 
rat lungs which were manifested by an  increase in biochemical parameters like  
bronchoalveolar lavage fluid protein (BALF-P) and lactate dehydrogenease activity (BALF-
LDH) and increases in lung tissue myeloperoxidase (MPO) activity and leukocyte migration.  
Choi et al. (2010) reported increased expression of pro-inflammatory cytokines (IL-1β, IL-6, 
and TNF-α) and chemokine (MIP-1α) in lung 1 to 24 h after intratracheal instillation of 
hydrophobically modified glycol-chitosan nanoparticles into mice. According to a report by 
Witschi & Mrsny (1999), chitosan microparticles, applied apically, induced basolateral 
release of IL-6 and IL-8 from polarized Calu-3 cells. However, release of other cytokines, such 
as IL-1β, TNF-α, GM-CSF and TGF-β, were not affected. Some authors, however, reported 
opposite findings. For example, Sivadas et al. (2008) studied IL-8 release from Calu-3 cell 
monolayers treated with protein-loaded inhalable microparticles of a range of polymers 
including chitosan, hydroxypropyl cellulose (HPC), hyaluronic acid, alginate, gelatin, 
ovalbumin and poly(lactide-co-glycolide) (PLGA) on the pulmonary epithelium. After 4 h of 
apical exposure to the polymeric microparticles, only PLGA and gelatin microparticles were 
found to cause a significant increase in IL-8 release. In a study by Mura et al. (2011)  PLGA-
chitosan nanoparticles were demonstrated not to induce an increase in IL-6 or IL-8 levels 
upon incubation with Calu-3 cells in concentrations up to 0.2 mg/mL. 
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2.10.4 Interleukin-8 (IL-8) 
IL-8 is the best characterized member of the family of chemokines — the proinflammatory 
cytokines that chemoattract and activate blood cells (Ben-Baruch et al., 1995; Oppenheim et 
al., 1991). This chemokine has a wide range of proinflammatory properties ranging from its 
main function as chemoattractant for neutrophils, basophils and a subpopulation of 
lymphocytes to activation of neutrophils (Fitzgerald, 2001). Besides its central role in 
inflammation, other biological functions of IL-8 include T cell chemotaxis (Taub et al., 1996), 
angiogenesis (Koch et al., 1992), and hematopoiesis (Cacalano et al., 1994). Expression of 
this chemokine is a typical characteristic of pulmonary inflammatory and immune conditions 
(Erger & Casale, 1998; Pease & Sabroe, 2002).  It is produced in abundance by mononuclear 
phagocytic cells as well as a number of non-inflammatory cells including fibroblasts and 
pulmonary epithelial cells (Kunkel et al., 1991).  
 
2.10.5 BEAS-2B – the In Vitro Cell Model for the Assessment of Toxicity and 
Inflammatory Activity 
BEAS-2B (Reddel et al., 1988) is an adenovirus 12-SV40 virus hybrid (Ad12SV40) transformed 
human epithelial cell line, which was isolated from normal human bronchial epithelium 
obtained from autopsy of noncancerous individuals. It has been reported that cultures of 
BEAS-2B S.6 cells can develop significant trans-epithelial resistance and exhibit tight junction 
formation (Wan et al., 2000). The cell line has also been used as an established in vitro 
model of induced IL-8 secretion after treatment with various model inflammatory stimuli 
such as tumor necrosis factor-α (TNF-α), ozone, or air pollution particles (Devlin et al., 1994; 
Lakshminarayanan et al., 1997; Quay et al., 1998). Unlike some malignant pulmonary 
epithelial cell lines like Calu-3 and A-549 as reported above, no study has so far been 
performed on this cell line to investigate the impact of chitosan or its derivatives on the cell 
viability, trans-epithelial permeability or inflammatory response.  It can be considered 
intriguing to explore the effect of chitosan and its L-leucine conjugate on this cell line that 
will not merely assess their safety, but will also provide information about the behaviour of 
a non-malignant respiratory epithelial cell line in response to them.   
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2.11 Model Drug: Diltiazem Hydrochloride (a systemically acting 
antihypertensive Agent)  
Diltiazem hydrochloride (DH) (Fig. 2-16) is a benzothiazepine calcium channel blocker.  It has 
widely been used in the treatment of hypertension, angina and cardiac arrhythmias (Buckley 
et al., 1990). In recent past, a large prospective study demonstrated that diltiazem was as 
effective as β-blockers and thiazide diuretics in preventing cardiovascular events in 
hypertensive patients (Hansson et al., 2000). Thus, from  an  evidence-based  point  of  view,  
diltiazem appears to be a first-line alternative among antihypertensive drugs. The drug has a 
relatively short half-life (3–5 h) and is usually administered 3–4 times daily in the form of an 
immediate release formulation (Buckley et al., 1990). After oral administration, the drug 
undergoes extensive first-pass metabolism giving an absolute bioavailability of only about 
40% with a large inter-individual variation (Buckley et al., 1990; Yeung et al., 1993). Lee et al. 
(1991) reported that the extraction ratios of diltiazem in the small intestine and the liver 
were about 85% and 63%, respectively after an oral administration to rats, suggesting that 
both the small intestine and the liver had a significant contribution to the first-pass 
elimination of the drug.  
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Figure 2- 16: The Structure of Diltiazem Hydrochloride 
 
In order to improve its bioavailability and ensure a more uniform blood profile, researchers 
are trying to employ other routes, including transdermal, buccal and nasal routes, as non-
invasive alternatives to the oral route for the delivery of the drug. But, to our knowledge, no 
effort has so far been made to explore the potential of the pulmonary route as a mode of 
delivery of the drug for the treatment of systemic hypertension. Given the enormous 
vasculature and extensive surface area for absorption, absence of variability of pH found in 
different regions of GIT and avoidance of extensive intestinal and hepatic metabolism, the 
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lungs can be a promising alternative to the oral route that has the potential to assure better 
bioavailability of the drug with a reduced dose. So, it will be interesting to explore the 
potential of designing a DPI formulation using diltiazem as the model drug.  
 
  
 
  
 
 
 
 
  
 
Chapter 3 General Methods 
 
 
40 
 
3.1 REAGENTS AND MATERIALS 
3.1.1 For Synthesis 
Low molecular weight chitosan (DDA 92%, MW 50-190 kDa), used as the starting material 
for the synthetic studies, was obtained from Sigma-Aldrich, Australia. Phthalic anhydride, 
acetic anhydride, trityl chloride, aqueous hydrazine hydrate (50-60%), Boc-L-leucine 
succinimide (Boc-leu-OSu) and 4M HCl in 1, 4-dioxane were used as the reagents at various 
steps of the synthesis. Phthalic anhydride was a Merck Schuchardt (Germany) product. All 
other reagents were supplied by Sigma-Aldrich (Australia) and were used as received 
without any further purification. N, N-Dimethylformamide (DMF) and pyridine were used as 
solvents. Both were Sigma-Aldrich (Australia) products. Pyridine was stored over 4 Å 
molecular sieves to prevent moisture absorption. Methanol (Chem-Supply, Australia), 
ethanol (Recochem, Australia) and diethyl ether (Merck, Australia) were used for 
precipitation and purification of reaction products. CDCl3, Pyridine-d5 and D2O were used for 
NMR characterization of synthetic products. They all were obtained from Sigma-Aldrich 
(Australia).  
  
3.1.2 For Pharmaceutical Studies 
Chitosan (as above) was used as the polymeric matrix for the preparation of nanoparticles. 
2% aq. solution of glacial acetic acid (Merck, Australia) was used for dissolution of chitosan. 
Paraffin oil heavy 68, viscosity: 66.0-70.0 cST @ 40 °C (Chem-Supply, Australia) was used as 
the external phase for the emulsification process and as the dispersant for Zetasizer analysis 
of nanoparticles. Span 80 (Professional Compounding Chemists of Australia — PCCA) was 
used as the emulsifier. 50% aqueous glutaradehyde (Merck, Australia) was used as cross-
linker for nanoparticle fabrication. Hexane (Merck, Australia) was used for washing off oil 
from nanoparticles and for preparing nanoparticle suspensions for SEM analysis. Di-ethyl 
ether (as above) was used for removing residual glutaraldehyde from nanoparticles. 
Diltiazem HCl (DH — a gift from Alpha-Pharm, Australia) was used as the model drug for 
nanoparticle formulations. Phosphate-buffered saline (PBS), pH 7.3±0.2 (Oxoid, England) 
was used as the release medium for the drug release study. The lactose monohydrate 
(Inhalac® 120) used in carrier-based dispersibility tests was obtained from Meggle Excipients 
and Technology, Germany. 
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3.1.3 For Cell Line Studies 
The bronchial epithelial cell line, BEAS-2B was a gift from Prof Philip Hansbro (School of 
Biomedical Sciences and Pharmacy, The University of Newcastle, Australia). Rosewell Park 
Memorial Institute, RPMI 1640 (Gibco®), foetal bovine serum, FBS (Lonza), L-glutamine 
(Gibco®) and Penicillin-Streptomycin (Gibco®) were used as the ingredients of the cell 
culture medium. These were supplied by Life Technologies Australia Pty. Ltd. 3(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, MTT and dimethyl sulfoxide, DMSO 
(spectrophotometric grade), used for cytotoxicity assay, were obtained from Sigma-Aldrich 
(Australia). Sodium fluorescein, Na Flu (Sigma-Aldrich, Australia) was used as a paracellular 
marker for trans-epithelial permeability experiments. Analysis of the cytokine, IL-8 was done 
by Human IL-8 ELISA MAXTM Deluxe kit (Biolegend, USA). 0.5% Trypsin-EDTA (Gibco®, Life 
Technologies, Australia), diluted to 0.01% in PBS, was used for splitting cells. 
3.2 METHODS 
This section describes the experimental methods followed in course of this research project 
to achieve the stated aims and objectives. Broadly speaking, the experiments performed to 
this end may be considered in three general headings: 
a) Conjuation of chitosan with L-leucine 
b) Preparation of chitosan and chitosan-L-Leucine conjugate nanoparticles and in vitro 
studies on their aerosolization performance and drug release 
c) In vitro evaluation of toxicity and inflammatory activity on the pulmonary epithelial 
cell line, BEAS-2B 
 
A bird’s eye view of the methods followed in this work is presented in the Fig.3-1. 
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Figure 3- 1: A Bird's Eye View of the Whole Project 
 
3.2.1 Conjugation of Chitosan with L-Leucine 
3.2.1.1 Characterization 
The synthetic products were characterized by Fourier transform infrared (FTIR) and 1H and 
13C nuclear magnetic resonance (NMR) spectroscopy and elemental analysis. The last two 
products in the synthetic pathway, 6-O-trityl-chitosan-N-Boc-L-leucine and chitosan-L-
leucine.HCl, being new to the existing literature, were also characterized by 2D 1H-13C 
gradient-enhanced heteronuclear single quantum correlation (ge-HSQC) NMR spectroscopy. 
The final product, chitosan-N-L-leucine. HCl was further characterized by X-ray 
photoelectron spectroscopy (XPS). XPS analysis was also performed on chitosan and              
L-Leucine for comparison. 
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3.2.1.1.1 Fourier Transform Infrared (FTIR) Spectroscopy  
Infrared spectra were recorded on a Nicolet 5700 FT-IR ATR spectrophotometer (Thermo 
Electron Corporation, Madison, Wisconsin, USA) equipped with a Smart Endurance diamond 
internal reflection element (IRE) under dry air at ambient temperature (25   ͦC). The spectra 
were collected by using standard spectral collection techniques and the software Omnic 32 
over the wave number range 4000–650 cm−1 using 64 scans at a resolution of 4 cm−1. 
 
3.2.1.1.2 Nuclear Magnetic Resonance (NMR) Spectroscopy 
1H, 13C and 2D HSQC NMR spectra were recorded on a Bruker AVANCE 400 high resolution 
spectrometer (Bruker BioSpin GmbH, Germany) using QNP quad nucleus probe (tunable for 
1H, 19F, 31P, 13C) under a static magnetic field of 400 and 100 MHz, respectively, at 298K. 
Spectra of 16384 data points were recorded over a spectral width of 12.0144 ppm using the 
accumulation of 32 transients and an exponential line broadening (LB) of 0.30 Hz was 
applied prior to Fourier transformation for 1H NMR. 13C NMR spectra were recorded over a 
spectral window of 219.8552 ppm with 16384 data points and 6144 transients using proton 
decoupling. Prior to Fourier transformation, 2.00 Hz LB was applied. The 1H-13C ge-HSQC 
experiments were performed in phase-sensitive mode using Echo/Antiecho-TPPI gradient 
selection. The data matrix was 256 x 2048 with spectral widths of 4807.69 Hz for proton and 
18,115.94 Hz for carbon. The evolution time was set to 1/(8JCH) = 0.89 ms. Four gradients 
pulses were applied along the z axis with  ratios of 80,  20.1,  11 and  -5, respectively and a 
duration of 1 ms. 18 transients were accumulated for each increment. A square sine window 
function was applied in both dimensions prior to Fourier transformation. CDCl3, pyridine-d5 
and D2O were the solvents used for preparing NMR solutions of the intermediates and the 
final product according to their solubility. A concentration of approximately 1 mmol was 
used for preparing the NMR samples. After adding the sample to the solvent in a vial, it was 
stirred for several hours on a magnetic stirrer to thoroughly mix and dissolve it, and finally 
centrifuged to settle down any un-dissolved solid. Approximately 0.6 mL of the sample 
solution was transferred to a 5 mm NMR tube, which was inserted in the magnet to perform 
the experiment. Chemical shifts were recorded in parts per million (ppm) and were 
referenced to solvent peaks (at 7.24 ppm and 77.23 ppm, for example, for 1H and 13C NMR in 
CDCl3). 
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3.2.1.1.3 Elemental Analysis 
Elemental analyses were performed by the Microanalytical Service, School of Chemistry and 
Molecular Biosciences, the University of Queensland. The samples were extensively (ca.       
24 h) dried in vacuo at 60 °C. The C/N ratio determined with elemental analysis was used to 
evaluate the degree of substitution (DS) of the intermediates and the final product. 
 
3.2.1.1.4 X-ray Photoelectron Spectroscopy (XPS) 
The XPS analysis of chitosan, L-leucine and chitosan-N-L-leucine.HCl was performed with a 
Kratos Axis Ultra Spectrophotometer (Kratos Analytical, Manchester, UK) equipped with 
monochromatized Aluminium X-ray source (powered at 10 mA and 15 KV), 165 mm radius 
hemispherical analyser (HSA) and 8-channel electron multiplier (channeltron) detection 
system. Samples were mounted onto stainless steel sample holders using double-sided 
adhesive tape and the spectra were collected using an analysis area of 700 x 300 µm. Low-
resolution wide scans (survey spectrum) in the binding energy scale (0–1200 eV with 1.0 eV 
steps) were collected at a constant analyser pass energy of 160 eV to identify the elements 
present. High-resolution narrow scans (multiplex spectra) were collected at 20 eV with    
0.05 eV steps for O1s, N1s, C1s, and Cl2p to identify their chemical status. The data were 
processed using Casa XPS software Version 2.3.14.  Binding energies (BE) of the various 
elements were referenced to the C1s line at 285.0 eV. 
     
3.2.1.2 Synthesis 
The sequence of steps followed in the synthesis of chitosan-N-L-Leucine.HCl (6) from 
chitosan (1) are shown in the Fig. 3-2. Fig. 3-3 shows the schemes followed for the synthesis 
of N-phthaloyl-3,6-di-O-acetyl-chitosan (2a) and N-phthaloyl-3-O-acetyl-6-O-trityl-chitosan 
(3a) — two additional products with enhanced solubility synthesized as a tool for further 
structural elucidation and confirmation of the intermediates, N-phthaloyl-chitosan (2) and 
N-phthaloyl-6-O-trityl-chitosan (3). 
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Figure 3- 2: Synthetic Pathway for Conjugation of L-leucine to Chitosan (1) 
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3.2.1.2.1 N-Phthaloyl-chitosan (2) 
N-Phthaloyl-chitosoan (2) was synthesized according to the method of Holappa et al. (2004) 
with some modifications. Briefly, phthalic anhydride (2.43 g, 16.4 mmol) was added to a 
dispersion of chitosan obtained by overnight stirring of chitosan (1 g, 5.48 mmol free –NH2 
group) in DMF (20 mL) containing 5% (v/v) water. The mixture was heated with stirring at 
130 °C for 8 h, cooled to room temperature and finally poured into ice water. The 
precipitate was collected by filtration, washed with copious amounts of methanol and dried 
to give 1.56 g (94.70%) of a pale tan powder. DS: 0.91. IR (ATR): ν 3700-3100 (O─H stretch 
overlapping N─H stretch), 2980-2830 (C─H stretch, pyranose), 1774 (C=O stretch, imide), 
1703 (C=O stretch, imide), 1612 (amide I, N-acetyl), 1547 (N─H bend overlapping amide II), 
1468 (asymmetric C─H bend in CH2), 1385 (C=C, phth), 1200-800 (C-O stretch, pyranose), 
718 cm-1 (arom, phthaloyl).  Elemental Analysis: Calcd.:  C, 53.73; H, 5.00; N, 4.63. Found:  C, 
51.25; H, 4.87; N, 4.44. 
 
3.2.1.2.2 N-Phthaloyl-3,6-Di-O-acetyl-chitosan (2a)  
N-Phthaloyl-3,6-Di-O-acetyl-chitosan (2a) was synthesized following the method described 
by Nishimura et al. (1991) with few modifications. In brief, acetic anhydride (10 mL, 105.8 
mmol) was added to a suspension of N-phthaloyl-chitosan 2 (100 mg, 0.33 mmol) in pyridine 
(20 mL) and heated with stirring at 130 °C overnight. The resulting homogeneous mixture 
was cooled to room temperature and precipitated in ice-water (60 mL). The precipitate was 
washed successively with ethanol and ether and dried to give 124 mg of 2a (97%). DS: 1.97. 
IR (ATR): ν 3700-3100 (O─H stretch overlapping N─H stretch), 2980-2830 (C─H stretch, 
pyranose), 1777 (C=O stretch, imide), 1743(C=O stretch, O-acetyl ester), 1711(C=O stretch, 
imide), 1613 (amide I, N-acetyl), 1543 (N─H bend overlapping amide II), 1469 (asymmetric 
C─H bend in CH2), 1430 (asymmetric  C─H bend in CH3), 1385 (C=C, phth), 1371 (symmetric  
C─H bend in CH3), 1219 (C─O stretch, O-acetyl), 1200-800 (C-O stretch, pyranose), 722 cm-1 
(arom, phthaloyl). 1H NMR (CDCl3): δ 1.63-2.19 (0- and N-acetyl), 2.80-5.90 (pyranose), 7.68, 
7.74 ppm (arom, phth). 13C NMR (CDCl3): δ 20.4 -20.8 (0- and N-acetyl), 55.3 (C-2), 62.1 (C-6), 
70.2 (C-3), 72.4 (C-5), and 75.3 (C-4), 97.2 (C-1), 124.0, 131.3 and 134.6 (arom, phth), 167.7-
170.2 ppm (C=O). Elemental Analysis: Calcd.: C, 54.47; H, 4.96; N, 3.63. Found: C, 54.48; H, 
4.88; N, 3.66. 
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3.2.1.2.3 N-Phthaloyl-6-O-trityl-chitosan (3) 
N-Phthaloyl-6-O-trityl-chitosan (3) was synthesized from N-phthaloyl-chitosan (2) according 
to the method of Zhang et al. (2008a) with few modifications. Briefly, N-phthaloyl-chitosan 2 
(1 g, 3.32 mmol free ─OH), suspended in pyridine (47 mL), was treated with trityl chloride 
(9.23 g, 33.1 mmol), stirred with heating at reflux (~115 °C) for 24 hours under Argon. After 
cooling to room temperature, the reaction mixture was poured into EtOH. The precipitate 
was collected by filtration and washed successively with EtOH and Et2O.  The yield of the 
product was 1.45 g (80%). DS: 1.06. IR (KBR): ν 3700-3100 (O─H stretch overlapping N─H 
stretch), 3100-3000 (C─H, trityl), 2980-2830 (C─H, pyranose and CH3), 1776 (C=O, imide), 
1712 (C=O, imide), 1611 (amide I, N-acetyl), 1591 (N─H bend overlapping amide II), 1490 
(C=C, trityl), 1468 (asymmetric C─H bend in CH2), 1448 (C=C, trityl), 1384 (C=C, phth) 1200-
800 (C-O, pyranose), 764 (arom, trityl), 746 (arom, trityl), 719 (arom, phth), 699 cm-1 (arom, 
trityl). Elemental Analysis: Calcd.:  C, 71.72; H, 5.38; N, 2.57. Found: C, 71.91; H, 5.27; N, 
2.50. 
 
3.2.1.2.4 N-Phthaloyl-3-O-acetyl-6-O-trityl-chitosan (3a)  
N-Phthaloyl-3-O-acetyl-6-O-trityl-chitosan (3a) was synthesized following the same 
procedure as described above for N-phthaloyl-3,6-di-O-acetyl-chitosan (2a). In brief, acetic 
anhydride (10 mL, 105.8 mmol) was added to a suspension of N-phthaloyl-6-O-trityl-chitosan 
3 (100 mg, 0.18 mmol) in pyridine (20 mL) and heated overnight at 130 °C with reflux. The 
resulting solution was cooled to room temperature and precipitated by pouring into ice-
water (60 mL). The precipitate was collected by filtration, washed successively with ethanol 
and ether and dried to give a yield of 90 mg. This was 83% of the theoretical yield assuming 
that 100% substitution has taken place. The microanalysis results were not satisfactory and 
so could not be used for calculating the actual DS. IR (ATR): ν 3700-3100 (O─H stretch 
overlapping N─H stretch), 3100-3000 (C─H, trityl), 2980-2830 (C-H stretch, pyranose and 
CH3), 1777 (C=O stretch, imide), 1745 (C=O stretch, O-acetyl ester), 1714 (C=O stretch, 
imide), 1612 (amide I, N-acetyl), 1595 (N─H bend), 1547 (amide II, N-acetyl), 1529 (C=C, 
trityl), 1491 (C=C, trityl), 1468 (asymmetric C─H bend in CH2), 1449 (C=C, trityl), 1385 (C=C, 
phth), 1220 (C─O stretch, O-acetyl), 1200-800  (C-O stretch, pyranose), 765 (arom, trityl), 
747 (arom, trityl), 721 (arom, phthaloyl),  704 cm-1 (arom, trityl). 1H NMR (CDCl3): δ 1.63-2.05 
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(0- and N-acetyl), 3.00-5.80 (pyranose), 6.89-7.28 (arom, trityl associated with residual 
solvent peak at 7.24), 7.68, 7.74 ppm (arom, phth). 13C NMR (CDCl3): δ 20.4 -20.8 (0- and N-
acetyl), 55.3 (C-2), 62.1 (C-6), 70.2 (C-3), 72.4 (C-5), and 75.3 (C-4), 97.2 (C-1), 123.9-147.0 
(arom, trityl and phth), 167.8-170.3 (C=O, N-acetyl and phth). Elemental Analysis: Calcd.:      
C, 70.68; H, 5.33; N, 2.39. Found: C, 61.65; H, 4.89; N, 3.05. 
 
3.2.1.2.5 6-O-Trityl-chitosan (4) 
Deprotection of the phthaloyl group from N-phthaloyl-6-O-trityl-chitosan (3) to produce       
6-O-trityl-chitosan (4) was performed according to the methods reported by other 
investigators (Nishimura et al., 1991; Zhang et al., 2008a) with some modifications. Briefly, a 
suspension of N-phthaloyl-6-O-trityl-chitosan 3 (1 g, 1.84 mmol ─NH2 group equivalent) in 
hydrazine hydrate (50-60%, 50 mL) was stirred with heating at reflux (~110 °C) for 18 hours 
under an argon atmosphere. The reaction mixture was cooled to room temperature and 
poured into water (500 mL). The precipitate was filtered off and washed with water (2 x 500 
mL) and finally with ethanol and ether. The yield of the product was 0.75 g (96%). 
Microanalytical data was unsatisfactory to calculate the actual degree of dephthaloylation. 
However, FT-IR and 1H NMR spectra indicate complete removal of the phthaloyl group.  IR 
(ATR): ν 3700-3100 (O─H stretch overlapping N─H stretch), 3100-3000 (C─H, trityl), 2980-
2830 (C─H, pyranose and CH3), 1661 (amide I, N-acetyl), 1596 (amide II overlapping N─H 
bend), 1490 (C=C, trityl), 1448 (C=C, trityl), 1374 (symmetric  C─H bend in CH3), 1318    
(amide III),  1200-800 (C-O, pyranose), 763 (arom, trityl), 746 (arom, trityl), 697 cm-1 (arom, 
trityl). 1H NMR: δ 1.67-2.13 (CH3, N-acetyl), 3.00-5.79 (pyranose), 7.28, 7.38, 7.79 ppm 
(arom, trityl). Elemental Analysis: Calcd.: C, 71.13; H, 6.44; N, 3.30. Found: C, 71.14; H, 6.13; 
N, 3.54.  
 
3.2.1.2.6 6-O-Trityl-chitosan-N-Boc-L-leucine (5) 
A solution of Boc-leu-OSu (1.16 g, 3.53 mmol) in pyridine (15 mL) was added drop-wise to    
6-O-trityl-chitosan 4 (500 mg, 1.18 mmol -NH2 group equivalent) at an ice-cooled 
temperature over a period of about 1 h under an argon atmosphere and the reaction 
mixture was stirred for 3 h at 0 °C. An additional 772.88 mg (2.35 mmol) of Boc-leu-OSu in 
pyridine (10 mL) was then added drop-wise to the reaction mixture and the reaction was 
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continued at room temperature under argon for a further 21 h until a clear solution was 
obtained. Finally, the product was precipitated by pouring the reaction mixture into diethyl 
ether (250 mL). The precipitate was washed with di-ethyl ether (x 3) and dried to give        
485 mg (70%) of 6-O-trityl-chitosan-N-Boc-L-leucine (5) as a solid. DS: 0.74. IR (ATR): ν 3700-
3100 (O─H stretch overlapping N─H stretch), 3100-3000 (C─H, trityl), 2980-2830 (C─H, 
pyranose & Boc-Leucine), 1683 (amide I, N-acetyl,  N-L-leucine and N-carbamide), 1597 
(amide II overlapping N─H bend), 1491 (C=C, trityl), 1448 (C=C, trityl), 1390 and 1367 (Boc     
t-butyl and leucine isopropyl), 1319 (amide III),  1200-800 (C-O, pyranose), 764 (arom, trityl), 
747 (arom, trityl), 702cm-1 (arom, trityl). 1H NMR: δ 0.90 (H-δ1, leu), 1.27 (H-γ, leu 
overlapped with t-butyl, Boc), 1.44 (t-butyl, Boc overlapped with CH3, N-acetyl at 1.66 ppm), 
1.92 (H-β, leu overlapped with H-δ1), 2.15 (CH3, N-acetyl), 2.65 (H-δ2, leu), 3.00-5.5 
(pyranose protons overlapped with H-α, leu at 4.51), 7.28, 7.40 and 7.78 ppm (arom, trityl).   
13C NMR (CDCl3): δ 20.7-23.8 (CH3, N-acetyl), 25.3 & 26.4 (C-δ1&2, leu), 28.9 (t-butyl, Boc), 
30.3 (C-γ, leu),  43.0 (C-β, leu), 54.5 (C-α, leu), 56.3 (C-2), 58.4 (C-6), 72.6 (C-3), 75.8 (C-5), 
77.4 (C-4), 79.2 (C(CH3)3), 87.1 (C-Ph3),  97.4, 101.0, 102.0, 104.5 and 104.8 (C-1), 127.8, 
128.7, 129.9, & 145.0 (arom, trityl), 156.9 (C=O, carbamide), 173.6 (C=O, N-leu), 176.3 ppm 
(C=O, N-acetyl). Elemental Analysis: Calcd.: C, 68.23; H, 7.25; N, 4.33. Found: C, 67.98; H, 
6.78; N, 4.14. 
 
3.2.1.2.7 Chitosan-N-L-leucine.HCl (6) 
4M HCl in 1, 4-dioxane (4 mL) was added drop-wise to 6-O-trityl-chitosan-N-Boc-L-Leucine 5 
(200 mg, 343 µmol) at ice-cold temperature under an argon atmosphere and stirred for       
15 min at this temperature. Stirring was continued at room temperature under argon for    
24 h. The reaction mixture was poured into di-ethyl ether (40 mL), filtered off, washed with 
ether (x 3) and dried to give the product, chitosan-N-L-Leucine.HCl 6 (80 mg, 66%). The 
microanlaytical data suggest that 91% of the protecting Boc and triytl groups have been 
removed. IR (ATR): ν 3700-3100 (O─H stretch overlapping N─H stretch), 2980-2830 (C─H, 
pyranose & L-leucine), 1672 & 1628 (amide I, N-acetyl overlapping N-L-leucine), 1558 & 1512 
(amide II overlapping symmetric N─H bend in NH3
+), 1390 and 1372 (isopropyl, leu), 1322 
(amide III), 1200-800 cm-1 (C-O, pyranose). 1H NMR: δ 0.98 (H-δ1&2, leu), 1.78 (H-δ2 and H-β 
of leu with some overlapping with H-δ1 and H-γ), 2.07 (N-acetyl and H-δ1, leu), 2.80 (H-γ, 
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leu), 3.19 (H-2, pyranose), 3.30-4.34 (H-2 to H-6, pyranose overlapped with H-α and H-β of 
leu), 4.50-5.54 ppm (H-1, pyranose), 13C NMR (CDCl3): δ 20.7 (CH3, N-acetyl), 21.7 & 23.5    
(C-δ1&2, leu), 25.0 (C-γ, leu), 40.0 (C-β, leu), 52.0 (C-α, leu), 55.6 (C-2), 59.8 (C-6), 69.-76.1   
(C-3, C-5, C-4), 97.3-101.1 (C-1), 170.8 (C=O, N-leu), 174.4 ppm (C=O, N-acetyl). Elemental 
Analysis: Calcd.: C, 43.81; H, 7.62; N, 8.40. Found: C, 36.84; H, 7.14; N, 6.93. XPS Analysis 
(Atom%): Chitosan: O, 28.59; C, 63.02; N, 7.34, Cl 1.05. L-leucine: O, 19.40; C, 69.44;              
N, 11.55. Chitosan-N-L-leucine.HCl: O, 25.68; C, 60.99; N, 9.31; F, 0.64; Cl, 3.38. 
 
3.2.2 Preparation of Chitosan and Chitosan-L-Leucine Conjugate Nanoparticles and 
In Vitro Studies on their Aerosolization Performance and Drug Release  
 
3.2.2.1 Preparation of Chitosan and Chitosan-L-leucine Conjugate Nanoparticles 
Chitosan and chitosan-L-leucine conjugate nanoparticles were prepared by water-in-oil 
(W/O) emulsification process in two different ways, viz. 1) emulsion-solvent evaporation and 
2) emulsion-glutaraldehyde cross-linking. Both the approaches shared a common initial step 
of emulsifying an aqueous solution of the polymer (with or without drug) into nano-droplets 
in heavy paraffin oil with a high-shear homogenizer, Heidolph Diax 900 (Sigma-Aldrich Pty 
Ltd., Australia). The droplets in the resulting water-in-oil (W/O) emulsion were then 
hardened into nanoparticles either by applying heat to evaporate the aqueous phase 
(Method-1) or by cross-linking with glutaraldehyde (Method-2). 
 
3.2.2.1.1 W/O Emulsion-Solvent Evaporation Method  
In this approach, chitosan and conjugate nanoparticles were prepared by a technique 
modified from that reported previously for fabrication of chitosan microparticles (Abd El-
Hameed & Kellaway, 1997; Lim et al., 2000; Onishi et al., 2005). In brief, for fabricating blank 
chitosan nanoparticles, 2.5 mL of a 2% solution of chitosan in 2% acetic acid was added 
drop-wise at a temperature of 60 °C to 100 g heavy paraffin oil containing 1 mL span 80 and 
homogenized into a W/O emulsion at 11,000 rpm for 10 min. The emulsion was stirred 
overnight at 5000 rpm and 60 °C using an IKa® Eurostar Digital overhead stirrer (IKA® Works 
(Asia), Inc.) to remove the internal water phase and harden the droplets into nanoparticles. 
Then, the nanoparticles were separated from the oil phase by centrifugation overnight at 
5,000 x g using an Allegra X15R Bench top Centrifuge (Beckman-Coulter, Inc. USA), washed 3 
times with hexane to remove excess oil and dried under vacuum at 60 °C.  
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For making blank chitosan-L-leucine conjugate nanoparticles, the same protocol was 
followed except that, being freely soluble in water, no acetic acid was required for preparing 
the solution of the conjugate in water. 
 
For preparing drug-loaded chitosan and conjugate nanoparticles, 50% of the polymer was 
replaced by the drug, DH. All other conditions were kept unchanged. To clarify, a solution 
containing 1% each of chitosan and DH in 2% acetic acid was added drop-wise at a 
temperature of 60 °C to 100 g heavy paraffin oil containing 1 mL span 80 and homogenized 
into a W/O emulsion at 11,000 rpm for 10 min. The emulsion was stirred overnight at 5000 
rpm and 60 °C using an IKa® Eurostar Digital overhead stirrer (IKA® Works (Asia), Inc.) to 
remove the internal water phase and harden the droplets into nanoparticles. Then, the 
nanoparticles were separated from the oil phase by centrifugation overnight at 5,000 x g 
using an Allegra X15R Bench top Centrifuge (Beckman-Coulter, Inc. USA), washed 3 times 
with hexane to remove excess oil and dried under vacuum at 60 °C. 
 
3.2.2.1.2 W/O Emulsion-Glutaraldehyde Crosslinking Method 
In this approach, the same protocol was followed as described above except that no heat 
was applied either during emulsification of the aqueous polymeric solution into the oil or 
later. Instead, for hardening of the droplets into particles, a 50% aqueous solution of 
glutaraldehyde (1 mL and 0.75 mL per 25 mg of chitosan and conjugate, respectively) was 
added and the mixture was stirred as above at 5000 rpm for 12 h. The addition of the 
glutaraldehyde solution was done in 3 portions (1 × 0.5 mL and 2 × 0.25 mL for chitosan and 
3 × 0.25 mL for the conjugate) at intervals of 10 minutes, 1 hour and 2 hour as reported 
previously by Deveswaran et al.  (2007). Then, the nanoparticles were separated from the oil 
phase by centrifugation overnight at 5,000 x g using an Allegra X15R Bench top Centrifuge 
(Beckman-Coulter, Inc. USA), washed 3 times with hexane to remove excess oil. Finally,  the  
isolated  particles  were  additionally  washed  3-5  times  with  diethyl  ether  to remove 
residual glutaraldehyde. Water and ethanol were not considered appropriate for this 
purpose to avoid leaching of the drug, DH, which is highly soluble in these solvents. 
Chapter 3 General Methods 
 
 
52 
 
 
Figure 3- 4: A Simplified Scheme of Methods Used for the Preparation of Nanoparticles 
[N.B. : Method 1 — Emusion- solvent evaporation, Method-2 — Emulsion- glutaraldehyde crosslinking] 
 
3.2.2.2 Scanning Electron Microscopy 
The size, shape and surface morphology of chitosan and chitosan-L-leucine conjugate 
nanoparticles were investigated by scanning electron microscopy (SEM).  The SEM imaging 
was done on an ultra-high resolution scanning electron microscope, JEOL 7001F (JEOL 
Australasia Pty Ltd, Frenchs Forest, Australia). A tiny drop (5 μL) of nanoparticle suspension 
in hexane (100 µg/mL) was placed on carbon adhesive tape adhered onto a properly labelled 
aluminium stub. The specimen stubs were then sputter coated with a thin layer of gold with 
a Leica EM SCD005 sputter coater (Leica Microsystems, North Ryde, Australia) at 30 mA for 
1.5 min using an argon gas purge. The specimens were examined with the SEM under high 
vacuum using a spot size of 10 with an accelerating voltage of 20.0 kV and a working 
distance (WD) of 10 mm. Several photomicrographs (secondary electron images) of the 
samples were recorded at different magnifications. 
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3.2.2.3 Zetasizer Analysis 
The size distribution and polydispersity index (PDI) of chitosan and chitosan-L-leucine 
conjugate nanoparticles were measured by dynamic light scattering (DLS) using a ZetaSizer 
Nano S instrument (Malvern Instruments Ltd., UK) equipped with a 4 mW He–Ne laser 
operating at a wavelength of 633 nm. The analysis was performed at 25 °C with a detection 
angle of 173°. For analysis, the particles were diluted to an appropriate concentration        
(ca. 0.1%) with heavy mineral oil containing 1% span 80 as the dispersant and placed in a 
glass cuvette with square aperture (Sarstedt AG & Co., Nümbrecht, Germany). The 
measurement was done in triplicate and averaged. The reported size is the Z-average (or 
“cumulants mean”) for the particle hydrodynamic diameters calculated from the intensity of 
scattered light, and the PDI is a width parameter, which was also calculated from the 
cumulants analysis of the signal intensity. Data acquisition and analysis was done by Malvern 
Zetasizer Software version 6.32. The viscosity and refractive index values of the dispersant, 
heavy paraffin oil with 1% span 80 (used for data analysis) were determined to be 73.00 cps 
(at 25 °C) and 1.482, respectively by a Cannon-Fenske Routine Viscometer (Poulten, Selfe 
and Lee, Ltd. England) and an Abbe Refractometer (Atago Co., Ltd., Tokyo, Japan), 
respectively.  
 
3.2.2.4 Estimation of Production Yield, Drug Loading and Entrapment Efficiency 
3.2.2.4.1 Production Yield 
The yields of nanoparticles were quantified as the percentage of anticipated yields. The total 
amount of nanoparticles obtained was weighed and the percentage yield was calculated 
using the following formula (Dandge & Dehghan, 2009):  
 
Production yield (%) = 𝑊1
𝑊2
 x 100                                                                                                         (1) 
Where  W1 = weight of dried nanoparticle 
              W2 = sum of dry weight of the starting materials. 
 
The measurement was done in triplicate (n=3). 
 
 
Chapter 3 General Methods 
 
 
54 
 
3.2.2.4.2 Drug Loading and Entrapment Efficiency 
To determine drug loading and entrapment efficiency, an aliquot (5 mL) of the external oil 
phase was centrifuged to remove the particles. Then, the free drug in the supernatant was 
extracted into an excess of PBS (1:4) and analyzed by UV spectrophotometry (Beckman 
Coulter DU 800 UV/Vis Spectrophotometer, USA) at 235 nm. Each sample was assayed in 
triplicate (n = 3). Amount of drug in the supernatant was subtracted from the total amount 
of drug initially added for making nanoparticles. The drug loading and entrapment efficiency 
were calculated as follows (Chimote & Banerjee, 2009; Grenha et al., 2007): 
 
Drug loading (%) = Total drug−Free drug
Nanoparticle weight  x 100                                                                                    (2) 
 
Entrapment efficiency (%) = Total drug−Free drug
Total drug  x 100                                                                   (3) 
3.2.2.5 In Vitro Drug Release Study 
Drug release from the nanoparticles was studied according to the method reported by 
Masotti et al. (2007) with few modifications. Briefly, an aliquot of nanoparticles equivalent 
to 2.5 mg DH was incubated in 50 mL PBS (pH = 7.3±0.2, 37 °C) under gentle magnetic 
stirring (100 rpm). At fixed time intervals (0.5 h, 1 h, 2 h, 4 h, 6 h, 12 h, 24 h and later every 
24 h up to 30 days), the samples were centrifuged and 5 mL aliquots of supernatant  was 
removed. An equal volume of fresh buffer was replaced immediately. The withdrawn 
samples were analysed by UV spectrophotometry. All measurements were performed in 
triplicate (n=3).  
 
To ascertain the release kinetics and the mechanism of release, the release data were 
analysed by fitting to commonly used mathematical models, viz. zero order model, 1st order 
model, Higuchi’s square root model (Higuchi, 1963), Hixson-Crowell model (Hixson & 
Crowell, 1931) and Korsmeyer-Peppas model (Korsmeyer et al., 1983)  according to the 
following equations: 
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Zero order model: F=kot                                                                                                                      (4) 
1st order model: ln (1-F)=-k1t                                                                                                              (5) 
Higuchi model: F=KHt1/2                                                                                                                       (6) 
Hixson-Crowell model: 1-(1-F)1/3=k1/3t                                                                                             (7) 
Korsmeyer-Peppas model: F=kK-Ptn                                                                                                   (8) 
 
where F denotes cumulative fraction of drug released at time t.  k0, k1, kH, k1/3 and kK-P are 
the apparent release rate constants of the respective mathematical models.  
 
n is the release exponent of the Korsmeyer-Peppas model, indicative of the mechanism of 
drug release. n ≤ 0.45 corresponds to a Fickian diffusion (case I transport), 0.45 < n ≤ 0.89 to 
an anomalous (non-Fickian) transport, n = 0.89 to a zero-order (case II) release kinetics, and 
n > 0.89 to a super case II transport. Case II and supercase II transports indicate involvement 
of polymer chain relaxation and erosion in drug release. 
 
The initial loading dose (DL) providing for prompt achievement of the desired blood level and 
the desired maintenance dose release rate (MDR)  to maintain the desired blood level over 
extended period of time can be given by the following equations (Lingam et al., 2008; Prasad 
& Kishore, 2012): 
 
DL = Cd.Vd/F                                                                                                                                            (9) 
 
MDR = ke.Cd.Vd                                                                                                                                    (10) 
 
where Cd is the desired blood level, Vd is the apparent volume of distribution, ke is the first 
order rate constant for overall drug elimination and F is the fraction of the dose absorbed. 
 
For DH, Cd = 0.05 μg/mL, Vd = 3.1 L/Kg and ke = 0.19/h (Prasad & Kishore, 2012). Assuming 
F=1 for the pulmonary route, for a 70-Kg healthy adult the DL and MDR for DH stand out to 
be 10.85 mg and 2.06 mg/h, respectively. 
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3.2.2.6 In Vitro Evaluation of Aerosolization and Lung Deposition 
The aerosolization efficiency of the dry powder inhaler (DPI) formulations (chitosan and 
chitosan-L-leucine conjugate nanoparticles) was investigated in vitro by a Twin Stage 
Impinger (TSI, Copley Scientific, Nottingham, UK) (Fig. 3-5) using the method described in 
the British Pharmacopoeia (TSI apparatus, British Pharmacopoeia, 2013). Rotahaler® (Glaxo 
Wellcome) was used as the DPI device and PBS as the collection liquid in the upper and 
lower stages of the apparatus. 7 mL of PBS was placed in stage-1 (S1) and 30 mL in stage-2 
(S2) of the TSI. PBS was used to maintain a consistency with the spectrometric analyses 
made during drug release study and determination of entrapment efficiency. The airflow 
through the TSI was controlled at 65±5 L/min by a vacuum pump (D-63150, Erweka, 
Germany) using a calibrated digital flow meter (Fisher and Porter, Model 10A3567SAX, UK).  
 
For each actuation, a size 3 hard gelatin capsule (Fawns and McAllan Pty Ltd., Australia) filled 
with 20 mg of nanoparticle formulation was inserted into the Rotahaler placed into a 
moulded mouthpiece attached to the TSI apparatus. The capsule was twisted to release the 
powder into the body of the DPI device. The liberated powder was drawn through the TSI at 
a flow rate of 65±5 L/min for 5 seconds. This procedure was repeated at least three times 
for each formulation. 
 
Each stage (Rotahaler, S1 and S2) was washed separately and collected in appropriate 
vessels. Washings from each stage was filtered repeatedly for at least 5 times through     
pre-weighed nylon filters of 0.20 µm pore size and 47 mm diameter (Phenomenex, USA) 
(that were dried at 60 °C temperature until reaching a constant weight). The filtration was 
repeated until the filtrate became completely free from any sign of turbidity. The filters, 
with retained particles, were dried at 60 °C until a constant weight was reached. The weight 
of the particles deposited was determined by subtracting the weight of blank filter from the 
total weight.  
 
In case of drug-loaded nanoparticles, before collecting by filtration, the volume of washings 
from each section was adjusted to 50 mL and incubated with gentle stirring for an 
appropriate length of time (2 weeks for chitosan nanoparticles and 3 weeks  for conjugate 
nanoparticles)  to allow for the drug release. Finally, the filtrate was analysed for drug 
content by UV spectrophotometry at 235 nm.   
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For carrier-based dispersibility tests, the drug-loaded chitosan and conjugate nanoparticles 
were mixed with inhalation grade lactose monohydrate (Inhalac® 120) microparticles used 
as carriers to make binary interactive mixtures for inhalation by a hand mixing technique 
(Alway et al., 1996; Liu & Stewart, 1998). The nanoparticles (5%) were placed between two 
layers of lactose particles in a glass test tube together with 3 ceramic beads of 
approximately 10 mm in diameter and shaken vigorously for 10 minutes to ensure adequate 
mixing. The ceramic beads provide a ball milling effect for breaking up the aggregates 
formed during the mixing process. 
 
The total amount of particles or drug collected from the inhaler, stage-1 (S1) and stage-2 
(S2) are termed as the recovered dose (RD).   
 
The emitted dose (ED) refers to the fraction of the RD delivered from the inhaler into stages 
1 and 2 expressed as a percentage:  
 
ED = S1+S2 
RD
 x 100                                                                                                                                 (11) 
 
The fine particle fraction (FPF) is defined as the fraction of the RD deposited in the stage-2 of 
TSI expressed as percentage:   
 
FPF =  S2
RD
  x 100                                                                                                                               (12)           
 
Although the rotahaler®, a unit-dose capsule-based DPI device, has been reported to be less 
efficient in producing respirable fraction than many of the recently developed devices (e.g. 
Aeroliser®, Dinkihaler®, Inhalator®) (Louey et al., 2004; Tang et al., 2009), it has been chosen 
for this study because of its simple internal geometry and gentle mechanism for capsule 
emptying and powder deagglomeration (Chan et al., 1997; Xu & Hickey, 2013). Moreover, it 
represents a low-resistance device and so could be readily used by patients with impaired 
lung function at the inspiratory flow rate of 60 L/min used in this study (Clark & Bailey, 
1996).  
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Figure 3- 5: Twin Stage Impinger (TSI) 
 
TSI is an officially approved instrument for the assessment of deposition of the emitted dose 
from inhalation aerosols (British Pharmacopoeia, 2013). Since its first description in the 
literature it has been extensively used and shown to be a convenient and reliable tool for 
distinguishing ‘good’ and ‘poor’ aerosols (Hallworth & Westmoreland, 1987). The apparatus 
was chosen for this study because of its simplicity and ease of operation. It is true that it 
divides the whole sample only into two size categories with a cut-off diameter of 6.4 µm 
(Hiller et al., 1980; Timsina et al., 1994) and the separation between the two categories is 
also not perfectly sharp; but, though multistage devices can give actual size distribution, 
they are slow and tedious because chemical and physical quantification of collected particles 
is very time consuming (Miller et al., 1992). Besides, some investigators (Holzner & Mueller, 
1995) have shown that the fractions below and above 6.4 μm in the TSI and the MSLI     
(multi-stage liquid impinger) were identical. 
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3.2.3 In Vitro Evaluation of Toxicity and Inflammatory Activity on the Pulmonary 
Epithelial Cell Line, BEAS-2B 
 
3.2.3.1 Cell line 
For in vitro toxicological and immunological evaluation of chitosan, its L-leucine conjugate 
and their nanoparticles, the bronchial epithelial cell line, BEAS-2B was used. This is a non-
malignant cell line derived from normal human bronchial epithelial cells immortalized by an 
SV40/adenovirus-12 hybrid virus (Graness et al., 2002; Murphy, 2007). Cell cultures were 
grown using 75 cm2 flasks in a humidified incubator in an atmosphere of 5% CO2/95% air at 
37 °C. The same conditions were maintained for incubation of the cells in the experiments to 
follow. 
 
The cell culture medium (CCM) used consisted of 500 mL RPMI 1640, 50mL FBS (heat-
inactivated), 5 mL L-glutamine (200 mM) and 5 mL penicillin-streptomycin (10K µg/mL). Cells 
were subcultured every 2-3 days when they became nearly confluent. 
 
3.2.3.2 In Vitro Evaluation of Cytotoxicity on the Respiratory Epithelial Cell Line BEAS-2B 
by MTT Assay 
The MTT assay was performed according to previous reports (Grenha et al., 2007; Manca et 
al., 2008) with some modifications. 100 µl of the culture medium containing 5 X 104 cells 
was placed in each of 11 wells in a 96-well plate (Costar®, Corning Incorporated, USA) and 
incubated for 24 hours. Then the medium in 10 wells (each) was replaced with 100 µl fresh 
medium containing a range of concentrations (viz. 0.125, 0.25, 0.375, 0.50, 1.0, 2.0, 4.0, 8.0, 
12.0 and 16.0 mg/mL) of the test material leaving one well untreated for control.  After 12, 
24 or 48 h of cell incubation with the test materials, 50 μl of MTT solution (0.5 mg/mL in 
PBS) was added to each well. The cells were incubated for a further 4 h and the medium was 
removed. The formazan crystals generated by the cells were solubilised with 100 μl DMSO 
and the absorbance of each well was measured by an xMarkTM Microplate 
Spectrophotometer (Bio-Rad Laboratories, USA) at 550 nm and corrected for background 
absorbance using DMSO as the blank. 
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The relative cell viability (%) was calculated as follows: 
 
Viability (%) = 𝐴−𝑆
CM−𝑆
 x 100                                                                                                                  (13)  
 
Where,   
A is the absorbance obtained for the test substance 
S is the absorbance obtained for DMSO (blank) and  
CM is the absorbance obtained for untreated cells (incubated with CCM).  
The latter reading was assumed to correspond to 100% cell viability.  
 
 
Figure 3- 6: A Simplified Scheme of MTT Cell Viability Assay 
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The concentration causing 50% inhibition of cell growth (IC50) was determined by regression 
analysis using the points on the steep portion of the concentration effect curve according to 
Adamson et al. (1991). 
 
The assay was performed on two occasions with 3 replicates of each concentration of the 
test substance in each instance. 
 
3.2.3.3 In Vitro Evaluation of the Effect on the Integrity of Respiratory Epithelium by 
Sodium Fluorescein Transport Assay across BEAS-2B Cell Monolayers 
3.2.3.3.1 Determination of the Polarisation Time of the BEAS-2B Cell Culture by Trans-
Epithelial Electrical Resistance (TEER) Measurement 
To determine the time taken for the cells to get polarised, 200 μl of BEAS-2B cell suspension 
in the cell culture medium was seeded in triplicate at a density of 5 × 105 cells/cm2 in the 
apical chamber of Corning® collagen-coated PTFE transwell inserts (0.4 µm, 0.33 cm2) placed 
on a 24-well plate (Costar®, Corning Incorporated, USA) and 700 μl of medium was added to 
the basolateral chamber. The cells were incubated and the media were replaced every 
alternate day both in the apical and basolateral chambers. A blank (no cell) insert was 
maintained under the same conditions. The TEER across the inserts was measured by 
Millicell ERS Volt-Ohm Meter (Millipore Australia Pty. Ltd.)  at 24 h intervals for 10 days. Net 
TEER was determined by subtracting that measured for a blank insert. The experiment was 
performed twice.  
 
 
 
Figure 3- 7: Transwell Insert 
(adapted from Transwell® Permeable Supports Selection and Use Guide – Corning)   
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3.2.3.3.2 Comparison of the Permeability of a Transwell Containing BEAS-2B Cell 
Monolayer and a Blank Transwell by Sodium Fluorescein Transport Assay 
To compare the permeability of a transwell containing a confluent BEAS-2B cell monolayer 
with that of a blank transwell, the permeability to Na Flu was tested according to the 
method described by Grenha et al. (2007) with some modifications.  Following the same 
protocol as described in the section 3.2.3.3.1, cells were apically seeded in triplicate in 
transwells and incubated. Blank transwell inserts were maintained under the same 
conditions. After 4-5 days when the TEER reached a stable maximum value, 200 μl of 
medium, containing 0.2 mg/mL of Na Flu, was replaced in the apical chamber and incubated 
for equilibration for a further 30 min. Then, 100 μl samples were transferred from 
basolateral chambers to black 96-well plates (Greiner Bio One, Germany) and diluted with 
100 μl of 1 mM NaOH solution. The fluorescence was measured using a fluorometer, 
POLARstar OPTIMA microplate reader   (BMG LABTECH, Inc., USA) setting the excitation and 
emission wavelengths at 485 and 530 nm, respectively. The experiment was repeated twice. 
The concentration of Na Flu was determined from a standard curve drawn concurrently 
from a series of Na Flu concentrations.   
 
The apparent permeability coefficient (Papp) was measured using the following equation: 
Papp (cm/s) = 
d𝑄
d𝑡
   x  1
𝐴𝐶0
                                                                                                                      (14) 
where 
d𝑄
d𝑡
 is the transport rate (cumulative amount of Na Flu, Q permeated across the cell 
monolayers over time, t) 
A is the surface area of the transwell insert (0.33 cm2) and  
C0 is the initial concentration of Na Flu in the apical chamber.  
 
3.2.3.3.3 Effect of Chitosan, Conjugate and their Nanoparticles on the Permeability of 
BEAS-2B Cell Monolayer 
The effect of different concentrations of chitosan, conjugate and their nanoparticles on the 
permeability of polarised BEAS-2B cell monolayer was investigated using Na Flu as a 
permeability marker following the protocol described in the section 3.2.3.3.2. The cells were 
seeded in 5 transwell inserts and incubated. After the cells became confluent, 200 µl of CCM 
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containing the test substance with 0.2 mg/mL of Na Flu was replaced in the apical chamber.  
Four concentrations of the test substance (viz.  0.5, 1, 2 and 4 mg/mL) were applied leaving 
one insert untreated for control. No blank inserts were maintained. The cells were incubated 
for 48 h and 100 μl media were withdrawn from the basolateral chambers at 0.5, 1, 2 4, 6, 
12, 24 and 48 h time-points. The samples were assayed by fluorimety as described in the 
previous section. The experiment was performed on two occasions and each sample was 
repeated in each instance in triplicate. 
 
 
 
Figure 3- 8: A Simplified Scheme of Na Flu Transport Assay 
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3.2.3.4 In Vitro Evaluation of Inflammatory Effect by Chemokine (IL-8) Release Study  
The potential inflammatory effect of the test materials was evaluated on BEAS-2B cell line 
according to the method reported (Fujisawa et al., 2000; Schulz et al., 2002) with some 
modifications. Briefly, 100 µl of cell culture medium containing 5 X 104 cells was placed in 
each of 5 wells in a 96-well plate (Costar®, Corning Incorporated, USA) and incubated. When 
the cells reached 80-90% confluency, the medium was replaced by 100 μl of medium 
containing a range of concentrations (0.5, 1, 2 and 4 mg/mL) of the test material leaving one  
well untreated for control. After 24 h of incubation, supernatants were harvested and stored 
at -20 °C until analysis. The supernatants were analyzed for IL-8 levels using ELISA MAX™ Kit 
(Biolegend, Inc., USA) following manufacturer’s protocol (Fig. 3-9) (2011). The experiments 
were done on two occasions with three replicates for each concentration. 
 
 
 
Figure 3- 9: A Simplified Scheme for Evaluation of IL-8 Induction in BEAS-2B Cells by ELISA 
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3.2.4 Statistical Analysis 
All the pharmaceutical and cell line experiments were performed in triplicates and the 
results were expressed as mean ± standard error (SE). The statistical significance of the 
differences was assessed by one-way and two-way Analysis of Variance (ANOVA) with      
post-hoc (Tukey-HSD) analysis; differences with a p-value of 0.05 or less were considered as 
significant.
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4.1 Summary 
The objective of validation of an analytical method is to demonstrate that the procedure, 
when correctly applied, produces results that are fit for the intended purpose. To be fit for 
the intended purpose, the method must meet certain validation criteria. Typical validation 
criteria, which should be considered, are: linearity, accuracy, precision, limit of detection 
(LOD) and limit of quantitation (LOQ). 
 
This chapter details the analytical validation for the following: 
1) UV assay of diltiazem hydrochloride (DH) for determination of drug loading and 
entrapment efficiency and in in vitro drug release and aerosolization studies. 
2) Spectrofluorometric assay of sodium fluorescein (Na Flu) in trans-epithelial permeability 
studies.  
3) Enzyme-linked immunosorbent assay (ELISA) of Interleukin-8 (IL-8) 
4) In vitro aerosolization study 
5) Nanoparticle preparation — batch-to-batch variability 
 
4.2 Analytical Validation 
4.2.1 UV Spectrophotometric Assay 
The UV spectrum of DH in PBS was determined and the wavelength of maximum 
absorbance (λmax) was found to be 235 nm (Fig. 4-1). Beer-Lambert’s calibration curve of DH 
solution in PBS representing the UV absorbance at 235nm in a concentration range of 0-
25µg/mL is presented in the Fig. 4-2.  A linear curve was obtained with a coefficient of 
determination (r2) of 0.9989.  The accuracy and precision of the assay were examined using 
low, medium and high concentrations (Table 4-1). The accuracy was in the range of         
97.8-102.5% and the coefficient of variation ranged from 0.002-0.006.  The limit of 
detection (LOD) and limit of quantitation (LOQ) were estimated to be 0.85 µg/mL and 2.82 
µg/mL, respectively from the standard calibration curve. 
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Table 4- 1: Accuracy and Precision for UV assay of Diltiazem Hydrochloride (n=3) 
Concentration (µg/mL) Accuracy (%) 
Coefficient of Variation 
(CV) 
5 102.5 0.002 
15 98.0 0.006 
25 97.8 0.004 
 
 
 
Figure 4- 1: UV Scan of Diltiazem Hydrochloride in PBS over the Range of 200-400 nm  
 
 
 
Figure 4- 2: Beer-Lambert’s Calibration Curve of Diltiazem Hydrochloride Solution in PBS (n=3)  
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4.2.2 Spectrofluorometric Assay 
The fluorescence intensity was measured for a series of concentrations of Na Flu in 1:1 
mixture of RPMI and 1mM NaOH at excitation and emission wavelengths of 485 and 
530 nm, respectively. A linear relationship was found between the fluorescence intensity 
and Na Flu concentration in the range of 0.02-2 µg/mL with a coefficient of determination 
(r²) of 0.9999 (Fig. 4-3). The accuracy for concentrations 0.02, 0.2 and 2 µg/mL was 99.1%, 
100.4% and 100.0%, respectively. The coefficient of variation for these concentrations was 
0.40, 0.05 and 0.01, respectively (Table 4-2). The LOD and LOQ were estimated to be 0.004 
µg/mL and 0.015 µg/mL, respectively. 
 
 
Figure 4- 3: Calibration Curve of Na Flu in 1:1 RPMI-NaOH (1mM) (n=3)  
 
Table 4- 2: Accuracy and Precision for Spectrofluorometric Assay of Na Flu in 1:1 RPMI-
NaOH (1mM)   (n=3) 
Concentration (µg/mL) Accuracy (%) 
Coefficient of Variation 
(CV) 
0.02 99.1 0.40 
0.2 100.4 0.05 
2 100.0 0.01 
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4.2.3 Enzyme-linked Immunosorbent Assay (ELISA) 
Fig. 4-4 presents the log-log plot of the UV absorbance at 450 nm for a series of 
concentrations of Human Interleukin-8 (IL-8) analysed by ELISA using Human IL-8 ELISA 
MaxTM Deluxe Kit (Biolegend, USA) according to manufacturer’s protocol (2011). A linear 
relationship was obtained in the concentration range of 15.625-1000 pg/mL with a 
coefficient of determination (r2) of 0.9998.  The accuracy and precision (coefficient of 
variation) were in the range of 98.7-104.3% and 0.0007-0.0304, respectively (Table 4-3). The 
LOD and LOQ were estimated to be 13.92 and 46.40 pg/mL, respectively. 
 
 
Figure 4- 4: Calibration Curve for Estimation of Human IL-8 by ELISA (n=2)  
 
Table 4- 3: Accuracy and Precision for Estimation of Human IL-8 by ELISA   (n=2) 
Concentration (pg/mL) Accuracy (%) Coefficient of variation (CV) 
15.625 101.3 0.0021 
31.25 98.7 0.0007 
62.5 100.0 0.0021 
125 102.7 0.0099 
250 104.3 0.0007 
500 101.8 0.0304 
1000 100.3 0.0099 
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4.2.4 In Vitro Aerosolization Study 
The in vitro aerosol depositions from 3 replicates of chitosan nanoparticle formulations are 
presented in the Fig. 4-5.  The coefficient of variation (CV) for the emitted dose, stage-1 and 
stage-2 deposition were 0.01, 0.04 and 0.08, respectively. This implies that there was no 
significant variation among the 3 replicates in terms of aerosolization and deposition of 
nanoparticles.  This, in turn, indicates that the overall aerosolization, washing and analytical 
procedures were reliable and reproducible.  
 
 
Figure 4- 5: Comparison of TSI Deposition from 3 Replicates of Chitosan Nanoparticle 
Formulation (determined by gravimetric analysis)  
 
4.2.5 Preparation of Nanoparticles —  Batch-to-Batch Variability 
The Figs. 4-6 a, b and c presents the production yield, drug loading and entrapment 
efficiency of 3 batches of drug-loaded chitosan nanoparticle formulations. The coefficients 
of variation were 0.08, 0.11 and 0.05.  
 
Fig. 4-7 presents the SEM micrographs of 3 different batches of drug-loaded chitosan 
nanoparticles. The particles are similar in size (10-20 nm), shape and surface morphology 
suggesting batch-to-batch reproducibility of the particles.  
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a b c 
Figure 4- 6: (a) Production Yield (%), (b) Drug Loading (%) and (c) Entrapment Efficiency (%)  
of 3 Batches of Drug-loaded Chitosan Nanoparticles 
 
 
   
Batch-1 Batch-2 Batch-3 
Figure 4- 7: SEM Micrographs of 3 Batches of Drug-loaded Chitosan Nanoparticles              
(at x100,000 magnification) 
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5.1 INTRODUCTION 
As already deatailed in Chpater 2, the natural biopolymer chitosan has got many attractive 
features and thus earned a special attention of scientists in diverse fields including 
medicine, pharmacy and biotechnology (Denkbas & Ottenbrite, 2006; Krajewska, 2004; Lim 
& Hudson, 2003; Roy et al., 1999; van der Lubben et al., 2001). Over the years, the polymer 
has been the subject of an active interest of synthetic chemists for chemical derivatizatrion 
in order to improve its functional applicability (Bobu et al., 2011; Jayakumar, 2007; Kim & 
Choi, 1998 ; Kurita et al., 2002b; Mourya et al., 2010; Nud'ga et al., 1973). 
 
For many years, there has been a keen interest in chemical conjugation of amino acids  with 
chitosan for potential utilization in various fields including adsorption of heavy metals (Ishii 
et al., 1995; Oshita et al., 2007b; Oshita et al., 2003), removal of low density lipoproteins (Fu 
et al., 2004a) and immobilization of lipases (Yi et al., 2009). Recent reports on enhanced 
dispersibility from a chitosan-based dry powder inhaler (DPI) upon addition of the amino 
acid, L-leucine (Learoyd et al., 2008a, 2008b, 2009)  prompted this investigator to explore 
the impact of chemical conjugation of chitosan with L-leucine on the dispersibility of 
particles from a DPI.  As noted in the Chapter 1, based on the structural features of                
L-leucine and previously reported orientation of the hydrophobic part of L-leucine (added to 
a particle formulation) at the particle-air interface, it was assumed that, upon conjugation, 
the L-leucine residue will be oriented around the chitosan backbone with its hydrophobic 
part being projected outward, resulting in a reduced inter-particle interaction (between 
particles made of conjugated chitosan) (Section 1.2, Fig. 1-1). Based on this educated guess, 
it was hypothesized that the L-leucine conjugation of chitosan would enhance the 
dispersiblity of the particles (made of the conjugate) from a DPI (Section 1.2).  
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H3C OH
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Figure 5- 1: Structure of Chitosan and L-Leucine 
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For testing the hypothesis, this work was designed to synthesize a conjugate of L-leucine to 
chitosan that was later used for fabrication of a nanoparticulate DPI formulation. As a first 
approach to this end, a conjugate of L-leucine with chitosan was synthesized by amidation 
with the primary amino group at C-2. The product was found to have improved solubility in 
water and was adequately characterised by FT-IR, 1H, 13C and 2D 1H-13C HSQC NMR 
spectroscopy, elemental analysis and XPS.  
 
Following the style of synthetic chemistry, the analytical data have been presented in the 
experimental sections (Sections 3.2.1.2.1 to 3.2.1.2.7) in the Chapter 3 and the results are 
discussed here without making separate sections for results and discussion as have been 
done for formulation and toxicological works to be presented in the forthcoming Chapters 6 
and 7. 
5.2 RESULTS AND DISCUSSION 
There are three available options for conjugating L-leucine to chitosan: first, selectively to 
the free ─amino group at the C-2 position; second, selectively to the primary ─OH group at 
C-6; and third, simultaneously both at the C-2 and C-6 positions. Because of the insolubility 
of chitosan in ordinary organic solvents and the presence of three different kinds of reactive 
groups (─NH2 and primary and secondary ─OH) in its repeating units, it is not very easy to 
effect controlled chemical modification reactions. For regioselective modification of the 
polymer at a specified position, it is imperative to apply appropriate protection-
deprotection strategies and to perform reactions in solution using organosoluble 
intermediates. Thus, for controlled functionalization at C-2 of chitosan with L-leucine, it was 
important to protect the C-6 position with an appropriate group. The trityl moiety was 
selected for this purpose, because this bulky, lipophilic group gives sufficient 
organosolubility to chitosan for carrying out controlled functionalization of the free amino 
group at C-2 (Holappa et al., 2004; Holappa et al., 2005). But, since chitosan per se is not 
sufficiently organosoluble to allow its reaction with trityl chloride, it was first reacted with 
phthalic anhydride to give N-phthaloyl-chitosan, which has been found to be the most 
attractive option from the viewpoints of  solubilization and subsequent deprotection (Kurita 
et al., 1982; Nishimura et al., 1991).  The deprotection of the phthaloyl group was effected 
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by hydrazinolysis in aqueous solution and the resulting amine was coupled with Boc-L-
leucine succinimide (Boc-leu-OSu). Finally, both the Boc and trityl protection was removed 
simultaneously by treating with 4M HCl in 1,4-dioxane to give the target conjugate as the 
hydrochloride salt. 
 
5.2.1 Synthesis and Characterization of N-Phthaloyl-Chitosan 
The intractability of chitosan has been attributed to its rigid crystalline structure (Saito et al., 
1981; Saito et al., 1987) and the amino functionality of the glucosamine residue is 
considered to have an important contribution to it by forming intra- and inter-chain 
hydrogen bonding as shown in Fig. 5-2 (Liu et al., 2004; Nishimura et al., 1991). Therefore, 
chemical modification of the amino group, e.g. by N-phthaloylation, can be expected to 
disrupt its inherent crystalline structure and improve solubility in general organic solvents 
(Fig. 5-2) (Kurita et al., 1982; Nishimura et al., 1991). The resulting N-phthaloyl-chitosan 
shows much improved solubility in organic solvents like DMF, DMAc, DMSO and pyridine 
(Nishimura et al., 1991; Nishimura et al., 1990). The phthaloyl group can later be 
deprotected easily to regenerate the free amino group paving way for further 
functionalization at this site. Because of these advantages, N-phthaloyl-chitosan has been 
utilized as a key intermediate for some regioselective and quantitative chemical 
modification of chitosan (Kurita et al., 2002b; Kurita et al., 2000a; Kurita et al., 1998; 
Nishimura et al., 1991; Yoksan et al., 2001; Yoksan et al., 2003). 
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Figure 5- 2: Hydrogen Bonding in Chitosan and its Disruption by N-Phthaloylation  
[adapted from Nishimura et al. (1991)] 
 
Protection of the C-2 amino group of chitosan (DDA 92%, MW 50-190 kDa) was successfully 
performed by employing a 3-fold excess of phthalic anhydride in DMF containing 5% (v/v) 
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water  at 130 °C without any added base according to the method of Holappa et al. (2004) 
with some modifications. Under these conditions, the reaction mixture turned to a viscous 
gel after 7-8 hours. Before adding phthalic anhydride, chitosan was soaked in the solvent 
overnight to let it swell after Rout et al. (1993) who reported that pre-swelling of chitosan 
enhanced the reaction process by increasing the accessibility of the amino groups to the 
reagent.  
 
The structure of the compound was confirmed by FT-IR spectroscopy and elemental 
analysis. Figs. 5-3 A and A 5-1.1 (Appendix 5-1) show the FTIR spectrum of N-phthaloyl-
chitosan. The peaks at 1703 and 1774 cm-1 for phthalimide carbonyl groups and at 718 cm-1 
for the aromatic ring confirm successful substitution of the phthaloyl group for the amino 
group of chitosan. Replacement of the twin broad band observed in chitosan at ~3700-3100 
cm-1 region (due to overlapping O-H and N-H stretches) by a single broad band also indicates 
removal of the free amino group. In addition, the peak for the primary amino group at     
1584 cm−1 also almost disappeared. The peaks at 1612 and 1547 cm-1 are assigned to amide 
I and amide II functionalities, respectively. The sharp band at 1385 cm-1 is assigned to 
phthaloyl C=C. No absorptions around 1850 cm-1 and 1790 cm-1 (ascribable to aromatic 
anhydride carbonyl bond) were observed in the spectrum indicating that purification of the 
reaction product by washing with methanol completely removed any un-reacted phthalic 
anhydride. These interpretations are in agreement with previously published data (Holappa 
et al., 2004; Stefanescu et al., 2008; Zhang et al., 2003). 
 
The microanalytical data of the product (C, 51.25%; H, 4.87%; N, 4.44%) closely resemble 
the theoretical values (C, 53.73%; H, 5.00%; N, 4.63%) calculated for complete 
phthaloylation of starting chitosan (DDA 0.92).  To determine the degree of substitution 
(DS), the expected C/N values were calculated for different levels of DS (0 to 0.92) and a 
standard calibration curve was drawn by plotting the DS values against C/N ratios. The DS 
value found by plotting the C/N ratio (51.25%/4.44%=11.54) on the standard calibration 
curve was 0.91 (Fig. 5-4).  With 92% DDA of the starting material, this means that 99% of the 
free amino groups were substituted. The yield of the product based on this DS value was 
calculated to be 95%. 
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Figure 5- 3: A Combined Presentation of the FT-IR Spectra of: (A) N-Phthaloyl-Chitosan,            
(B) N-Phthaloyl-3,6-Di-O-Acetyl-Chitosan, (C) N-Phthaloyl-6-O-Trityl-Chitosan, (D) N-Phthaloyl-
3-O-Acetyl-6-O-Trityl-Chitosan, (E) 6-O-Trityl-Chitosan, (F) 6-O-Tritylchtiosan-N-Boc-L-Leucine 
and (G) Chitosan-N-L-Leucine.HCl 
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Figure 5- 4: Determination of Degree of Substitution (DS) of N-Phthaloyl-Chitosan from 
C/N Ratio Obtained by Elemental Analysis 
 
It has been reported that treatment of chitosan with phthalic anhydride often results in 
partial O-phthaloylation in addition to N-substitution and shows some characteristic signs in 
the IR spectrum of the product [viz. weak bands at 2600−2700 cm-1 (free carboxyl), medium 
bands at 1250 -1290 cm-1 (ester), broadened imide carbonyl band at 1710 cm-1 owing to 
overlapping with the resulting ester linkage (Kurita et al., 2002b; Kurita et al., 2000b)]. 
Although the mixed N,O-phthaloylated product is still a convenient organosoluble precursor 
for some modification reactions (Rout et al., 1994; Rout et al., 1993), the O-phthaloyl group 
is an obstacle in most cases to quantitative and regioselective substitution. However, it has 
been demonstrated that this side reaction could be avoided by using a mixed solvent 
containing DMF and water at 95:5 ratio  (Kurita et al., 2002b). This protocol was followed 
here and minimal reaction at C-3 and C-6 were detected by IR spectroscopy. Weak bands 
were observed at 1250 -1290 cm-1; these may be due to trace amounts of O-phthaloylation. 
There is no other sign indicative of O-phthaloylation as evident from the absence of bands 
characteristic of carboxyl groups at 2600-2700 cm-1, presence of strong C-H aromatic bands 
due  to  aromatic  rings at around 2900 cm-1 and the sharp imide carbonyl band at 1703 cm-1 
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Figure 5- 5: A Combined Presentation of the 1H NMR Spectra of (A) N-Phthaloyl-3,6-Di-O-
Acetyl-Chitosan (in CDCl3), (B) N-Phthaloyl-3-O-Acetyl-6-O-Trityl-Chitosan (in CDCl3),         
(C) 6-O-Trityl-Chitosan (in Pyridine-d5), (D) 6-O-Trityl-Chitosan-N-Boc-L-Leucine (in 
Pyridine-d5) and (E) Chitosan-N-L-Leucine.HCl (in D2O)  
 
(Ikeda et al., 2002; Kurita et al., 2007; Kurita et al., 2002b; Kurita et al., 2000b). This is 
further supported by microanalytical data giving a DS of 0.91, which otherwise might have 
exceeded the DDA value of 0.92. 
 
Although the phthaloylated product was soluble enough for further modification reactions, 
its solubility did not prove sufficient for solution-state NMR characterization. NMR 
characterization of the product in a solvent like DMSO-d6 has been reported (Huang & Fang, 
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2006; Liu et al., 2004; Zhang et al., 2003). It is possible that this difference in solubility arose 
from differences in the MW and DDA of the chitosan used as the starting material.  
 
In order to obtain a more soluble compound to enable further structural characterization of 
the product by 1H and 13C NMR spectroscopy, the 3,6-di-O-acetylated derivative of the         
N-phthaloylated chitosan was prepared.  Complete O-acetylation was achieved by treating 
the compound with excess acetic anhydride and pyridine at 130 °C for 12 h as reported by 
Nishimura et al. (1991; 1990). However, the reaction could not be effected at room 
temperature as was reported. This is again probably because of the differences in MW and 
DDA of chitosan used for the reaction. The IR spectrum of the derivative showed 
characteristic absorptions of O-acetyl groups at 1743 and 1219   cm-1 (Figs. 5-3 B and A 5-1.2 
in Appendix 5-1). As expected and reported earlier by Nishimura et al. (1991; 1990), the 
peracetate derivative showed appreciable solubility in chloroform, allowing for a more 
definitive analysis of the structure by 1H and 13C NMR spectroscopy. The 1H NMR spectrum 
of the derivative in CDCl3 (Figs. 5-5 A and  A 5-2.1 in Appendix 5-2) showed conspicuous 
peaks at 7.68 and 7.74 ppm for phthaloyl groups in addition to peaks for pyranose ring 
protons at 2.80-5.90 ppm. The peaks for N-acetyl and O-acetyl protons appeared at         
1.63-2.19 ppm. The 13C NMR data of the compound in CDCl3 was very conspicuous           
(Figs. 5-6 A and A 5-3.1 in Appendix 5-3). The spectrum shows typical signals for phthaloyl 
group at 124.0, 131.3 and 134.6 ppm. The signals for CH3 carbons and C=O carbons for     
N,O-acetyl groups appeared at 20.4-20.8 and 167.7-170.2 ppm, respectively. The signals due 
to ring carbons of hexosamine residues (55.3-97.2 ppm) were also readily assigned by 
comparison with the literature. The IR and NMR data are in good agreement with that 
reported earlier by Nishimura et al. (1991; 1990).  
 
The microanalytical data (C, 54.48%; H, 4.88%; N, 3.66%) are in good agreement with 
theoretical values (C, 54.47%; H, 4.96%; N, 3.63%). The DS value as calculated from the C/N 
ratio (54.48%/3.66%=14.89) of analysis was 1.97 per monosaccharide residue (Fig. A 5-4.1 in 
Appendix 5-4). Based on this DS value, the yield was calculated to be 97%. This means, 
under the conditions applied, the reaction proceeded to completion (the theoretical 
maximum DS for O-acetylation being 2.0). This further suggests that phthaloylation has 
taken place exclusively at C-2. 
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5.2.2 Synthesis and Characterization of N-Phthaloyl-6-O-Trityl-Chitosan 
Once the N-phthaloylation of chitosan had been achieved, the next step in the sequence 
was introduction of trityl group at C-6. The resulting product, upon subsequent 
dephthaloylation, gives trityl-chitosan, which is soluble in organic solvents and allows 
modification of the free amino group in solution.  The trityl group can be easily removed at a 
later stage by heating in aqueous acetic acid or by treatment with stronger acids without 
heating (Nishimura et al., 1991). Due to the higher reactivity of the primary hydroxyl group 
and steric bulk of the trityl moiety, the reaction takes place selectively at C-6 (Nishimura et 
al., 1990). However, the substitution gradually extends to the secondary hydroxyl functions 
with increasing DS levels. In addition, the selectivity can also be affected  upon using a larger 
excess of trityl chloride (Finch, 1999). 
 
The reaction was successfully performed by heating N-phthaloyl-chitosan in pyridine at 
reflux (~115 °C) with a 10-fold excess of trityl chloride under an argon atmosphere for 24 h. 
The procedure, except using the reflux condition, was based on that reported by Zhang et 
al. (2008a). Other researchers (Holappa et al., 2004; Kurita et al., 2007; Nishimura et al., 
1991; Nishimura et al., 1990; Zhang et al., 2008a) conducted the reaction at 80 or 90 °C with 
a 3-fold excess of trityl chloride, but under these conditions conversion to the product was 
low. The reaction was very sensitive to the presence of moisture necessitating strict 
measures for its exclusion, including dying the solvent, pyridine, over molecular sieves and 
running the reaction under a constant flow of argon.  
 
The product was characterized by IR and gave satisfactory elemental analysis. As shown in 
the Figs. 5-3 C and A 5-1.3 (Appendix 5-1), in addition to peaks attributed to the phthaloyl 
absorption, the IR spectrum also shows characteristic new peaks at 3100-2900, 1490, 1448, 
764, 746 and 699 cm-1 that unambiguously confirm the presence of substituted 
triphenylmethyl (trityl) group on the N-phthaloylated glucosamine residues. The peaks at 
3100-2900 cm-1 are attributed to the stretching vibrations of trityl CH. The bands at 1490 
and 1448 cm-1 are characteristic of the aromatic C=C stretch. The peaks at 764, 746 and 699 
cm-1 correspond to monosubstitued aromatic rings. These assignments agree well with 
previous reports in the literature (Holappa et al., 2004; Stefanescu et al., 2008; Yu et al., 
2006; Zhang et al., 2008a).  
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The microanalytical data (C, 71.91%; H, 5.27%; N, 2.50%) are close to the theoretical values 
(C, 71.72%; H, 5.38%; N, 2.57%) calculated taking 92% degree of deacetylation and 91% 
degree of N-phthaloylation into consideration. The degree of substitution, as calculated 
from C/N ratio of elemental analysis (71.91%/2.50%=28.76), was 1.06 (Fig. A 5-4.2 in 
Appendix 5-4). Assuming that tritylation has taken place selectively at 6-OH, this is slightly 
higher than the theoretical maximum of 1.0. This means that, in addition to the primary 
─OH groups at C-6, some tritylation has also taken place at the secondary ─OH at C-3, 
though to a very small extent (6%).  Based on the DS value, the yield of the product was 
calculated to be 80%. 
 
As expected, this product was more organosoluble than the starting N-phthaloyl-chitosan, 
but still not enough for obtaining satisfactory solution NMR spectra. So, again, following the 
report of Nishimura (1991), the strategy of acetylating the 3-OH group with excess acetic 
anhydride and pyridine was undertaken. As evident from the 1H NMR spectrum (CDCl3) 
presented in the Figs. 5-5 B and A 5-2.2 (Appendix 5-2), there appeared additional peaks in 
the aromatic region at 6.89-7.28 ppm for monosubstituted phenyl rings of the trityl moiety 
(associated with residual solvent peak at 7.24 ppm) in addition to the phthaloyl peaks at 
7.68 and 7.74 ppm. The signals for pyranose protons appeared at 3.00-5.80 ppm. The peaks 
at 1.63-2.05  ppm  are  for  N- and  O-acetyl  groups. The  13C  NMR spectrum (Figs. 5-6 B and 
A 5-3.2 in Appendix 5-3) shows a series of signals (123.9-147.0 ppm) in the aromatic region. 
There are more signals in this region compared to the 13C spectrum of 3,6-di-O-acetyl-N-
pthaloyl-chitosan presented in the Figs. 5-6 A and  5-3.1 (Appendix 5-3). The additional 
signals (127.5-129.9, 145.4 and 147.0 ppm) are assigned to the trityl group. The spectrum 
shows other expected signals as usual (viz. signals for pyranose ring carbons at                  
55.3-97.2 ppm, signal for CH3 at 20.3 -20.8 ppm and signals for C=O at 167.8-170.3 ppm). 
The IR spectrum (Figs. 5-3 D and A 5-1.4 in Appendix 5-1) shows characteristic absorptions 
at 1745 and 1220 cm-1 due to C=O and C-O vibrations of O-acetyl groups and a decrease is 
observed in the ─OH stretch vibration at 3700-3100 cm-l.       
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Figure 5- 6: A Combined Presentation of 13C NMR Spectra of (A) N-Phthaloyl-3,6-Di-O-
Acetyl-Chitosan (in CDCl3), (B) N-Phthaloyl-3-O-Acetyl-6-O-Trityl-Chitosan (in CDCl3),          
(C) 6-O-Trityl-Chitosan-N-Boc-L-Leucine (in Pyridine-d5) and (D) Chitosan-N-L-Leucine.HCl 
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It is noteworthy that some earlier workers (Kurita et al., 2007; Yu et al., 2006) reported NMR 
characterization of N-phthaloyl-6-O-trityl-chitosan in solution in DMSO-d6 and pyridine-d5 
without any further modification. This again may be due to the differences in the MW and 
DDA of the chitosan used. 
 
The microanalytical data for the compound (C, 61.65%; H, 4.89%; N, 3.05%) was not close 
enough to the theoretical values (C, 70.68%; H, 5.33%; N, 2.39%) to be considered 
satisfactory and an attempt to calculate the degree of substitution based on C/N ratio found 
by analysis failed to produce any meaningful outcome. The results indicate that there is less 
C and more N than expected. One possible explanation for this may be that some 
detritylation has taken place during the acetylation process because of the high 
temperature (130 °C) applied. This explanation is supported by the changes in the relative 
intensities of aromatic phthaloyl and trityl peaks in the IR spectrum of N-phthaloyl-3-O-
acetyl-6-O-trityl-chitosan compared to those in the spectrum of N-phthaloyl-6-O-trityl-
chitosan (Fig. 5-3 (C) and (D)).  
 
5.2.3 Synthesis and Characterization of 6-O-Trityl-Chitosan 
The next step in the sequence of reactions was selective deprotection of the phthaloyl 
group from the C-2 position in order to make the ─NH2 group free for subsequent 
conjugation to L-leucine. Removal of the phthaloyl group from N-phthaloyl-6-O-trityl-
chitosan was efficiently done by heating with an aqueous solution of hydrazine hydrate at 
reflux (110 °C) for 18 h under an argon atmosphere.   
 
As evident from the IR spectrum (Figs. 5-3 E and A 5-1.5 in Appendix 5-1) of the resulting 
product, 6-O-trityl-chitosan, absorptions at 1776 and 1712 cm-1 due to phthalimido groups 
and at 719 cm-1 due to phthaloyl aromatic ring disappeared completely. On the other hand, 
it shows a characteristic absorption at 1596 cm-1 for the deprotected primary amino group, 
in addition to those due to trityl groups (at 3100-3000, 1490, 1448, 763, 746 and 697 cm-1). 
These spectral data agree well with the literature (Hu et al., 2005; Nishimura et al., 1991; Yu 
et al., 2006).  
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The degree of organosolubility of the product permitted the running of the 1H NMR 
spectrum in pyridine-d5, but it was not enough for obtaining satisfactory 13C NMR data. 
Attempted peracetylation proved unsuccessful for this product. Some workers (Yu et al., 
2006), however, reported 13C NMR analysis for this product in pyridine-d5. The Figs. 5-5 C 
and A 5-2.3 (Appendix 5-2) present the 1H NMR spectrum of the compound in pyrindine-d5. 
The spectrum shows trityl peaks at 7.28, 7.38 and 7.79 ppm. A broad set of peaks appear at 
3.00-5.78 ppm for pyranose protons. The peaks at 1.67-2.13 ppm are for acetyl protons. 
There are peaks at 5.06, 7.22, 7.59 and 8.73 for residual solvent (pyridine-d5). The signals 
shifted a little downfield compared to their position in the NMR spectrum of N-phthaloyl-3-
O-acetyl-6-O-trityl-chitosan in CDCl3 (Figs. 5-5 B and A 5-2.2 in Appendix 5-2).  This sort of 
downfield shift of NMR signals in pyridine-d5 has previously been reported by Bernet et al. 
(2000); they attributed it to the anisotropy effect of the pyridine ring.   
 
The microanalytical data (C, 71.14%; H, 6.13%; N, 3.54%) shows slightly lower percentage of 
H and higher percentage of N compared with the expected theoretical values (C, 71.13%; H, 
6.44%; N, 3.30%). This suggests a greater degree of depthaloylation than the theoretical 
maximum (0.91) when the observed C/N value (71.14%/3.54% = 20.10) was plotted in the 
standard calibration curve (Fig. A 5-4.3 in Appendix 5-4).  But, this is practically unlikely. This 
aberration may again be due to removal of some trityl groups during dephthaloylation by 
hydrazinolysis at high temperature condition (110 °C).  
 
Use of appropriate concentration of hydrazine hydrate solution appeared to be crucial for 
completion of the dephthaloylation process. Some earlier workers (Holappa et al., 2004; 
Nishimura et al., 1991) reported dilution of hydrazine hydrate with 2 times water when 
adding to the reaction mixture. The reagent used in this work contained hydrazine hydrate 
in 50-60% concentration. Any further dilution of the reagent resulted in incomplete 
deprotection of phthaloyl groups leaving a weak band at 1716 cm-1 in the IR spectrum (Fig. A 
5-1.6 in Appendix 5-1).  
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5.2.4 Synthesis and Characterization of 6-O-Trityl-Chitosan-N-Boc-L-Leucine 
The next step in the synthetic pathway was conjugation of L-leucine to the C-2 position of    
6-O-trityI-chitosan. There are numerous reports in the literature on conjugation of various 
amino acids with glucosamine or other amino sugars (Bergmann & Zervas, 1932; Kochetkov 
et al., 1962; Ohnishi et al., 2000; Sosnovsky & Gnewuch, 1994).  Jeon & Kim (2001) reported 
conjugation of a number of amino acids to chitooligosaccharides (<10kDa). Some workers 
also reported conjugation of peptides/ oligopeptides to 6-O-trityl-chitosan (Nishiyama et al., 
1999; Nishiyama et al., 2000). Some other studies described conjugation of L-leucine and 
other amino acids onto the chitosan beads using epichlorohydrin (ECH) or ethylene glycol 
diglycidyl ether (EGDE) as a spacer arm (Fu et al., 2004a; Oshita et al., 2007a; Yi et al., 2009). 
But, no attempt has so far been reported for direct conjugation of L-leucine to chitosan or  
6-O-trityl-chitosan. 
 
The conjugation was performed by reacting 6-O-trityl-chitosan with 3 equivalents of Boc-L-
leucine-succinimide in pyridine under an atmosphere of argon.  A solution of Boc-L-leucine-
succinimide in pyridine was added drop-wise to 6-O-trityl-chitosan at an extremely slow rate 
(10-12 drops/min) at 0 °C. The reaction was conducted at this temperature for the first 
three hours and then continued for a further 21 h at room temperature. The method was 
primarily based on an earlier report of Kurita et al. (2002a) on an analogous amidation 
reaction of 6-O-trityl-chitosan with N-nicotinoyl-phenylalanine. Various conditions were 
investigated to optimize the reaction. Addition of further 2 equivalents of Boc-L-leucine-
succinimide 2-3 h after starting the reaction resulted in an improved yield. A constant flow 
of Argon to eliminate moisture from the system was found to be critical for the success of 
the reaction. Both DMF and pyridine have been found to be effective as solvents, but 
pyridine gave a better dispersion of 6-O-tritylchtosan.  When the reaction was run at room 
temperature right from the very beginning, it gave a relatively poor yield and also resulted 
in reduced intensity of the amide peak in the IR spectrum. Use of low temperature 
throughout the whole length of the reaction also was not useful for an efficient outcome. 
Running the experiment at an increased temperature of 60 °C was found to cause failure of 
the reaction presumably by decomposition of the reagent, Boc-L-leucine-succinimide. 
Addition of the reagent, Boc-L-leucine-succinimide, to 6-O-trityl-chitosan in one portion 
(rather than drop-wise) was devastating; the IR spectrum suggests that even the trityl 
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groups were removed from the chitosan backbone. It indicates that such quick addition of 
the reagent caused vigorous reaction causing generation of heat that decomposed Boc-L-
leucine-succinimide. The generated free amino acid probably in turn cleaved the trityl 
groups off the chitosan backbone. This also justifies the need for adding the reagent drop-
wise at 0 °C. Diethyl ether was found to be useful for precipitation of the product and 
washing off the impurities. 10 volumes of di-ethyl ether were required for complete 
precipitation of the product from the reaction mixture. It was followed by further treatment 
with a modest amount (2-3 volumes) of ether for removing any remaining impurities. Use of 
acetone or alcohols (methanol/ethanol) for purification reduced the yield, apparently by 
dissolving part of the product. Methyl and ethyl alcohol seemed to soften the product 
indicating a better solubility of the product in these solvents.  
 
The structure of the product was confirmed by IR spectroscopy in combination with 1H and 
13C NMR spectroscopy and elemental analysis. Two dimensional 1H-13C HSQC NMR 
spectroscopy was also run to further confirm 1H and 13C NMR assignments and resolve 
overlaps in the 1H NMR spectrum. Appearance of a strong amide band at 1683 cm-1 and a 
doublet for isopropyl (L-leucine)/ t-butyl (Boc) at 1390 cm-1 and 1367 cm-1 in the IR spectrum 
(Figs. 5-3 F and A 5-1.7 in Appendix 5-1) confirms successful conjugation of Boc-L-leucine to 
6-O-trityl-chitosan. However, a weak band at 1597 cm-1 indicates that some unconjugated 
free amino groups are left. The bands at 2980-2830 cm-1 represent aliphatic C─H stretches 
of the CH, CH2 and CH3 groups in the pyranose ring and Boc-L-leucine side chain. The 
expected bands for trityl groups are also evident. 
 
The organosolubility of the product was poor for running NMR spectra, especially for 
resolving the pyranose signals. In the 1H NMR spectrum (Figs. 5-5 D and A 5-2.4 in Appendix 
5-2), the pyranose protons gave rise to a few extremely broad peaks at 3.0-5.8 ppm, while 
peaks for pyranose carbons in the 13C NMR spectrum (Figs. 5-6 C and A 5-3.3 in Appendix    
5-3)  were barely discernible even after 60 h. However, both proton and carbon NMR 
spectra showed well defined peaks for Boc t-butyl group and L-leucine residue, in addition 
to the trityl group, at appropriate positions. The peaks for Boc t-butyl appeared at 1.44 ppm 
and 28.9 ppm in 1H and 13C NMR spectra, respectively. The peaks at 25.3, 26.4, 30.3, 43.0 
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and 54.5 ppm in the 13C NMR spectrum were assigned to C-δ1, C-δ2, C-γ, C-β, and C-α of L-
leucine residue.  The chemical shifts at 22.7 and 23.8 in the 13C NMR spectrum were 
assigned to –CH3 (N-acetyl) carbon. Pyranose and trityl carbons resonated at their typical 
positions. NMR signals were also observed for C=O of carbamide, L-leucine and N-acetyl at 
156.9, 173.6 and 176.3 ppm respectively as well as for the quaternary carbons of Boc and 
trityl moieties at 79.2 and 87.1 ppm, respectively. These assignments for L-leucine, Boc and 
trityl residues are based on some products reported in the literature, which contained the 
same residues as part of their structures (Braga et al., 2004 ; Krohn et al., 2012; Perich et al., 
1987). However, as compared to these reports, the signals seem to have shifted slightly 
downfield because of the anisotropic effect of the pyridine ring as shown before for 6-O-
trityl-chitosan too. The 1H-13C 2D correlation data (Fig. 5-7) was helpful in confirming the 
chemical shifts of some carbons that did not give very well-defined peaks in the 1-D 13C 
NMR spectrum (viz. pyranose carbons). The 2D data were also useful in assigning the signals 
of different protons in the 1H NMR spectrum that showed a lot of overlap. The N-acetyl peak 
at 1.66 ppm is overlapped by t-butyl, Boc signal, while the peaks for H-γ, leu and t-butyl, Boc 
overlap at 1.27 ppm. On the other hand, the signals for H-β and H-δ1 of L-leucine overlap at 
1.92 ppm. In addition, the chemical shift of H-α of L-leucine (4.32-4.87 ppm) overlaps on H-2 
(4.37-4.58 ppm) and H-4 (4.45-4.65 ppm) of the pyranose. One limitation of the 2D 
spectrum was the absence of any data points corresponding to C-1 signals. However, this 
shortcoming was circumvented by the 2D data of the next and final compound in the 
pathway (chitosan-N-L-leucine.HCl) that show clear data points correlating C-1 signals to 
corresponding H-1 peaks (Fig. 5-8). 
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Figure 5- 7: 1H-13C HSQC NMR Spectrum of 6-O-Trityl-Chitosan-N-Boc-L-Leucine in Pyridine-d5 
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The microanalytical data of the product (C, 67.98%; H, 6.78%; N, 4.14%) were in close 
agreement with the expected values (C, 68.23%; H, 7.25%; N, 4.33%). The plot of obtained 
C/N ratio (67.98%/4.14%=16.42) in the standard calibration curve drawn gave a DS value of 
0.74 (Fig. A 5-4.4 in Appendix 5-4). With a DDA of 0.92 and assuming that complete 
dephthaloylation has been achieved in the previous step, this means 80% of the available 
primary ─NH2 groups have been substituted by Boc-L-leucine residues. On the basis of this 
degree of substitution, the yield was calculated to be 70%.  
 
5.2.5 Synthesis and Characterization of Chitosan-N-L-Leucine.HCl 
The protecting groups, trityl and Boc, were removed from 6-O-trityl-chitosan-N-Boc-L-
Leucine by global deprotection using an excess of 4M HCl in Dioxane. Though other 
researchers reported deprotection of these groups by half an hour to 2 h treatment with 4M 
HCl in Dioxane (Dellaria et al., 1990; Lee & Boger, 2009; Scozzafava & Supuran, 2000 ; Tan et 
al., 2007), in the present work incomplete removal of the trityl group was detected by NMR 
spectroscopy even after running the experiment for 24 hours. The resulting final product 
chitosan-N-L-leucine.HCl showed an appreciable water solubility that enabled 
characterisation by 1H and 13C NMR spectroscopy in addition to IR spectroscopic 
characterisation.  
 
The structural details of the compound were elucidated by IR, 1H and 13C NMR spectroscopy, 
elemental analysis and XPS. The IR spectrum of the product (Figs. 5-3 G and A 5-1.8 in 
Appendix 5-1) shows that HCl treatment of 6-O-trityl-chitosan-N-Boc-L-leucine removed all 
the characteristic peaks attributable to trityl groups without breaking the amide linkage. 
Since both the isopropyl group of L-leucine and t-butyl group of Boc show characteristic 
doublet peaks at the same position (around 1366 and 1390 cm-1), it was difficult to infer 
from the IR spectrum if Boc protection has been removed or not and the role of NMR 
spectra became more significant to reach a decision here. It is evident both from the 1H and 
13C NMR spectra (Fig. 5-5 E, Fig. 5-6 D and Figs. A 5-2.5 and A 5-3.4 in Appendices 5-2 and 
5-3, respectively) that peaks attributable to Boc t-butyl (1.44 ppm in 1H NMR and 28.9 ppm 
in 13C NMR) have completely been removed. The NMR spectra also confirm nearly complete  
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Figure 5- 8: 1H-13C HSQC NMR Spectrum of Chitosan-N-L-Leucine.HCl in D2O 
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(Crini et al., 1997; Heras et al., 2000). The HSQC spectrum (Fig. 5-8) shows that, in contrast 
to the multiplicity of the carbon signals, the proton signals were overlapped. The resonance 
of H-δ1&2 of L-leucine overlaps to give the intense signal at 0.98 ppm. H-δ2 and H-β of            
L-leucine combined to give the signal at 1.78 ppm. This signal also has slight overlapping 
with H-δ1 and H-γ. Finally, the composite signal from H2-H6 of pyranose (3.38-4.33 ppm) 
overlaps with H-α and H-β of L-leucine at 3.87-4.30 and 4.04 ppm, respectively. The 2D 
spectrum also reveals shifting in the resonances of some protons from their original position 
in the starting material, 6-O-trityl-chitosan-N-Boc-L-leucine. Most prominent was the H-γ of 
L-leucine that shifts from 1.27 ppm (most upfield of all L-leucine protons) downfield to 2.80 
ppm just before the broad composite signal for H2-6 of pyranose, H-α and H-β of L-leucine. 
 
For further confirmation of conjugation of L-leucine to chitosan, X-ray photoelectron 
spectroscopic analysis (XPS) was performed on chitosan, L-leucine and the synthetic 
conjugate, chitosan-N-L-Leucine.HCl. A low-resolution wide (survey) scan was performed to 
detect the elements present and their relative content (Fig. A 5-5.1 in Appendix 5-5) and 
then high-resolution narrow scan was performed on the major elements, viz. C, N and O to 
have an in-depth look at their chemical status and to compare the spectra obtained for the 
conjugate with those of chitosan and L-leucine. Figs. 5-10 and 5-11 present the multiplex 
spectra for N and C. The multiplex spectrum for O is presented in Fig. A 5-5.2 in the 
Appendix 5-5. 
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Figure 5- 9: Structure of Chitosan, L-Leucine and and Chitosan-N-L-Leucine.HCl 
 
The N atom in chitosan exists in three different chemical states: NH (i.e. N in free ─NH2), 
Namide (i.e. N in amide linkage, ─NHCO), and N+ (i.e. quaternized N in ─NH3Cl, the amino 
group attached to HCl present as impurity). As it is evident from structures of chitosan,                        
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L-leucine and chitosan-L-leucine.HCl (Fig. 5-9), the conjugation of L-leucine to chitosan 
transforms free ─NH2 into an amide (─NHCO), thus there is a reduction in NH and a 
simultaneous increase in Namide. Besides, one N+ is added per molecule of L-leucine and 
hence there is an elevation in the quantity of N+. So, changes in signal intensity of different 
chemical states of N could be taken as an indication of conjugation of L-leucine to chitosan. 
As shown in the Fig. 5-10, XPS analysis shows that the signal intensity of NH is reduced from 
5.94% (in chitosan) to 0.68% (in conjugate).  On the other hand, there is a great elevation in 
the intensity of the signals for Namide (from 0.72% to 5.14%) and N+ (from 0.78% to 2.99%). 
These changes in the signal intensity of different chemical states of N clearly support 
successful conjugation of L-leucine to chitosan. 
 
A comparative analysis of the structures of chitosan, L-leucine and chitosan-N-L-leucine.HCl 
(Fig. 5-9) further reveals that conjugation of L-leucine to chitosan adds 3 C-C carbon atoms 
per molecule that resonates at 285 eV and so an elevation is expected in the signal intensity 
of carbon atom in this state. Fig. 5-11 shows that the signal intensity of C-C has been 
enhanced from 12.39% (in chitosan) to 19.14% (in conjugate) as expected from their 
chemical structure. This provides a further evidence of conjugation of L-leucine to chitosan.  
 
 
Figure 5- 10: XPS Multiplex spectra of Chitosan, L-Leucine and Chitosan-N-L-leucine.HCl for 
Nitrogen 
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Figure 5- 11: XPS Multiplex Spectra of Chitosan, L-Leucine and Chitosan-N-L-Leucine.HCl for 
Carbon 
 
An analysis of stoichiometric C/N and C/O ratios of chitosan-N-L-leucine.HCl at different 
degrees of substitution (from 0 to 100%) indicates that, with increased degree of 
conjugation, the C/N ratio decreases while the C/O ratio increases (Fig. 5-12 (a) and (b)). 
The stoichiometric and experimental C/N and C/O ratios of the chitosan and its conjugate 
under consideration are listed in the Table 5-1.  Although the C/N and C/O ratios 
determined by XPS are larger than those predicted from their structures, there is reduction 
in C/N and elevation in C/O as expected. The deviation of experimental values from the 
theoretical ones can be attributed to the presence of possible carbonaceous impurities with 
chitosan and traces of trityl protection remaining with the conjugate. Furthermore, since 
XPS is a surface analysis covering only a depth of 5-10 nm from the sample surface, it cannot 
be expected to represent the whole sample quantitatively. 
 
Table 5- 1: Stoichiometric and Experimental C/N And C/O Ratios of Chitosan and the 
Synthesized Chitosan-N-L-Leucine.HCl 
Samples 
Stoichiometrical Experimental 
C/N C/O C/N C/O 
Chitosan 6.16 1.21 8.59 2.20 
Chitosan-N-L-leucine.HCl 6.10 1.75 6.55 2.38 
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a 
 
 
b 
Figure 5- 12: (a) C/N and (b) C/O Ratios of Chitosan-N-L-Leucine.HCl at Different DS Ratios 
 
5.3 CONCLUSION 
A conjugate of L-leucine and chitosan was successfully synthesized and characterised by IR 
and NMR spectroscopy, XPS and elemental analysis. Among a few drawbacks in the work 
was the failure to obtain satisfactory elemental analysis data for N-phthaloyl-3-O-acetyl-6-
O-trityl-chitosan. However, the purpose of synthesizing this product was to further 
characterize the precursor N-phthaloyl-6-O-trityl-chitosan by 1H and 13C NMR spectroscopy 
and the compound served the purpose adequately. Moreover, the parent compound           
N-phthaloyl-6-O-trityl-chitosan provided satisfactory elemental analysis data. Another 
limitation was the higher than expected value in elemental analysis for the dephthaloylated 
product. This was attributed to probable removal of some of the trityl groups due to high 
temperature conditions applied during the reaction. However, the IR and NMR data for the 
compound confirms that the phthaloyl group was efficiently removed. 
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6.1 INTRODUCTION 
Chitosan micro- and nano-particles have drawn special attention for controlled drug delivery 
applications through the respiratory system (Al-Qadi et al., 2012; Andrade et al., 2011). In 
addition to well reported biocompatibility and biodegradability, one important feature of 
the polymer is its mucoadhesiveness that helps to retain the administered formulation at 
the absorbing epithelial membrane, thereby prolonging drug release (Huang et al., 2003; 
Learoyd et al., 2008a). Because of this interesting feature, in addition to being used as a tool 
for controlling drug release, chitosan has also been widely investigated as a formulation 
excipient intended to prolong drug residence at the absorbing mucosal surfaces (Boonyo et 
al., 2007; Dyer et al., 2002; Illum, 1998; Soane et al., 1999).  
 
The use of nanoparticulate systems is particularly promising both from the point of drug 
transport to the lung and sustained drug action. Upon normal respiration, inhaled 
nanoparticles of different sizes can target all the three regions (viz. nasopharyngeal, 
tracheobronchial and alveolar) of the respiratory airways; however, nanoparticles of less 
than 100 nm diameter are deposited mainly in the alveolar region (Hoet et al., 2004; 
Oberdorster et al., 2005). Moreover, nanoparticles can escape mucociliary clearance and 
phagocytic removal by alveolar macrophages ensuring prolonged residence of the 
administered drug in the lungs for release and absorption (Ahsan et al., 2002; Grenha et al., 
2005). 
 
One major challenge associated with a DPI system is strong cohesion shown by micronized 
particles that affects their dispersibility and greatly reduces deposition of inhaled particles 
to lungs. Various measures have been tried to overcome the problem which include, among 
others, addition of an interactive carrier (e.g. lactose) and/or a ternary component like 
magnesium stearate or L-leucine (Begat et al., 2005). Considering the promising effect of      
L-leucine as an aerosolization enhancer upon physical addition to a chitosan-based 
controlled release DPI formulation, as previously reported in the literature (Learoyd et al., 
2008a, 2008b, 2009), this work was designed to explore the effect of chemical conjugation 
of L-leucine to chitosan from this perspective. 
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Detailed literature review addressing these points has already been presented in the 
Chapter 2. This chapter details the preparation of nanoparticles from chitosan and its           
L-leucine conjugate as controlled release DPI formulations using the antihypertensive drug 
diltiazem HCl (DH) as the model drug. In view of the extensive first-pass metabolism of the 
drug following oral administration that could potentially be bypassed by respiratory 
administration, it was considered as a good candidate for this work. The suitability of the 
particles for pulmonary delivery is ascertained in terms of their size and morphology. A 
comprehensive comparison is made between the dispersibility and drug release pattern of 
the nanoparticle formulations of the two species. 
6.2 RESULTS 
6.2.1 Preparation of Chitosan and Chitosan-L-leucine Conjugate Nanoparticles 
Nanoparticles of chitosan and its L-leucine conjugate were successfully prepared using both 
approaches, viz.  emulsion- solvent evaporation (method-1) and emulsion- glutaraldehyde 
cross-linking (method-2), as described in the Section 3.2.2.1 of the Chapter 3. However, the 
solvent evaporation technique could not load the model drug, DH into chitosan particles 
and showed extensive agglomeration of conjugate particles, upon incorporation of the drug, 
so that the particles turned into a lump during isolation. 
 
6.2.2 Morphology and Particle Size Analysis 
6.2.2.1 Scanning Electron Microscopy 
Figs. 6-1 A and B present the SEM micrographs of blank chitosan and chitosan-L-leucine 
conjugate nanoparticles, respectively, prepared by the method-1. The particles are mostly 
spherical with a diameter predominantly in the range of 10-30 nm. On average, the 
conjugate nanoparticles tend to be slightly larger than those made of unmodified chitosan. 
Many particles, particularly ones with larger diameters, seem to be oblate, rather than 
perfect spheres. The surface of the particles is smooth and no pores or cracks are observed. 
Occasionally, some of the big particles seem to have indentations on their surface. They 
appear to have arisen from fusion of multiple small particles into bigger ones. The particles 
showed an aggregation tendency, though there appears to be some isolated single ones, 
too.  
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SEM images of blank chitosan and conjugate nanoparticles prepared by method-2 are 
shown in the Figs. 6-1 C and D, respectively. They are similar to ones made by method-1 in 
size, shape and surface morphology.  
 
Drug loaded nanoparticles of chitosan and conjugate made by method-2 are presented in 
the Figs. 6-1 E and F, respectively. The particles appear to be slightly smaller in diameter 
(approximately 10-20 nm) than the blank nanoparticles made by either method. They 
appear to consist of more regular spheres. The particles are dense with no pores, 
depressions or indentations on their surface. There is no evidence of drug crystals deposited 
on the particle surface. 
 
6.2.2.2 Zetasizer Analysis 
The zetasizer analysis of chitosan and conjugate nanoparticles is presented in the              
Figs. 6-2 A-F and the corresponding numerical data are summarized in the Table A6-1 
(Apppendix-6).  
 
The zetasizer analysis of both the blank chitosan and conjugate nanoparticles made by the 
method-1 showed a uni-modal size distribution with Z-averages of 67.25±2.82 r.nm and 
76.61±1.23 r.nm, respectively; corresponding polydispersity indices were 0.58±0.26 and 
0.35±0.08, respectively (Table A6-1 in Appendix-6, Figs. 6-2 A and B). On the other hand, 
both the blank and drug-loaded nanoparticles made of chitosan and the conjugate by the 
method-2 showed multi-modal size distribution (Figs. 6-2 C-F). Three of these formulations, 
viz. blank and drug-loaded chitosan nanoparticles and blank conjugate nanoparticles 
showed bi-modal distributions, comprising a population of particles at 10-16 r.nm size range 
and another between 194-263 r.nm (Table A6-1 in Appendix-6, Figs. 6-2 C-E). The overall    
Z-averages for the three formulations were 70.34±3.99 r.nm, 32.23±1.29 r.nm and 
21.17±0.52 r.nm, respectively (Table A6-1 in Appendix-6). The drug-loaded nanoparticles of 
conjugate showed a tri-modal distribution with mean sizes of 0.49±0.01 r.nm, 15.02±0.93 
r.nm and 248.57±10.67 r.nm, the overall Z-average being 9.26±0.99 r.nm (Fig. 6-2 F). All the 
four samples showed the highest polydispersity index of 1.00 (Table A6-1 in Appendix-6). 
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Figure 6- 1: Scanning Electron Micrographs of A) Blank Chitosan Nanoparticles (Method-1), 
B) Blank Conjugate Nanoparticles (Method-1), C) Blank Chitosan Nanoparticles      
(Method-2), D) Blank Conjugate Nanoparticles (Method-2), E) Drug-loaded Chitosan 
Nanoparticles (Method-2) and F) Drug-loaded Conjugate Nanoparticles (Method-2) at 
X100,000 magnification 
 [Note: Dimension bar is shown under each micrograph. The cracks in the images are artefacts of processing for 
microscopy.] 
Size:10-30 nm Size:10-30 nm 
Size:10-30 nm Size:10-30 nm 
Size:10-20 nm Size:10-20 nm 
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E F 
Figure 6- 2: Particle Size Distribution of A) Blank Chitosan Nanoparticles (Method-1),          
B) Blank Conjugate Nanoparticles (Method-1), C) Blank Chitosan Nanoparticles       
(Method-2), D) Blank Conjugate Nanoparticles (Method-2), E) Drug-loaded Chitosan 
Nanoparticles (Method-2) and F) Drug-loaded Conjugate Nanoparticles (Method-2) 
 
[Note: Particle size distribution was determined in heavy paraffin oil suspension by dynamic light scattering 
with Malvern Zetasizer Nano-S. The sizes are presented as r.nm (hydrodynamic radius in nm).] 
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6.2.3 Production Yield, Drug Loading and Entrapment Efficiency 
The yield of both the blank and drug-loaded nanoparticles of chitosan and the conjugate 
prepared by either method and the drug loading and entrapment efficiency of drug-loaded 
nanoparticles prepared by the method-2 were determined using the equations (1), (2) and 
(3), respectively as described in the Section 3.2.2.4 of the Chapter 3. The results are 
summarized in the Table 6-1 and discussed in the Section 6.3.3. 
 
Table 6- 1: Production Yield, Drug Loading and Entrapment Efficiency of Chitosan and 
Conjugate Nanoparticles (mean±SE, n=3) 
Method of 
Preparation 
Formulation Production Yield 
(%) 
Drug loading 
(%) 
Entrapment 
efficiency (%) 
Method-1 
Chitosan nanoparticles (blank) 69±2 - - 
Conjugate nanoparticles (blank) 57±2 - - 
Method-2 
Chitosan nanoparticles (blank) 191±5 - - 
Conjugate nanoparticles (blank) 169±4 - - 
Chitosan nanoparticles (drug-loaded)  125±6 16±1 38±1 
Conjugate nanoparticles (drug-loaded) 119±5 20±1 46±1 
 
6.2.4 In Vitro Drug Release Study 
The release of the drug, DH from glutaraldehyde cross-linked chitosan and                 
chitosan-L-leucine conjugate nanoparticles was studied in phosphate buffered saline (pH 
7.3±0.2) at 37 °C as described in the Section 3.2.2.5 of the Chapter 3 and the data are 
presented in the Table A6-2 (Appendix 6) as cumulative % of drug released and retained at 
different time points. The release data are plotted according to various kinetic models [zero 
order, first order, Higuchi (Higuchi, 1963) and Hixson-Crowell (Hixson & Crowell, 1931)] in 
Figs. 6-3.1 to 6-3.4. For gaining an insight into the mechanism of drug release, the data were 
also analysed by Korsmeyer-Peppas model (Korsmeyer et al., 1983) (Fig. 6-3.5).  A 
summarized account of the applied kinetic models is given in the Table 6-2.  
 
As shown in the Table A6-2 (Appendix 6) and the Fig. 6-3.1, both chitosan and conjugate 
nanoparticles exhibited a large initial burst followed by a controlled release at a slow rate 
over a period of approximately 1-2 weeks . Chitosan nanoparticles showed an initial burst 
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release of 16±0.32% and a maximum cumulative % release of 23±0.31% at the end of 192 
hours (8 days). The corresponding values for conjugate nanoparticles were 31±1.98% and 
52±1.55%, respectively. The release from conjugate nanoparticles continued for a longer 
period and reached the maximum at the end of 384 hours (16 days). Although the 
experiment was continued for a period of 30 days, no further increase in the amount of drug 
released was observed after 8 and 16 days periods from chitosan and conjugate 
nanoparticles, respectively. 
 
Table 6- 2: Mathematical Models Applied to the Release Data of Diltiazem Hydrochloride 
Loaded into Chitosan and Conjugate Nanoparticles 
Mathematical models Equation 
Zero order model F=kot 
First order model ln (1-F)=-k1t 
Higuchi model F=KHt1/2 
Hixson-Crowell model 1-(1-F)1/3=k1/3t 
Korsmeyer-Peppas model F=kK-Ptn 
 
Note: F is cumulative fraction of drug released at time t.  k0, k1, kH, k1/3 and kK-P are the apparent release rate 
constants of the respective mathematical models. n is the release exponent of the Korsmeyer-Peppas model, 
indicative of the mechanism of drug release.   
 
To determine the goodness of fit of various models, the release data were analysed by 
simple linear regression (using the data points until the time at which cumulative drug 
release reached its maximum — i.e. 8  and 16 days for chitosan and conjugate nanoparticles 
respectively). The determination coefficients (r2) and release rate constants determined by 
fitting the release data to various kinetic models and regression analysis are presented in 
the Table 6-3. For Korsmeyer-Peppas model, the table records the values of release 
exponent, n. 
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Table 6- 3: Release Rate Constants and Determination Coefficients for Drug Release Profile 
according to Various Kinetic Models 
Models Zero order First order Higuchi Hixson-Crowell Korsmeyer-
Peppas 
Formulations k0             
(×10-2 
h-1) 
r2 k1      
(×10-2 
h-1) 
r2 kH     
(×10-2 
h-1) 
r2 K1/3    
(×10-2 
h-1) 
r2 n r2 
Chitosan 
nanoparticle 
0.0313 0.8868 0.0005 0.8921 0.4709 0.9808 0.0006 0.8903 0.0568 0.9611 
Conjugate 
nanoparticle 
0.0513 0.8334 0.0009 0.8593 1.1159 0.9661 0.0012 0.8509 0.0856 0.9709 
 
Note: k0, k1, kH, k1/3 and kK-P are the apparent release rate constants of the respective mathematical models. n 
is the release exponent of the Korsmeyer-Peppas model, indicative of the mechanism of drug release.   
 
 
 
 
Figure 6-3. 1:  Release Profile of Diltiazem HCl from Chitosan ( ) and Chitosan-L-
Leucine Conjugate ( ) Nanoparticles in PBS (pH 7.3±0.2, 37 °C) (Zero Order Model) 
[Note: Samples were analysed by UV spectrophotometry at intervals of 0.5, 1, 2, 4, 6, 12 and 24h time-points 
and later every 24 h upto 30 days. Drug loading: chitosan nanoparticles, 16% and conjugate nanoparticles, 
20%. Each point in the graphs represents mean±SE (n=3). The linear regression was performed for the data 
points until the time at which the cumulative drug release reached its maximum, i.e. 8 and 16 days for chitosan 
and conjugate nanoparticles, respectively.] 
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Figure 6-3. 2:  Release Profile of Diltiazem HCl from Chitosan ( ) and Chitosan-L-
Leucine Conjugate ( ) Nanoparticles in PBS (pH 7.3±0.2, 37 °C) (1st Order Model) 
[Note: Samples were analysed by UV spectrophotometry at intervals of 0.5, 1, 2, 4, 6, 12 and 24 h time-points 
and later every 24 h upto 30 days. Drug loading: chitosan nanoparticles, 16% and conjugate nanoparticles, 
20%. Each point in the graphs represents mean±SE (n=3). The linear regression was performed for the data 
points until the time at which the cumulative drug release reached its maximum, i.e. 8 and 16 days for chitosan 
and conjugate nanoparticles, respectively.]  
 
 
Figure 6-3. 3:  Release Profile of Diltiazem HCl from Chitosan ( ) and Chitosan-L-
Leucine Conjugate ( ) Nanoparticles in PBS (pH 7.3±0.2, 37 °C) (Higuchi Model) 
[Note: Samples were analysed by UV spectrophotometry at intervals of 0.5, 1, 2, 4, 6, 12 and 24 h time-points 
and later every 24 h upto 30 days. Drug loading: chitosan nanoparticles, 16% and conjugate nanoparticles, 
20%. Each point in the graphs represents mean±SE (n=3). The linear regression was performed for the data 
points until the time at which the cumulative drug release reached its maximum, i.e. 8 and 16 days for chitosan 
and conjugate nanoparticles respectively.] 
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Figure 6-3. 4:  Release Profile of Diltiazem HCl from Chitosan ( ) and Chitosan-L-
Leucine Conjugate ( ) Nanoparticles in PBS (pH 7.3±0.2, 37 °C) (Hixson-Crowell Model) 
[Note: Samples were analysed by UV spectrophotometry at intervals of 0.5, 1, 2, 4, 6, 12 and 24h time-points 
and later every 24h upto 30 days. Drug loading: chitosan nanoparticles, 16% and conjugate nanoparticles, 20%. 
Each point in the graphs represents mean±SE (n=3). The linear regression was performed for the data points 
until the time at which the cumulative drug release reached its maximum, i.e. 8 and 16 days for chitosan and 
conjugate nanoparticles respectively.] 
 
 
Figure 6-3. 5:  Release Profile of Diltiazem HCl from Chitosan ( ) and Chitosan-L-
Leucine Conjugate ( ) Nanoparticles in PBS (pH 7.3±0.2, 37 °C) (Peppas-Korsmeyer 
Model) 
[Note: Samples were analysed by UV spectrophotometry at intervals of 0.5, 1, 2, 4, 6, 12 and 24 h time-points 
and later every 24 h upto 30 days. Drug loading: chitosan nanoparticles, 16% and conjugate nanoparticles, 
20%. Each point in the graphs represents mean±SE (n=3). The linear regression was performed for the data 
points until the time at which the cumulative drug release reached its maximum, i.e. 8 and 16 days for chitosan 
and conjugate nanoparticles respectively.]  
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6.2.5 In Vitro Aerosolization Study 
The dispersibility of both the blank and drug-loaded chitosan and conjugate nanoparticles 
prepared by emulsification glutaraldehyde cross-linking was studied using a twin-stage 
impinger (TSI). The particles deposited in different stages were collected using PBS as the 
solvent and analysed gravimetrically using 0.2 µm membrane filters for collecting particles. 
For further confirmation, drug loaded particles were also analysed spectrophotometrically 
by determining the amount of drug released from the particles.  PBS was used as the 
collection solvent in the stages I and II of the TSI to maintain a consistency with the 
spectrophotometric analyses made during drug release study and determination of 
entrapment efficiency. Although 0.2 µm is a much higher pore size compared to the size of 
the prepared nanoparticles, repeated circulation of the liquid containing the particles 
through the filter enabled complete removal of particles, because of the tendency of 
particles to form agglomerates and gradually block the pores. The filtrate was finally 
checked both visually and under microscope to ensure freedom from any remaining 
particles.   
 
Table A6-3 (Appendix 6) summarises the numerical data representing relative particle 
deposition in different stages of the TSI apparatus, recovered dose (RD) and emitted dose 
(ED) and fine particle fraction (FPF) expressed in percentage. Fine particle fraction (FPF) 
actually represents the stage II deposition as a fraction of the total recovered dose (RD). 
 
Fig. 6-4.1 illustrates the relative deposition of particles in different stages of the TSI as 
estimated by gravimetric analysis. The recovered dose (RD), emitted dose (ED) and fine 
particle fraction (FPF) are presented in Figs. 6-4.2, 6-4.3 and 6-4.4, respectively.  
 
As per gravimetric analysis, the total doses of the formulations recovered from all the stages 
of TSI ranged between of 74 and 87% of the loaded doses (Fig. 6-4.2, Table A6-3 in 
Appendix 6). The fraction of the total dose emitted in the upper and lower stages was in the 
range of 73-85%, with the exception of the blank chitosan nanoparticle that had a relatively 
low emitted dose of 62% only (Fig. 6-4.3, Table A6-3 in Appendix 6). Statistical analyses 
showed that there was no difference between emitted doses of drug-loaded chitosan and 
conjugate nanoparticles (73±1.96% vs. 79±2.52%, p>0.05), but the emitted dose of blank 
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conjugate nanoparticles was significantly higher than that of blank chitosan nanoparticles 
(85±0.94% vs. 62±0.39%, p<0.05). The fine particle fractions (FPF) of the formulations were 
between 15 and 24% (Fig. 6-4.4, Table A6-3 in Appendix 6). The FPFs of both blank and 
drug-loaded conjugate nanoparticles were significantly higher than those of corresponding 
chitosan nanoparticles (24±0.8% and 21±0.7% vs. 19±1.01% and 15±1.5%, respectively; 
p<0.05). The drug-loaded nanoparticles of both chitosan and the conjugate had lower FPFs 
than corresponding blank ones (15±1.5% and 21±0.7% vs. 19±1.01% and 24±0.8%, 
respectively), but analysis of variance showed the difference to be insignificant (p>0.05).   
 
 
Figure 6-4. 1: Particle Deposition in Different Stages of TSI (estimated by gravimetric 
analysis) 
[Note: Particle deposition in different stages was collected in PBS, flitered using 0.2 μm filters and weighed 
after drying. The net weight of particles was determined by subtracting the weight of blank filters. Data 
represent mean±SE, n=3.] 
 
 
Figure 6-4. 2: Recovered Doses (RD) from Different Formulations (estimated by 
gravimetric analysis of TSI depositions)  
[Note: Data represent mean ± SE, n=3.] 
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Figure 6-4. 3: Emitted Doses (ED) from Different Formulations (estimated by gravimetric 
analysis of TSI depositions) 
 [Note: Data represent mean ± SE, n=3. Significance level, p < 0.05.] 
 
 
 
Figure 6-4. 4: Fine Particle Fraction (FPF) of Different Formulations (estimated by 
gravimetric analysis of TSI depositions) 
[Note: Data represent mean ± SE, n=3. Significance level, p < 0.05.] 
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Figs. 6-5.1 to 6-5.4 present the results of drug deposition from drug-loaded chitosan and 
conjugate nanoparticles in different stages of the TSI according to spectrophotometric 
analysis.   
 
 
Figure 6-5. 1: Drug Deposition in Different Stages of TSI (estimated by UV 
spectrophotometric analysis) 
[Note: Particles deposited in different stages of TSI were collected in PBS, incubated at 37 °C for 2 weeks (for 
chitosan) / 3 weeks (for conjugate), after which the release medium was analysed spectrophotometrically to 
determine the amount of DH.  Data represent mean ± SE, n=3.] 
 
 
Figure 6-5. 2: Recovered Doses (RD) from Different Formulations (determined by UV 
spectrophotometric analysis of TSI depositions) 
[Note: Data represent mean ± SE, n=3.] 
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Figure 6-5. 3: Emitted Doses (RD) from Different Formulations (estimated by UV 
spectrophotometric analysis of TSI depositions) 
 [Note: Data represent mean±SE, n=3.] 
 
 
 
Figure 6-5. 4: Fine Particle Fraction (FPF) of Different Formulations (estimated by UV 
spectrophotometric analysis of TSI depositions) 
[Note: Data represent mean±SE, n=3.] 
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Figs. 6-6.1 and 6-6.2 (A-C) present the results of particle deposition from interactive 
mixtures of drug-loaded chitosan and conjugate nanoparticles with lactose monohydrate in 
different stages of the TSI according to gravimetric analysis.   
 
 
Figure 6-6. 1: Particle Deposition in Different Stages of TSI from Inteactive Mixtures of 
Drug-loaded Chitosan and Conjugate Nanoparticles with Lactose Monohydrate (estimated 
by gravimetric analysis) 
[Note: Particle deposition in different stages was collected in PBS, flitered using 0.2 μm filters and weighed 
after drying. The net weight of particles was determined by subtracting the weight of blank filters. Data 
represent mean±SE, n=3.] 
 
 
Figure 6-6. 2: (A) Recovered Dose (RD), (B) Emitted Dose (ED) and (C) Fine Particle Fraction 
(FPF) of Inteactive Mixtures of Drug-loaded Chitosan and Conjugate Nanoparticles with 
Lactose Monohydrate (estimated by gravimetric analysis) 
[Note: Data represent mean ± SE, n=3.] 
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6.3 DISCUSSION 
6.3.1 Preparation of Chitosan and Chitosan-L-Leucine Conjugate Nanoparticles 
This work was aimed at preparing nanoparticulate DPI formulation loaded with the model 
drug, DH. Of various techniques reported in the literature, emulsification was chosen for this 
work. The underlying reason was that the technique is simple and inexpensive and has been 
used both at the bench-top and industrial scale for fabrication of polymeric particles 
(Berkland et al., 2001). The method allows getting particles in desired size range by 
adjusting the time and/or speed of stirring during emulsification (Dubey & Parikh, 2004). 
Besides, it also allows fabrication of particles with a more optimized release of the 
encapsulated drug by ensuring a uniform dispersion of the drug throughout the polymeric 
matrix (Obeidat, 2009). 
 
Considering the concerns raised by some investigators on possible harmful effect (e.g. 
irritation of mucous membranes) of any residual glutaraldehyde in particles (Lim et al., 
1997; Richards & Knowles, 1968), this work was primarily focussed on fabrication of 
nanoparticles by the solvent evaporation approach (method-1). To generate discrete 
particles in the desired size range, three major changes were made in the previously 
reported methods (Abd El-Hameed & Kellaway, 1997; Lim et al., 2000; Onishi et al., 2005) by 
progressive trial and error.  These included: 1) use of heavy mineral oil instead of light 
mineral oil or light-heavy mixture, 2) increasing the speed of the overhead stirrer to 5000 
rpm and 3) reducing the total solid content to a maximum of 50 mg/100g of oil. These 
changes prevented coalescence and agglomeration of particles during the hardening phase. 
Although the method was successful to generate discrete particles in the desired size range, 
the attempts to load the model drug, DH failed. Microscopic examination of the emulsion 
samples at intervals during the hardening phase showed precipitation of the drug as needle-
shaped crystals at a certain point of time (often within 2-6 h after starting the stirring 
process). The problem was not encountered when glutaraldehyde cross-linking was applied 
instead for hardening of the particles. It seems that the drug crystallized under heat and 
precipitated out before solidification of the polymer. Another possibility is failure of the 
particles to retain the drug crystals formed because of their small size. It would be relevant 
to note here that previous reports on this technique described preparation of particles in 
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micrometer range and this attempt was, in fact, the first of its kind to prepare nanoparticles 
in this way. Although the method failed to incorporate DH — the model drug chosen for this 
work, it might prove useful for incorporating other drugs with different physicochemical 
properties. Besides, attempts could also be made to load the drug into pre-formed particles 
by passive absorption from aqueous solution as has been reported previously by some 
investigators for loading various drugs in chitosan particles (Gupta & Jabrail, 2006, 2007a, 
2007b; Jameela et al., 1994b; Ubaidulla et al., 2007). When attempt was made to fabricate 
drug-loaded conjugate particles by this method, the particles formed aggregates and turned 
into a lump during isolation process. This difference could be due to higher hydrophilicity of 
the conjugate that was further augmented upon incorporation of DH — a highly water 
soluble drug. An increased agglomeration of chitosan particles has been reported previously 
upon incorporation of the hydrophilic drug, propranolol hydrochloride (Patel et al., 2007).      
 
The glutaraldehyde cross-linking method was found to be superior, especially in the sense 
that it did not encounter problem with drug loading as found with solvent evaporation 
approach. Although there are concerns about possible toxic effect of residual 
glutaraldehyde upon administration of the particles in vivo, some investigators have shown 
absence of any untoward effect on living tissues with particles made by this technique 
(Jameela & Jayakrishnan, 1995; Jameela et al., 1994a). In addition, this technique has an 
added advantage of avoiding the use of heat which could be harmful, if sufficiently high, for 
a drug like DH. 
 
6.3.2 Particle Size and Morphology  
Scanning electron microscopy (SEM) was used in this study to visualize the size, shape, and 
surface morphology of the nanoparticles. The size and size distribution were further 
analysed by dynamic light scattering (DLS) using a Zetasizer. It may be noted here that SEM 
has widely been used for size analysis in conjunction with laser diffraction/dynamic light 
scattering. Some investigators depended solely on SEM for this purpose (Gupta & Jabrail, 
2006; Janoria & Mitra, 2007; Nie et al., 2008; Onishi et al., 2005).  
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The blank particles, prepared by either method, were found to be spherical-to-oblate in 
shape (Figs. 6-1 A-D), suggesting that these particles were weak in mechanical strength and 
had a tendency of deformation under pressure. In contrast, drug-loaded particles were 
found to be nearly perfect spheres (Figs. 6-1 E-F). This implies that the drug-polymer 
mixture increased the compactness and rigidity of the particles compared to the polymers 
alone.   
 
With few exceptions, the surface of the particles was smooth with no cracks or pores (Figs. 
6-1 A-F). This apparently suggests that the internal structure of the particles was compact 
and nonporous. There was no sign of the presence of any drug crystal on the particle 
surfaces. This suggests that the drug and polymer have uniformly been mixed together in 
the process of particle formation. 
 
As shown in the Figs. 6-1 A-F, the size of the nanoparticles was below 100 nm implying that 
they were well-suited for pulmonary delivery, because it has been reported that particles of 
this size range are primarily deposited in the alveolar region of the lungs upon inhalation 
(Hoet et al., 2004; Oberdorster et al., 2005).   The size was only slightly affected by the 
nature of the polymeric matrix (i.e. chitosan/ conjugate) or the method of preparation (i.e. 
solvent evaporation / glutaraldehyde cross-linking). However, drug loading brought a 
reduction in the size of both chitosan and conjugate nanoparticles (Figs. 6-1 E & F). This 
effect could be attributed to reduced viscosity of the solution due to replacement of half of 
the polymeric material with drug that made dispersion of the aqueous phase into oil easier 
giving rise to smaller sizes of droplets, ultimately giving smaller particles. This is supported 
by the findings of Denkbas & Odabasi  (2000) who demonstrated a decrease in particle size 
with decrease in chitosan concentration in the aqueous phase.  One negative aspect of all 
the formulations was that the particles showed a tendency to form agglomerates (Figs. 6-1 
A-F). However, this is a common phenomenon with nanoparticles, which results from high 
surface area and associated surface energy of particles in this size range. 
 
 
Chapter 6 Preparation of Nanoparticles and In Vitro Studies on their Aerosolization and Drug Release 
 
 
114 
 
Zetasizer analysis of blank chitosan and conjugate nanoparticles made by the method-1 
gave a unimodal particle size distribution with a Z-average of ~70 r.nm, which was much 
higher compared to the diameter of the particles observed by SEM (10-30 nm) (Table A6-1 
in Appendix 6, Figs. 6-1 A and B, 6-2 A and B). However, consistent with SEM micrographs, 
the Z-average of conjugate nanoparticles appeared to be larger than that of chitosan 
nanoparticles (76.61±1.23 r.nm vs. 67.25±2.82 r.nm) (Table A6-1). On the other hand, all the 
formulations made by method-2 showed multimodal distribution with a population of 
particles having  Z-average in the range of 9-16 r.nm and another population with                  
Z-averages between 194 and 263 r.nm. The drug-loaded nanoparticles of the conjugate 
showed an additional population with Z-average of ~0.5 r.nm (Table A6-1 in Appendix 6, 
Figs. 6-2 C-F). SEM micrographs of these formulations clearly indicate that the diameter of 
the blank chitosan and conjugate nanoparticles made by this method predominantly fall in 
the range of 10-30 nm (Figs. 6-1 C-D), while the drug-loaded particles had a close, but  
relatively narrower, diameter range of 10-20 nm (Figs. 6-1 E-F). This suggests that the larger 
size populations observed during particle sizing reflects aggregates arising from cohesion of 
small individual particles. Similar observations have been reported by a number of 
investigators in relation to various polymeric and non-polymeric microparticles (Li & Birchall, 
2006; Li et al., 2005; Rabbani & Seville, 2005; Steckel et al., 2003). The high polydispersity 
index (1.00) of the samples also gives an indication of a high agglomeration tendency of the 
particles. This phenomenon implies potential poor performance of the particles during 
aerosolization, which is explained later in the Section 6.3.5. However, as long as the 
agglomerates had their sizes in the order of 200-250 r.nm, the particles are expected be 
good enough to reach deeper regions of the respiratory system. It remains a question here 
why particles prepared by method-1 do not show a peak at 10-30 nm diameter despite the 
fact that they have lower polydispersity indices in the range of 0.3-0.5; however, the 
agglomerate sizes obtained for them (49 and 70 r.nm for chitosan and conjugate 
nanoparticles, respectively) are much smaller than those of the nanoparticles prepared by 
the method-2 (200-250 r.nm) which is consistent with their smaller polydispersity indices 
(Table A6-1 in Appendix 6).  
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6.3.3 Production Yield, Drug Loading and Entrapment Efficiency 
The solvent evaporation procedure produced a yield of 69±2% and 57±2% for chitosan and 
conjugate nanoparticles, respectively (Table 6-1). This apparently low yield can be 
attributed to the small scale of production that could have resulted in relatively large losses 
of materials through adhesion to the vessel walls and propeller shaft and blades and 
subsequent centrifugation performed for isolation and purification. On the contrary, the 
glutaraldehyde cross-linking technique apparently produced more than 100% yield 
(chitosan, 191±5% and conjugate, 169±4%) (Table 6-1); this could be attributed to an 
increase in the bulk of the starting polymers due to incorporation of glutaraldehyde 
moieties between polymer chains. Again, although still more than 100%, drug-loaded 
nanoparticles had relatively lower yield (chitosan, 125±6% and conjugate, 119±5%) (Table 6-
1). This could reasonably be attributed to replacement of 50% polymer with the drug, DH 
that did not interact with the cross-linker, glutaraldehyde in the way that the polymers did. 
It would be pertinent to note here that, in addition to incorporation of crooslinked 
glutaraldehyde moieties between the polymer chains, residual moisture left in the particles 
might also have contributed to the increase in the bulk of polymeric materials resulting in 
more than 100% percent yield compared to the starting material. 
 
The entrapment efficiency is the fraction of the total drug input that has been encapsulated 
into the particles. During the process of forming drug-loaded nanoparticles, the drug is often 
lost to some extent, and thus a 100% entrapment efficiency of any drug is unlikely. The 
entrapment efficiency of 38±1% and 46±1% as achieved here for chitosan and conjugate 
nanoparticles (Table 6-1) means that about 60% of the drug has practically been lost. Many 
factors could be responsible for this relatively low incorporation efficiency. Firstly, some 
drug is obviously partitioned out to the external oil phase. Though the solubility of the drug, 
DH in oil was negligible, the oil phase was still able to accommodate a good deal of the drug 
because of its large volume (79 times higher than the drug-containing water phase). 
Secondly, during the cross-linking and hardening process, water is exuded from the particles 
taking along the dissolved drug; this could also contribute to decrease in the incorporation 
efficiency (Jameela & Jayakrishnan, 1995). Finally, small size of the particles might also have 
contributed to the low entrapment. It has been reported that efficiency of particles to 
entrap drugs falls with decrease in particle size (Hadinoto et al., 2007).  
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The drug loading (%) refers to the amount of drug per 100 g of particle. Drug loading 
obtained for chitosan and conjugate nanoparticles was 16±1% and 20±1%, respectively 
(Table 6-1). As explained above, this apparently low % loading was due to the loss of some 
drug to the external oil phase and, possibly, also for anticipated poor entrapment of drug 
because of small particle size. However, these figures could be higher if the particle yield did 
not exceed 100% (chitosan, 125±6% and conjugate, 119±5%) (Table 6-1) owing possibly to 
glutaraldehyde cross-linking. 
 
The higher entrapment efficiency and drug loading of conjugate nanoparticles compared to 
chitosan nanoparticles (46±1% and 20±1% vs. 38±1% and 16±1%, respectively) (Table 6-1) 
could be attributed to the higher solubility of the conjugate in water that enabled its better 
association with the water soluble drug, DH. This is because the entrapment of drug is 
dependent on the successful molecular-level association of the drug with the polymer 
(Kockisch et al., 2005). 
 
6.3.4 In Vitro Drug Release Study 
Ideally, a controlled release formulation should initially provide quick release of an amount 
of drug that would allow to promptly achieve an effective plasma concentration followed by 
a slow, continued release of an amount that would be adequate to replace the amount of 
drug eliminated from the body and maintain a constant blood level of the drug over time 
within the therapeutic window. As shown in the results section (Section 6.2.4), although the 
rate and extent of drug release varied, both chitosan and conjugate nanoparticles showed a 
bi-phasic drug release with a large initial burst followed by a slow, controlled release over a 
period of 8 and 16 days, respectively (Fig. 6-3.1, Table A6-2 in Appendix 6). The initial burst 
accounted for 16±0.32%, and 31±1.98% of drug release from chitosan and conjugate 
nanoparticles, respectively within the first 30 min, leaving 84±0.55% and 69±3.42% back in 
the particles for slow, steady release. This kind of bi-phasic release might prove useful to 
satisfy the pattern of release required of a controlled release formulation to quickly achieve 
a therapeutic blood level (burst release) and maintain it over time (controlled release). 
Previous investigators also observed similar type of release for various drugs (e.g.                   
5-fluorouracil, methotrexate, centchroman, mitoxantrone, and bovine serum albumin (BSA)) 
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from chitosan particles made by glutaraldehyde cross-linking (Dubey & Parikh, 2004; Gupta 
& Jabrail, 2007b; Jameela & Jayakrishnan, 1995; Jameela et al., 1994a) as well as  for some 
drugs (e.g. for clozapine, BSA) from particles made by other techniques (Agnihotri & 
Aminabhavi, 2004; Gan & Wang, 2007). The phenomenon has also been reported for drug 
release from other polymeric particles (such as PLGA and PLA) (Erden & Celebi, 1996; 
Ibrahim et al., 2005). The large initial burst release is attributed to the drug located at or 
near the surface (Agnihotri & Aminabhavi, 2004). It could be reasoned that the hydrophilic 
nature of chitosan and high aqueous solubility of DH allowed the hydration of the polymer 
surface and subsequent dissolution and release of the drug to occur in an exceedingly quick 
succession. The subsequent sustained release is attributed to the swelling of the polymer to 
form a gel layer that offers  a hindrance to the outward diffusion of the drug molecule from 
the core and thereby slows down the drug release (Denkbas et al., 1999; Dhawan & Singla, 
2003; Learoyd et al., 2008a; Lim et al., 2000).  
 
The release of drug both from chitosan and conjugate nanoparticles was not complete even 
after running the experiment for one month. The maximum cumulative release obtained 
was only 23% for chitosan nanoparticles and 52% for conjugate ones leaving back 77% and  
48%   drug, respectively, still unreleased (Fig. 6-3.1, Table A6-2 in Appendix 6). This sort of 
incomplete release has also been reported previously for chitosan particles (Agnihotri & 
Aminabhavi, 2004; Lim et al., 2000; Torres et al., 1998 ). This is attributed to binding of a 
fraction of incorporated drug to some components of the matrix though electrostatic or 
covalent interaction (Jameela et al., 1994a; Lim et al., 2000). In their studies, Jameela et al. 
(1994a) accounted interaction with the aldehyde moieties of the residual glutaraldehyde for 
incomplete release (~50%) of BSA.  
 
Both the initial burst and total release from conjugate nanoparticles were approximately 
twice as much higher as from chitosan nanoparticles (31% and 52% vs. 16% and 23%)      
(Fig. 6-3.1, Table A6-2 in Appendix 6)). This can be attributed to improved aqueous 
solubility shown by the conjugate compared to chitosan. While chitosan needed an 
overnight stirring with dilute acetic acid for dissolution, the conjugate dissolved immediately 
upon adding to water.  This higher solubility of conjugate, in one hand, allowed for 
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increased drug loading (Table 6-1) into the particles as has already been explained in the 
Section 6.3.3 and, on the other hand, conferred to them more wettability in water. Being a 
water soluble drug, DH could be expected to easily dissolve in hydrated polymeric 
environment. Therefore, the higher the drug loading, the more the drug dissolved in the 
hydrated polymeric matrix. This would have resulted in a higher diffusional driving force and 
in turn caused a faster drug release (31% for conjugate vs. 16% for chitosan within the first 
30 min) (Fig. 6-3.1, Table  A6-2 in Appendix 6). Similar reasoning has been made earlier by 
Patel et al. (2007) for explaining the release of another hydrophilic drug, propranolol 
hydrochloride from chitosan-based matrix.  Additionally, a better wettability of conjugate 
nanoparticles meant their quicker hydration and so faster dissolution and release of the 
incorporated drug. The higher solubility shown by the conjugate could be related to the 
surface changes induced by L-leucine conjugation. It has previously been hypothesized that, 
because of its surfactant like property, L-leucine conjugated to chitosan would impart an 
amphiphilic environment around the chitosan backbone (Section 1.2 and Fig. 1-1 in Chapter 
1).  This amphipathic environment could duly be expected to increase the solubility of the 
polymer. 
 
Besides exhibiting a higher rate and extent of drug release, the conjugate nanoparticles also 
continued releasing drug for a period twice as long as was shown by chitosan nanoparticles 
(16 days, 52% vs. 8 days, 23%) (Fig. 6-3.1, Table A6-2 in Appendix 6). Two factors could have 
contributed to this. First, conjugate nanoparticles had a higher percentage of drug loading 
(20±1% vs. 16±1%) (Table 6-1). Second, conjugate nanoparticles released twice as much 
drug as chitosan nanoparticles (52% vs. 23%) (Fig. 6-3.1, Table A6-2 in Appendix 6). This 
again apparently was due to the higher hydrophilicity of the conjugate that permitted easier 
access of the release media and in turn created a more favourable environment for drug 
dissolution and diffusion. 
 
For elucidating the kinetic pattern of drug release from both the chitosan and conjugate 
nanoparticles, the release data were fitted to 4 different kinetic models reported in the 
literature, including zero-order, 1st order, square root of time or Higuchi model (Higuchi, 
1963) and cube root or Hixson-Crowell model (Hixson & Crowell, 1931) (Figs. 6-3.1 to 6-3.4). 
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Of these, the first three models are used for studying kinetics of diffusion-controlled release 
from a matrix-type system, while Hixson-Crowell model is used to describe dissolution–type 
release kinetics where the drug is released by dissolution with change in the surface area or 
diameter of the particles (Asada et al., 2004; Filipovic-Grcic et al., 1996). Although literature 
reports suggest that controlled release of drug from chitosan-based systems in PBS/alkaline 
pH is governed by diffusion of the drug through hydrated swollen matrix (Agnihotri & 
Aminabhavi, 2004; Learoyd et al., 2008a; Lim et al., 2000), Hixson-Crowell model was also 
included in this study for kinetic analysis considering higher water solubility shown by the 
conjugate.  However, it would be relevant to note here that neither chitosan nor conjugate 
nanoparticles have practically shown any visible sign of matrix dissolution. The values of r2 
for zero order, first order, Higuchi and Hixson-Crowell models were 0.8868, 0.8921, 0.9808 
and 0.8903, respectively for chitosan nanoparticles and 0.8334, 0.8593, 0.9661and 0.8509, 
respectively for conjugate nanoparticles (Table 6-3). From the r2 values it can be inferred 
that, after the initial burst, the release of the drug from both chitosan and conjugate 
nanoparticles followed Higuchi’s square root of time kinetics.  This is in agreement with 
previous reports on drug release kinetics of chitosan micro- and nanoparticles (Dubey & 
Parikh, 2004; Filipovic-Grcic et al., 1996; Jameela & Jayakrishnan, 1995; Learoyd et al., 
2008a; Lim et al., 2000; Peniche et al., 2003). The release rate constants (KH) determined by 
fitting the data to the model were 0.4709 × 10-2 h-1 for chitosan nanoparticles and 1.1159 × 
10-2 h-1 for conjugate nanoparticles (Table 6-3). The small values of the rate constants 
further confirm that, after the large initial burst, the drug release from the nanoparticles 
proceeded at an extremely slow rate. Besides, their relative magnitude also corroborates 
that the release rate of drug from conjugate nanoparticles was nearly twice as high as that 
from chitosan nanoparticles.  
 
To better characterise the drug release behaviour for the polymeric systems under study, 
and particularly to gain some insight into the corresponding mechanism, the release data 
were also applied to the semi-empirical Korsmeyer-Peppas model (Korsmeyer et al., 1983) 
(Fig. 6-3.5). This model uses the value of the release exponent (n) obtained from the slope 
of a plot of log % cumulative release versus log time in order to characterize different 
release mechanisms. If n is 0.45 or less, the release mechanism is considered to follow 
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Fickian diffusion or case I transport, where drug release occurs through usual molecular 
diffusion because of a concentration (or chemical potential) gradient. Higher values of n 
between 0.45 and 0.89 indicate non-Fickian or anomalous transport, where release is 
controlled by a combination of diffusion and polymer relaxation/erosion. When n reaches a 
value of 0.89 or above, the mechanism of drug release is regarded as case-II or super case-II 
transport which mean that the drug release involves polymer relaxation and chain 
disentanglement/erosion and the rate does not change over time (Cox et al., 1999; Harland 
et al., 1988). As shown in the Table 6-3, application of drug release data to the model and 
regressional analysis resulted in a reasonably good fit giving coefficient of determination (r2) 
values of 0.9611 for chitosan nanoparticles and 0.9709 for conjugate nanoparticles.  The 
values for release exponent (n) were found to be 0.0568 and 0.0856, respectively. This 
suggests that after the initial burst, the release of drug from both the formulations occurred 
by Fickian diffusion through hydrated polymeric matrix. Similar findings on the mechanism 
of drug release from chitosan micro-/ nanoparticles have been reported by other 
investigators. For instance,  in tracine-loaded chitosan nanoparticles prepared by a similar 
method, Wilson et al. (2010) have shown that after an initial burst the particles offered a 
continuous, slow release and the mechanism of drug release as per the Korsmeyer model 
was Fickian.  In another study, Sivadas et al. (2008) reported Fickian diffusion-based release 
of BSA from chitosan microparticles prepared by spray drying. However, there are also 
reports in the literature describing non-Fickian release of drugs from chitosan micro- or 
nanoparticles (Dhawan & Singla, 2003; Patel et al., 2007; Sezer & Akbuga, 1995). On the 
other hand, Gupta & Jabrail (2006) reported a case of centchroman-loaded chitosan 
microspheres where the release of the drug initially was Fickian and became non-Fickian at 
later stage, which the authors attributed to ensuing structural variation in microspheres 
with progressive swelling and dissolution. It is, however, important to note here that these 
apparent disagreements of these reports are not surprising if we consider different types of 
preparation methods employed for making chitosan micro- and nanoparticles and variation 
in the physicochemical properties of incorporated drugs, all of which are intimately related 
to the mechanism of drug release from the particles. 
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With 16 and 20% drug loading (Table 6-1) and 16 and 31% burst release (Fig. 6-3.1) for 
chitosan and conjugate nanoparticles, respectively, the amounts of the drug released as the 
burst effect per 100 mg of chitosan and conjugate nanoparticles stand out to be 2.56 and 
6.20 mg, respectively. So, to provide an initial loading dose of 10.85 mg DH (as calculated in 
section 3.2.2.5 of chapter 3), a lung deposition of 423.83 and 175.00 mg of drug-loaded 
chitosan and conjugate nanoparticles would be required. However, with a release rate 
constant (kH) of 0.4709 ×10-2 and 1.1159×10-2 per hour (as determined by Higuchi model) for 
the controlled release period of chitosan and conjugate nanoparticles, the amount of drug 
released from 423 and 175 mg doses of chitosan and conjugate nanoparticles would be 1.99 
and 1.95 mg per hour, respectively. These values are close to the required maintenance 
dose release rate (MDR) of 2.06 mg/h for DH (as calculated in Section 3.2.2.5 of Chapter 3). 
So, it could be expected that, once the patient has received the required amount of lung 
deposition of drug-loaded chitosan and conjugate nanoparticles (423.83 and 175.00 mg, 
respectively), the concentration of the drug in blood would be maintained close to the 
desired level (0.05 μg/mL) during the controlled release period (8 and 16 days for chitosan 
and conjugate nanoparticles, respectively as shown in the Fig. 6-3.1). However, in 
consideration of patient convenience, further studies are required to increase drug 
entrapment/ loading and the rate and extent of drug release in order to reduce the dose 
size. One approach to this end may be to replace part of the polymer by a bulking agent like 
lactose or mannitol. According to previous literature, these agents can help increase the 
drug release by increasing the hydrophilicity of the matrix (Abd El-Hameed & Kellaway, 
1997; Jain et al., 2000; Li et al., 2009). In addition, they can probably also help improving 
drug loading and entrapment in the same way. It would be relevant to note that the present 
level of drug loading and release might prove satisfactory for potent drugs with smaller dose 
sizes. 
 
6.3.5 In Vitro Aerosolization Study 
The aerosolization performance of different formulations was characterised in terms of 
three parameters, viz. recovered dose (RD), emitted dose (ED) and fine particle fraction 
(FPF).  
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The recovered dose (RD) was presented as the percentage of the actual dose actuated from 
the capsule by Rotahaler® device. As per gravimetric analysis, the recovered doses from 
different formulations were between 74% and 86% (Fig. 6-4.2, Table A6- 3 in Appendix 6), 
indicating that about 15 to 25% of the actuated particles remained in the inhaler device and 
TSI chambers. Sticking of some particles to the glass surfaces of the TSI chambers might 
have primarily accounted for this loss. For drug-loaded particles, drug released from the 
particles in the collecting solvent (PBS) might also have some contribution to the loss. Thus, 
the relatively lower value of 74% for drug-loaded conjugate nanoparticles could be related 
to their higher drug content and quicker drug release rate as discussed in the Section 6.3.4. 
It would be interesting to note here that the addition of 16 and 31% of drug released in 
burst in the first 30 min from chitosan and conjugate nanoparticles respectively (Fig. 6-3.1) 
to the corresponding doses of 81 and 74% recovered from them in TSI study gives a total 
dose of 97 and 105%, respectively which are within ± 5% of their total doses. 
 
The emitted dose (ED) was the amount of drug released from the inhaler device, i.e. the 
sum of drug collected at the upper and lower stages of the TSI modelling for the upper and 
lower respiratory airways. The emission of particles from the inhaler device was reasonably 
good for most formulations with the values ranging from 73 to 85% (Fig. 6-4.3, Table A6-3 in 
Appendix 6). However, blank chitosan particles showed a poor performance and the 
emission was found to be significantly lower than corresponding conjugate particles 
(62±0.39% vs. 85±0.94%; p<0.05) (Fig. 6-4.3, Table A6-3 in Appendix 6). Analogous to the 
difference observed with water solubility, this difference in emission could also be due to 
leucinization induced surface changes (an amphiphilic environment around the chitosan 
backbone) as previously hypothesized, which is expected to reduce the interparticle 
interaction and increase the aerosolization of the particles (Section 1.2 and  Fig. 1-1 in 
Chapter 1). On the contrary, no difference was seen between chitosan and the conjugate in 
the emission of drug-loaded nanoparticles (73±1.96% vs. 79±2.52%; p>0.05) (Fig. 6-4.3, 
Table A6-3 in Appendix 6). SEM studies showed that drug loading reduced the particle size 
of both chitosan and conjugate and they had very similar particle sizes (Fig 6-1 E-F). This 
could be related to the similar emission shown by the two formulations. 
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Although drug-loaded chitosan and conjugate nanoparticles showed equivalent emission 
from the DPI device, both blank and drug-loaded conjugate nanoparticles showed a 
significantly (p<0.05) higher FPF than corresponding chitosan nanoparticles (24±0.8% and 
21±0.7% vs. 19±1.01% and 15±1.5%, respectively) (Fig. 6-4.4, Table A6- 3 in Appendix 6). 
This is an important finding that further corroborates the hypothesis made as the original 
background of this project (Section 1.2 and Fig. 1-1 in Chapter 1). The higher FPF values of 
conjugate nanoparticles establish higher dispersibility of the compound. However, the 
increase in FPF shown by the conjugate nanoparticles was much less than that reported for 
microparticles prepared by physical addition of L-leucine to chitosan in a DPI formulation. 
Learoyd et al. (2008a, 2008b, 2009) demonstrated 82% FPF for a hydrophilic drug, 
terbutaline sulphate, 64% for a hydrophobic drug, beclomethasone diproprionate, and 76% 
for a combination of the two drugs from spray-dried chitosan (LMW: <190 kDa) 
microparticles containing L-leucine as an aerosolization enhancer. These formulations, 
however, also contained lactose as a bulking agent that might also have a significant 
contribution to the high degree of FPF observed. 
 
The results also show that, albeit statistically not significant, blank nanoparticles of both 
chitosan and conjugate, showed higher FPF than corresponding drug-loaded nanoparticles 
(19±1.01% and 24±0.8% vs. 15±1.5% and 21±0.7%, respectively; p>0.05) (Fig. 6-4.4, Table 
A6-3 in Appendix 6). The lower FPF of drug-loaded particles may be due to a higher 
agglomeration tendency caused by incorporation of DH — a highly water-soluble drug. Lim 
& Wan (1998) reported increased agglomeration of chitosan-based microspheres upon 
addition of a hydrophilic drug, propranolol hydrochloride. Besides, as per SEM analysis, 
drug-loaded nanoparticles had a smaller particle size than blank nanoparticles                  
(Figs. 6-1 A-F). The smaller particle size might also have contributed to their higher 
agglomeration limiting their transit from stage I to stage II of the TSI.  
 
Finally, in consideration of the 6.4 µm cut-off value for the lower impingement chamber, it 
may look a bit disappointing for particles of the order of 10-30 nm size to have an FPF of 
only 15-24%. But, as already explained in the literature review (Section 2.4 in Chapter 2), it 
is related to the higher cohesiveness exerted by micronized particles that makes the most 
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important challenge of a DPI system and made the background of this research as well. In 
this view, it is rather encouraging that the nanoparticle formulations of neither chitosan nor 
conjugate, prepared under this project, needed a carrier like lactose or mannitol to aid their 
dispersion from the inhaler depositing a substantial fraction into the stage II of the TSI. For 
free drugs of this size, it is unexpected to get such deposition in the lower stage of the TSI 
without being blended with a carrier. 
 
For further confirmation of the results of TSI depositions estimated by gravimetric method, 
the depositions from different stages were additionally examined by UV spectrophotometric 
estimation of drug released. The results obtained for drug deposition in different stages of 
TSI were similar to those obtained by gravimetric analysis (Figs. 6-5.1 to 6-5.4). This 
confirms the reliability of results obtained by gravimetric analysis. 
 
To investigate the possible effect of an interactive carrier on the dispersion of the 
nanoparticles, drug-loaded chitosan and conjugate nanoparticles were mixed (5%) with 
inhalation grade lactose monohydrate microparticles. As shown in Fig. 6-6.2(C), mixing with 
lactose carrier particles produced a significant (p<0.05) elevation in dispersion of both 
chitosan and conjugate nanoparticles (FPF: 28±0.71% & 37±0.58%) in comparison with 
carrier-free particles (FPF: 15±1.20% & 21±0.58%). This enhancement in nanoparticle 
dispersion could be attributed to the probable reduction of the strong cohesive force among 
the polymer nanoparticles and their de-agglomeration by the lactose monohydrate carrier 
microparticles as has been suggested previously for DPI formulations containing micronized 
drug particles with lactose as a carrier (Bisgaard et al., 2002; Hersey, 1975). Ideally, mixing 
of small quantities of micronized drug particles with larger carrier particles form an ordered 
blend, where a perfect mix consists in a regular coating of fine particles on the coarser 
constituent (Berard et al., 2002). The various forces contributing to this interaction include 
van der walls forces, capillary forces, electrostatic forces and mechanical interlocking (Desai 
et al., 2013). During inhalation, the particles are detached from the carrier surface by the 
inspiratory force (Pilcer & Amighi, 2010).   However, the extent of detachment is affected by 
the strength of the drug-carrier adhesive forces. A strong adhesion resists drug detachment 
and dispersion in the inhalation airstream and in turn reduces the overall lung deposition of 
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drug particles (Desai et al., 2013). Thus, the enhancement of nanoparticle dispersion in this 
study suggests formation of stable, but sufficiently weak bonds with the carrier 
microparticles to allow their release upon application of dispersive force (vacuum air-flow).   
Further studies using different nanoparticle- carrier ratios (e.g. 2.5 or 10%) and by changing 
carrier type, such as using different grades of lactose (e.g. anhydrous lactose, medium 
lactose, regular lactose, lactose crystals, foremost lactose) or other carriers (e.g., mannitol, 
sorbitol) could be tried to find best possible nanoparticle-microcarrier combination. Finally, 
once again, the conjugate nanoparticles showed significantly higher dispersibility compared 
with chitosan nanoparticles (28±0.71% vs. 37±0.58%, p<0.05). This further supports 
enhancement in dispersibility of chitosan upon leucinization.  
    
6.4 CONCLUSION 
Nanoparticles of chitosan and its conjugate with L-leucine were prepared and the model 
drug, DH was successfully loaded into them by emulsification- glutaraldehyde cross-linking 
method. The particles were less than 100 nm in size suggesting their suitability for 
deposition to deeper regions of lungs. Aerosolization studies with TSI showed that 
formulations were able to produce 15-25% FPF without addition of any carrier like lactose or 
mannitol. Nanoparticles made of conjugate were found to be more dispersible than those of 
chitosan, generating a higher FPF. However, if we consider the current challenges of DPI in 
terms of drug deposition in the lower airways, an FPF of 15-24% is not sufficiently high and 
so more studies are needed in that direction.  One attempt in this case was mixing the 
polymer nanoparticles with lactose monohydrate microparticles that demonstrated an 
encouraging enhancement in dispersibility of particles. Drug release studies showed a 
higher drug loading as well as higher percentage of drug release for an extended period of 
time for drug-loaded conjugate nanoparticles compared to chitosan nanoparticles. But, for a 
drug like DH, with bulky therapeutic dose, a drug loading of 15-19% cannot be deemed well 
enough and will require multiple puffs to make the required dose. Therefore, more 
extensive studies are required to optimize drug loading if the formulation is intended for 
pulmonary administration of this drug. However, the formulation could be a good ploy for 
respiratory administration of potent drugs with small dose sizes. Although the drug-loading 
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was unsuccessful with emulsion- solvent evaporation technique, the method could be useful 
for other drugs with different physicochemical properties. The prepared blank particles 
could also be tried for drug loading by passive absorption.  
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7.1 INTRODUCTION 
The respiratory system is already an established route of drug delivery for lung diseases like 
asthma and COPD and is gaining more attention for the delivery of drugs to systemic 
circulation. However, it is a relatively new portal of drug administration compared to oral or 
parenteral route and, so, to avoid any untoward effect on the respiratory system, it is 
important to ensure in the first place the biosafety of any formulation intended for 
inhalation. 
 
As discussed in details in the literature review in the Chapter 2, the biosafety of inhaled 
formulations can best be evaluated in vitro by a combination of a variety of toxicological 
tests on respiratory epithelial cell lines to provide complementary information. Cell viability 
assays, e.g. the MTT assay, are widely used to evaluate the biosafety of inhaled materials 
(Salama et al., 2009b; Sivadas et al., 2008; Zhang et al., 2009). The MTT assay relies on 
mitochondrial reduction of a yellow tertrazole dye, MTT [3(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide] into insoluble formazan crystal as an indicator of cell viability.  
Another indicator of adverse effects of inhaled agents on epithelial cell layers is any 
pernicious change in the permeability of the epithelial barrier. This results from disruption 
of intercellular tight junctions and can be assessed by measuring the permeability of a fluid 
phase marker like sodium fluorescein across a confluent cell monolayer (Gartlon & Clothier, 
2008 ; Grenha et al., 2007; Sivadas et al., 2008). Yet another important concern is to rule out 
any untoward inflammatory response of the respiratory epithelium to the inhaled product. 
This can be accomplished by checking the release of chemokines like IL-8 by an 
immunological technique such as ELISA (Saedisomeolia et al., 2009; Sivadas et al., 2008).     
IL-8 is a chemokine whose release is often associated with initiation of inflammatory 
processes in the lung tissue (Drumm et al., 2000).  
 
Previous studies on chitosan and its micro-/ nanoparticles on pulmonary epithelial cell lines 
like Calu-3 and A-549 indicate their low toxicity on respiratory airways (Grenha et al., 2007; 
Sivadas et al., 2008). TMC, a water soluble derivative of chitosan, has been reported to be 
more toxic than the precursor chitosan (Choksakulnimitr et al., 1995; Fischer et al., 2003; 
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Mao et al., 2005). The L-leucine conjugate of chitosan synthesized under this project is a 
new compound and has shown improved water solubility compared to chitosan. So, it 
warrants a thorough characterisation of its safety profile for using in a pulmonary delivery 
formulation.   
 
The respiratory epithelial cell models, used in previous toxicological investigations of 
chitosan and TMC (e.g. calu-3 and A-549), were derived from human lung tumor. BEAS-2B 
(Reddel et al., 1988) is a non-malignant human bronchial epithelial cell line immortalized 
using an SV40/adenovirus-12 hybrid virus (Graness et al., 2002). It has been widely used as 
an in vitro bronchial epithelial cell model (Wong et al., 2006). But, no study has so far been 
reported to investigate the toxicity of chitosan or any of its derivatives using this cell line. It 
can, therefore, be expected that a study of the toxicity of chitosan and the synthesized        
L-leucine conjugate using this cell line would enrich and complement the existing wealth of 
information.  
 
This chapter evaluates the biosafety of chitosan, its L-leucine conjugate and their 
nanoparticles made by emulsion-solvent evaporation technique in terms of the three      
well-recognised toxicity indicators (cell viability, trans-epithelial permeability and 
chemokine release) using BEAS-2B as an in vitro model. 
 
7.2 RESULTS 
7.2.1 In Vitro Evaluation of Cytotoxicity on the Respiratory Epithelial Cell Line 
BEAS-2B by MTT Assay  
7.2.1.1 MTT Assay of Chitosan, Chitosan-L-Leucine Conjugate and their Nanoparticles 
The Figs. 7-1.1 a, b, c and d present the results of MTT assay of neat chitosan, chitosan 
nanoparticles, neat chitosan-L-leucine conjugate and chitosan-L-leucine conjugate 
nanoparticles, respectively in terms of % survival of BEAS-2B cells at progressively increased 
concentrations  (between 0.125 and 16 mg/mL) applied over a period of 12, 24 and 48 
hours. The corresponding numerical data are presented in the Tables A7-1.1 (a), (b), (c) and 
(d), respectively in the Appendix 7-1. 
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As it is evident from the Fig. 7-1.1 a, the percent survival of the cells progressively decreased 
with an increase in concentration of chitosan, but it did not fall below 50% in any of the 
three treatment durations even at the highest concentration applied. Apparently, there was 
an increased effect on cell survival with an increase in duration of treatment, but analysis of 
variance (ANOVA) suggests that the effects were not significantly different (p >0.05). The 
IC50 of the sample for the 12, 24 and 48 h treatment durations was determined to be 48, 24 
and 17 mg/mL respectively. 
 
 
 
Figure 7-1.1 a: Effect of Chitosan on the Viability of BEAS-2B Cell Line 
The % survival of BEAS-2B cells was determined by MTT assay after 12, 24 and 48h exposure to increasing 
concentrations (viz. 0.125, 0.25, 0.375, 0.50, 1.0, 2.0, 4.0, 8.0, 12.0 and 16.0 mg/mL) of chitosan suspension in 
cell culture medium. Results presented as % survival relative to controls and expressed as the mean ± SE 
(n = 3).  
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As shown in the Fig. 7-1.1 b, up to a concentration of 4 mg/mL, chitosan nanoparticles also 
showed a rather gradual decline in the cell survival with increasing concentration and the 
value was  50% or above . However, beyond a concentration of 4 mg/mL, percentage of cell 
survival abruptly fell reaching nearly zero at a concentration of 8 mg/mL. As regards time 
effect, there was no significant difference between 12 and 24 h time periods   (p > 0.5), but 
the effect on cell survival produced following 48 h incubation was significantly higher 
compared to other two durations (p < 0.05). The IC50 of the sample for the 12, 24 and 48 h 
treatment was determined to be 6, 7 and 3 mg/mL, respectively. 
 
 
Figure 7-1.1 b: Effect of Chitosan Nanoparticle on the Viability of BEAS-2B Cell Line 
The % survival of BEAS-2B cells was determined by MTT assay after 12, 24 and 48h exposure to increasing 
concentrations (viz. 0.125, 0.25, 0.375, 0.50, 1.0, 2.0, 4.0, 8.0, 12.0 and 16.0 mg/mL) of chitosan nanoparticle 
suspension in cell culture medium. Results presented as % survival relative to controls and expressed as the 
mean ± SE (n = 3). 
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As evident from the Fig. 7-1.1 c, the chitosan-L-leucine conjugate also showed a 
concentration dependent effect on the cell survival and the effect appeared to be more 
pronounced than its precursor, chitosan. The effect on cell survival increased with increase 
in the duration of treatment. In case of the 12 h treatment, the percentage of viable cells 
was still higher than 50% up to a concentration of 4 mg/mL. The percentage of cell survival 
showed a linear decline beyond the concentration of 2 mg/mL, reaching to nearly zero at a 
concentration of 12 mg/mL. Prolonged treatments over 24h and 48h periods showed a 
more rapid decline in cell survival reaching a percentage of 50% at about just 2 mg/mL and it 
culminated to nearly zero at a concentration of 8 mg/mL. Apparently, the effects over 24 h 
and 48 h periods were close to each other, but statistical analysis shows that the effects 
were significantly different for all the three durations (p < 0.05). The IC50 of the samples for 
the 12, 24 and 48 h incubation was determined to be 6, 4 and 4 mg/mL, respectively. 
  
 
Figure 7-1.1 c: Effect of Chitosan-L-Leucine Conjugate on the Viability of BEAS-2B Cell Line 
The % survival of BEAS-2B cells was determined by MTT assay after 12, 24 and 48h exposure to increasing 
concentrations (viz. 0.125, 0.25, 0.375, 0.50, 1.0, 2.0, 4.0, 8.0, 12.0 and 16.0 mg/mL) of chitosan-L-leucine 
conjugate solution in cell culture medium. Results presented as % survival relative to controls and expressed as 
the mean ± SE (n = 3). 
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Conjugate nanoparticles also showed a concentration- and time- dependent effect on the 
cell viability (Fig. 7-1.1 d). However, the effect appeared to be more pronounced than neat 
conjugate, the cell viability falling to about 50% or below  at just 2 mg/mL concentration at 
all the three treatment durations. For 12h and 24h durations, concentration required to 
cause nearly 100% cell death was 12 mg/mL, while it was 8 mg/mL for 48h treatment 
duration. According to analysis of variance, there was no significant difference between the 
effects on cell viability observed over 12h and 24h durations (p>0.05); 48h effects were 
significantly higher than 12h or 24h effects (p<0.05). The IC50 of the sample for 12, 24 and   
48 h durations was determined to be 5, 4 and 2 mg/mL, respectively. 
 
 
Figure 7-1.1 d: Effect of Chitosan-L-Leucine Conjugate Nanoparticle on the Viability of 
BEAS-2B Cell Line 
The % survival of BEAS-2B cells was determined by MTT assay after 12, 24 and 48h exposure to increasing 
concentrations (viz. 0.125, 0.25, 0.375, 0.50, 1.0, 2.0, 4.0, 8.0, 12.0 and 16.0 mg/mL) of chitosan-L-leucine 
conjugate nanoparticle suspension in cell culture medium. Results presented as % survival relative to controls 
and expressed as the mean ± SE (n = 3). 
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7.2.1.2 MTT Assay of Diltiazem Hydrochloride 
Fig. 7-1.2 presents the effect of different concentrations of diltiazem hydrochloride (DH) on 
the viability of BEAS-2B cell line after incubation for the 3 different time intervals (12, 24 
and 48 h). Corresponding tabular data are presented in the Table A7-1.2 in the Appendix    
7-1. As shown in the Fig. 7-1.2 and further confirmed by ANOVA post-hoc analysis, the 
percentage of cell death progressively increased with increase in incubation period. In all 
the three cases, cell viability appeared to remain more or less unaffected (rather slightly 
enhanced) at 0.125 and 0.25 mg/mL concentration. But, beyond the concentration of 0.375 
mg/mL % survival abruptly fell to nearly zero. The IC50 of the sample for 12, 24 and 48 h 
treatment periods was determined to be 0.47, 0.43 and 0.37 mg/mL, respectively. 
 
 
Figure 7-1. 2: Effect of Diltiazem HCl on the Viability of BEAS-2B Cell Line 
The % survival of BEAS-2B cells was determined by MTT assay after 12, 24 and 48h exposure to increasing 
concentrations (viz. 0.125, 0.25, 0.375, 0.50, 1.0, 2.0, 4.0, 8.0, 12.0 and 16.0 mg/mL) of diltiazem hydrochloride 
solution in cell culture medium. Results presented as % survival relative to controls and expressed as the 
mean ± SE (n = 3).  
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7.2.2 In Vitro Evaluation of the Effect on the Integrity of Respiratory Epithelium by 
Sodium Fluorescein Transport Assay across BEAS-2B cell Monolayer 
7.2.2.1 Determination of the Polarisation Point of the BEAS-2B Cell Culture by TEER 
Measurement   
Fig. 7-2.1 presents 10 days’ transepithelial electrical resistance (TEER) measurement across 
BEAS-2B cell monolayer grown over 0.4 µm transwell inserts using RPMI as the culture 
medium. Corresponding numerical data are presented in the Table A7-2.1 in Appendix 7-2.     
The results suggest that the cell monolayers reach their maximum TEER at 4 days. 
 
 
Figure 7-2. 1: Time Course of TEER Development in BEAS-2B Cell Monolayers Grown on 
Transwell Inserts 
The TEER of cell monolayers was determined at 24 h intervals after seeding the inserts with BEAS-2B cells at a 
density of 5 × 105 cells/cm2. The monolayer TEER was corrected for the resistance of the filter support alone. 
Results expressed as the mean ± SE (n = 3). 
 
7.2.2.2 Comparison of the Permeability of a Transwell Containing Confluent BEAS-2B Cell 
Monolayer and a Blank Transwell 
The Fig. 7-2.2 presents the apparent permeability of the blank inserts (no cell) and seeded 
inserts to Na Flu at the polarization point. Corresponding tabular data are presented in the 
Table A7-2.2 in the Appendix 7-2. It clearly indicates that there was a comprehensive 
reduction to the permeability of seeded inserts compared to the blank inserts, confirming 
development of an effective barrier by BEAS-2B cells upon polarization.     
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Figure 7-2. 2: Permeability of Na Flu across a Blank Transwell and a Transwell Containing 
Confluent BEAS-2B Cell Monolayer 
The amount of Na Flu transported to the basolateral chambers of blank transwells and transwells containing 
confluent cell monolayers was determined spectrofluorometrically 0.5 h after apical treatment with cell 
culture medium containing Na Flu (0.2 mg/mL). The apparent permeability coefficient (Papp) values were 
calculated using the equation (14) as described in detail in the Chapter 3, Section 3.2.3.3.2.  Results expressed 
as the mean ± SE (n = 3). 
 
7.2.2.3 Effect of Chitosan, Conjugate and their Nanoparticles on Transport of Na Flu across 
BEAS-2B Cell Monolayer 
Figs. 7-2.3 a, b, c and d present the effect of chitosan, its L-leucine conjugate and their 
nanoparticles, respectively on the permeability of sodium fluorescein across polarized    
BEAS-2B cell monolayers at various concentrations (0.5-4 mg/mL) and time-points            
(0.5-48 h). Corresponding tabular data are presented in the Tables A7-2.3 a, b, c and d, 
respectively in the Appendix 7-2. 
703 
110 
0
100
200
300
400
500
600
700
800
Blank Transwell Transwell containing polarized
BEAS-2B monolayer
Ap
pa
re
nt
 P
er
m
ea
bi
lit
y 
 C
oe
ff
ic
ie
nt
, P
ap
p 
( n
m
/s
) 
Chapter 7 In Vitro Evaluation of Toxicity and Inflammatory Activity  
  
 
136 
 
As shown in the Fig. 7-2.3 a and further confirmed by ANOVA with post-hoc analysis, there 
was no significant change in the permeability of BEAS-2B cell monolayers treated with 
chitosan suspension compared to untreated cell monolayer irrespective of concentration 
and time (p value for concentration = 0.124 and p for concentration-time interaction = 
0.123). 
 
 
Figure 7-2.3 a: Effect of Chitosan on Na Flu Transport across the BEAS-2B Cell Monolayer 
Cumulative amounts of Na Flu transported to the basolateral chambers of transwells containing polarized cell 
monolayers were determined by spectrofluorometry at 0.5, 1, 2 4, 6, 12, 24 and 48 h time-points after apical 
treatment with increasing concentrations (viz.  0, 0.5, 1, 2 and 4 mg/mL) of chitosan suspension in cell culture 
medium containing Na Flu (0.2 mg/mL). Results expressed as the mean ± SE (n = 3). 
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Fig. 7-2.3 b suggests that chitosan nanoparticles also did not cause any appreciable change 
in the permeability of the cell monolayer compared to control. However, statistical analyses 
indicate that the permeability of the cell monolayer treated with a concentration of 4 
mg/mL was significantly lower than control (0 mg/mL) at initial time-points from 0.5 h up to 
6 hours (p < 0.05), but it levels off with passage of more time at 12h time-point (p = 0.317, 
0.780 and 0.079 at 12, 24 and 48 h, respectively). 
 
 
Figure 7-2.3 b: Effect of Chitosan Nanoparticle on Na Flu Transport across the BEAS-2B Cell 
Monolayer 
Cumulative amounts of Na Flu transported to the basolateral chambers of transwells containing polarized cell 
monolayers were determined by spectrofluorometry at 0.5, 1, 2 4, 6, 12, 24 and 48 h time-points after apical 
treatment with increasing concentrations (viz.  0, 0.5, 1, 2 and 4 mg/mL) of chitosan nanoparticle suspension in 
cell culture medium containing Na Flu (0.2 mg/mL). Results expressed as the mean ± SE (n = 3). 
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Fig. 7-2.3 c presenting the effect of the chitosan-L-leucine conjugate apparently shows no 
difference between the treatments and control. But, statistical analysis indicates that 
permeability of the cell monolayers receiving 0.5, 1 and 2 mg/mL concentrations of the 
conjugate were significantly higher than the control at most time-points (p = 0.003, 0.000, 
0.000 respectively). But, there was found no significant difference among these 3 
concentrations (p > 0.05).  On the other hand, the permeability of the cell monolayer at 4 
mg/mL concentration appeared not to be statistically different from that of the control (p = 
0.999).
 
Figure 7-2.3 c: Effect of Chitosan-L-Leucine Conjugate on Na Flu Transport across the BEAS-
2B Cell Monolayer 
Cumulative amounts of Na Flu transported to the basolateral chambers of transwells containing polarized cell 
monolayers were determined by spectrofluorometry at 0.5, 1, 2 4, 6, 12, 24 and 48 h time-points after apical 
treatment with increasing concentrations (viz.  0, 0.5, 1, 2 and 4 mg/mL) of chitosan-L-leucine conjugate 
solution in cell culture medium containing Na Flu (0.2 mg/mL). Results expressed as the mean ± SE (n = 3). 
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In case of conjugate nanoparticles (Fig. 7-2.3 d), the permeability of the cell monolayers was 
found to be significantly lower than control (p = 0.000) at all the 4 concentrations tested. 
However, there was a very clear-cut concentration-dependent gradation in the permeability 
— the highest concentration used in this experiment (4 mg/mL) showing a maximum that 
approached close to the control at the initial time-points and became equal to that at 24 
and 48 hour time-points.  
 
Figure 7-2.3 d: Effect of Chitosan-L-Leucine Conjugate Nanoparticle on Na Flu Transport 
across the BEAS-2B Cell Monolayer 
Cumulative amounts of Na Flu transported to the basolateral chambers of transwells containing polarized cell 
monolayers were determined by spectrofluorometry at 0.5, 1, 2 4, 6, 12, 24 and 48 h time-points after apical 
treatment with increasing concentrations (viz.  0, 0.5, 1, 2 and 4 mg/mL) of chitosan-L-leucine conjugate 
nanoparticle suspension in cell culture medium containing Na Flu (0.2 mg/mL). Results expressed as the 
mean ± SE (n = 3). 
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Fig. 7-2.4 compares the effects of the 4 different samples on the permeability of BEAS-2B 
cell monolayer in terms of the relative permeability (Papp, polymer/Papp, control) of the 
samples (at 2 mg/mL concentration) plotted against time. The concentration has been 
chosen based on MTT assay results that suggest that the percentage of cell death caused by 
all the four samples at this concentration is either below or around 50%.  As evident from 
the figure, the chitosan-L-leucine conjugate caused the highest permeation and its 
nanoparticles the lowest. The chitosan and its nanoparticles demonstrated a comparable 
permeability at most of the time-points and statistically there is no significant difference 
between them (p = 0.589).  
 
 
Figure 7-2. 4: Comparison of the Effect of Chitosan, Chitosan-L-Leucine Conjugate and their 
Nanoparticles on Na Flu Transport across the BEAS-2B Cell Monolayer 
Cumulative amounts of Na Flu in basolateral chambers of transwells containing confluent cell monolayers 
were determined by spectrofluorometry at 0.5, 1, 2 4, 6, 12, 24 and 48 h time-points after apical treatment 
with the test samples (2 mg/mL) suspended/dissolved in cell culture medium containing Na Flu (0.2 mg/mL). 
The apparent permeability coefficient (Papp) values were calculated using the equation (14) as described in 
detail in the Section 3.2.3.3.2 of Chapter 3. Results presented as apparent permeability of cell monolayer to    
Na Flu relative to control and expressed as the mean ± SE (n = 3).  
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7.2.3 In Vitro Evaluation of Inflammatory Effect by Chemokine (IL-8) Release Study  
Fig. 7-3 demonstrates the effect of increasing concentrations (0.5-4 mg/mL) of chitosan, 
chitosan-L-leucine conjugate and their nanoparticles on IL-8 release from BEAS-2B cells upon 
incubation for 24 hours compared to the no-treatment control (0 mg/mL). The 
corresponding numerical data are presented in the Table A7-3 in the Appendix 7-3.  
 
 
 
Figure 7- 3: Effect of Chitosan, its L-Leucine Conjugate and their Nanoparticles on IL-8 
Release by BEAS-2B Cells 
The IL-8 levels in culture supernatants were determined by ELISA 24 h after exposure of the cells with 
increasing concentrations (0, 0.5, 1, 2 and 4 mg/mL) of the test samples suspended/dissolved in the cell culture 
medium. Results expressed as the mean ± SE (n = 3).  
 
As shown in the Fig. 7-3, chitosan caused mild, but significant, induction of IL-8 release 
compared to control (0 mg/mL) at all the 4 concentrations applied. Although apparently 
there was a progressive increase in lL-8 release with increasing concentration, there was no 
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significant difference in responses to the 4 different concentrations as per statistical analysis 
(p>0.05).  Chitosan nanoparticles apparently elicited a higher response than neat chitosan at 
the lowest concentration applied (0.5 mg/mL), but statistical analysis suggests that there 
was no difference between the effects of chitosan and its nanoparticles at all the 
concentrations tested (p>0.05). The chitosan-L-leucine conjugate caused a concentration-
depended and statistically significant induction of IL-8 release (p>0.05) up to the 
concentration of 2 mg/mL, after which the response fell down at the concentration of 4 
mg/mL. The response to conjugate was slightly lower than chitosan and its nanoparticles; 
the difference was found to be statistically significant (p<0.05). In a pattern similar to neat 
conjugate, its nanoparticles also caused a concentration-dependent induction of IL-8 
expression up to a concentration of 2 mg/mL and a reduction in the effect at further higher 
concentration of 4 mg/mL. The response was particularly strong and much higher than all 
other 3 samples at 1 and 2 mg/mL concentration.  
  
7.3 DISCUSSION 
7.3.1 In Vitro Evaluation of Cytotoxicity on the Respiratory Epithelial Cell Line 
BEAS-2B by MTT Assay 
This experiment was meant to investigate in vitro the potential of the chemically 
synthesized chitosan-L-leucine conjugate and its nanoparticles to cause any toxicity to 
pulmonary epithelium in comparison to the parent commercially available polymer, 
chitosan and its nanoparticles. This was a prologue to other experiments designed in this 
series to evaluate the effect of these materials on trans-epithelial permeability and to assess 
their inflammatory potential. The study assessed effects of increasing concentrations of 
chitosan, its L-leucine conjugate and their nanoparticles on cell viability in order to elucidate 
the concentration-effect relationship and identify the highest concentration of the samples 
that would exhibit a tolerable level of toxicity towards the cell line. The concentrations 
exhibiting an accepted level of toxicity were then used to investigate the potential of the 
samples to modulate epithelial permeability or elicit inflammatory response.  
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As shown in the Figs. 7-1.1 a, b, c and d, in general, all the 4 samples viz. chitosan, chitosan 
nanoparticles, conjugate and conjugate nanoparticles, showed a concentration- and time-
dependent effect on the viability of cells — the percentage of cell survival showing a 
progressive decrease with increased concentration and longer exposure, although the 
magnitude of cell death varied with different samples. The intensity of the effect, as per 
statistical analysis, was progressively higher in the order of chitosan, chitosan nanoparticles, 
conjugate and conjugate nanoparticles (p<0.05). As shown in the Fig. 7-1.1 a, in agreement 
with previous literature that reported low cytotoxicity of chitosan in various respiratory cell 
lines like calu-3 or A-549 (Florea et al., 2006; Grenha et al., 2007; Huang et al., 2004; Lim et 
al., 2001; Smith et al., 2004; Smith et al., 2005), the BEAS-2B cell line used in this study also 
showed a high percentage of cell survival following treatment with chitosan over the entire 
concentration range applied and all the three time periods tested. The cell survival did not 
fall in any case below 50% (Fig. 7-1.1 a). Chitosan nanoparticles also showed a high 
percentage of cell survival up to a concentration of 4 mg/mL. However, beyond the 
concentration of 4 mg/mL, percentage of cell survival abruptly declined reaching nearly zero 
at a concentration of 8 mg/mL (Fig. 7-1.1 b). Although the nanoparticles caused higher 
percentage of cell death compared to the neat chitosan, it is consistent with the findings of 
some previous investigators in consideration of dose applied. For instance, Huang et al.  
(2004) reported a 70% reduction in the viability of A-549 cells by chitosan nanoparticles at a 
concentration of about 1 mg/mL. But, it is in contradiction to the report of Vllasaliu et al. 
(2010) who found the effect of the nanoparticles on the calu-3 cells to be lower than 
chitosan solution. Fig. 7-1.1 c suggests that the L-leucine conjugate of chitosan was more 
toxic than its precursor, chitosan. This finding appears to be reasonable if it is compared 
with another water-soluble derivative, trimethylchtiosan chloride (TMC) that has been 
reported to be more toxic than chitosan (Choksakulnimitr et al., 1995; Fischer et al., 2003; 
Mao et al., 2005). The increased toxicity has been attributed to its increased solubility that 
allows a better interaction with anionic cell surface components. The conjugate 
nanoparticles appeared to be more toxic than neat conjugate. Nonetheless, they still had an 
IC50 value of ≥ 2 mg/mL even at the longest exposure of 48 h (Fig. 7-1.1 d). 
 
Chapter 7 In Vitro Evaluation of Toxicity and Inflammatory Activity  
  
 
144 
 
Considering that the particles are intended for the delivery of the drug, DH to the lungs, an 
attempt was made to assess the effect of the drug as well on the viability of BEAS-2B cell 
line. As shown in the Fig. 7-1.2, the drug appeared to be rather more toxic to the cell line 
causing complete cell death above a concentration of 0.375 mg/mL. No study has been 
reported in the literature on the effect of DH on any of the pulmonary cell lines. There are, 
however, a few studies reporting significant inhibition of vascular smooth muscle cells 
(VSMCs) by the drug (Salabei et al., 2012; Yan et al., 2007). It would be appropriate to note 
here that the toxicity profile might improve upon loading the drug into polymeric 
nanoparticles. It has been shown earlier by Manca et al. (2008) that incorporation of the 
drug rifampicin into polymeric microparticles (PLGA, chitosan and chitosan-coated PLGA) 
substantially reduced drug toxicity to alveolar epithelial cell line, A-549. 
Using chitosan/ conjugate nanoparticles loaded with the model drug (DH), no experiments 
on the toxicity have been performed in this study. Therefore, it would be relevant to make a 
preliminary theoretical assessment of the toxicity status of such particles on the basis of the 
experimental data obtained on drug release from drug-loaded particles and cytotoxicity of 
blank particles. As shown in the Section 3.2.2.5 of the Chapter 3, DH would require a 
loading dose (DL) of 10.85 mg to initially achieve the desired blood level of 0.05 µg/ mL and 
maintenance dose release rate (MDR) of 2.06 mg/h for maintaining this blood level over an 
extended period of time. With an MDR of 2.06 mg/h, the amount of DH to be added as the 
maintenance dose (Dm) would be 24.72, 49.44 and 98.88 mg for 12, 24 and 48h, 
respectively. Added these values to the DL of 10.85 mg, the total doses of DH for a 
controlled release formulation stand out to be 35.57, 60.29 and 109.73 mg for 12, 24 and 
48h, respectively.  On the other hand, the IC50 values of blank chitosan and conjugate 
nanoparticles obtained in this study were 6, 7 and 3 mg/mL for chitosan NP and 5, 4 and 2 
mg/mL for conjugate NP for 12, 24 and 48h treatments, respectively (Figs. 7-1.1 b & d).  It 
has been reported that, in a healthy adult, lungs have an air surface liquid (ASL) volume of 
3.6 mL (Widdicombe, 2002). Therefore, taking primarily the IC50 values as the maximum 
permissible limits, it can be said that the amounts of nanoparticles to be deposited in the 
lungs should not exceed 21.6, 25.2 and 10.8 mg for chitosan NP and 18, 14.4 and 7.2 mg for 
conjugate NP for 12, 24 and 48h exposures, respectively. So, to achieve a DH blood level of 
0.05 µg/mL and maintain it over a period of 12, 24 and 48h duration, it will be required to 
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prepare nanoparticle formulations containing 35.57, 60.29 and 109.73 mg of DH with an 
amount of chitosan not exceeding 21.6, 25.2 and 10.8 mg or an amount of conjugate not 
exceeding 18, 14.4 and 7.2 mg, respectively. In addition, the release profiles of the prepared 
nanoparticle formulations should be such that 10.85 mg of drug would be released in burst 
and the rest in a controlled manner at a rate of 2.06 mg/h. As discussed in the Section 6.3.4 
of the Chapter 6, with the release profiles demonstrated by the prepared nanoparticles 
formulaitons, a lung deposition of 423.83 and 175.00 mg of DH-loaded chitosan and 
conjugate nanoparticles, respectively, would be required to achieve the desired blood level 
of 0.05 µg/mL, although, once deposited, they could be expected to release the drug at a 
rate close to the required MDR of 2.06 mg/h for a prolonged period of time (8 days for 
chitosan and 16 days for conjugate nanoparticles). These doses of chitosan and conjugate 
nanoparticle formulations are much higher than that could be considered acceptable from 
toxicity point of view as per above discussion. Therefore, further studies are required to 
reduce the dose size and increase the drug loading into the particles. One option in this 
direction could be to add in the nanoparticle formulations an agent like lactose or mmanitol 
either as a bulking agent or partial replacement of some polymer. As discussed in the 
Section 6.3.4 of Chapter 6, this can help in increasing drug loading and release. Additionally, 
they can also play a role in reducing the toxicity by reducing the polymer content in the 
formulation. It would be pertinent to note here that the toxicity level shown by the chitosan 
and conjugate nanoparticles could still be good enough for drugs with small dose sizes (such 
as salbutamol sulphate, morphine etc.).  Another concern here is the cytotoxicity profile of 
the model drug, DH showing an IC50 value of 0.47, 0.43 and 0.37 mg/mL for 12, 24 and 48 h, 
respectively. It has, however, already been noted that incorporation of the drug into the 
particles could potentially reduce its toxicity to a substantial extent (Manca et al., 2008). 
Besides, for a controlled release dosage form, kr (release rate constant) <<< ka (absorption 
rate constant). Thus, in the kinetic scheme of drug delivery from such a dosage form, the 
absorptive phase essentially becomes insignificant compared with the drug release phase 
(Fig. 7-4) (Troy & Beringer, 2006). So, the drug could be expected to be absorbed from the 
lungs into the blood stream as soon as it is released. This transient stay of the drug released 
from the nanoparticles in to the lungs could also be expected to reduce its toxicity on the 
pulmonary epithelium. 
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Figure 7- 4: Kinetic Scheme for Drug Disposition from Immediate Release and Controlled 
Release Dosage Forms  
 
7.3.2 In Vitro Evaluation of the Effect on the Integrity of Respiratory Epithelium by 
Sodium Fluorescein Transport Assay across BEAS-2B Cell Monolayer 
Chitosan, its L-leucine conjugate and their nanoparticles were investigated for their effect 
on the transepithelial permeability across polarized BEAS-2B cell monolayers by Na Flu 
transport assay. Before initiating the actual experiments, a preliminary study was performed 
to determine the time-point by which the cells reach the confluence level under the 
experimental conditions to be employed (Fig. 7-2.1). In addition, the sodium fluorescein 
transport assay was also performed to confirm the development of an effective 
permeability barrier upon polarization of cells    (Fig. 7-2.2).  Based on the MTT assay results, 
4 concentrations, viz. 0.5, 1, 2 and 4 mg/mL were selected for the experiment at which most 
samples showed a cell viability of 50% or above and beyond which there was an abrupt 
decline in % cell survival.  
 
As shown in the Fig. 7-2.3 a and confirmed by statistical analysis, in contradiction to 
previous literature reports on other cell lines (Bonferoni et al., 2008; Florea et al., 2006; 
Vllasaliu et al., 2010), chitosan did not cause any significant change to the permeability of 
BEAS-2B cell monolayer irrespective of concentration and time (p>0.05). This apparent 
contradiction might be related to the cell line difference, but the finding is not unexpected if 
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we consider the experimental pH of 7.4 — at which chitosan has been reported by some 
investigators (Borchard et al., 1996; Kotze et al., 1998a) to be ineffective as a permeability 
enhancer owing to its poor solubility that hinders an intimate contact (molecular 
interaction) between the substance and the cell.  A similar trend was shown by chitosan 
nanoparticles (Fig. 7-2.3 b) except at the highest concentration of 4 mg/mL applied that 
showed a statistically significant reduction in permeability at initial time-points up to a 
period of 6 h (p<0.05). There are contradictory reports in the literature about the effect of 
particulate chitosan on enhancing permeability across monolayers of the pulmonary 
epithelial cell line, calu-3 (Grenha et al., 2007; Sivadas et al., 2008; Vllasaliu et al., 2010). 
While Vllasaliu et al. (2010) reported a significant bronchoepithelial permeation 
enhancement across calu-3 cell monolayer, others (Grenha et al., 2007; Sivadas et al., 2008) 
observed that enhancement in permeability was statistically insignificant. Unlike neat 
chitosan, the L-leucine conjugate caused significant enhancement in permeability (p>0.05) 
up to a concentration of 2 mg/mL, but no difference was seen with further increase in 
concentration (p<0.05) (Fig. 7-2.3 c). A higher concentration of 4 mg/mL again showed a 
deviation from the usual trend demonstrating no significant difference from the control 
(p>0.05).  Considering higher solubility of the conjugate in water, an enhancement in cell 
layer permeability was a reasonable outcome if we compare with the other                        
well-investigated water-soluble chitosan derivative, TMC that has been reported to have a 
strong permeation enhancing effect (Kotze et al., 1997a; Thanou et al., 2000a; van der 
Merwe et al., 2004). In contrast to neat chitosan-L-leucine conjugate, its nanoparticles 
showed a significant reduction in permeability at all concentrations (p<0.05). However, 
there was a concentration-dependent increase in the permeability and, at the highest 
concentration of 4 mg/mL the permeability was very close to that of the control                 
(Fig. 7-2.3 d). The reduction in the permeability does not fit with the reports on the micro-/ 
nanoparticles of the other water-soluble derivative, TMC that have been found to induce 
permeation enhancement similar to neat TMC (Amidi et al., 2008a; Amidi et al., 2008b; 
Chen et al., 2008; Coco et al., 2013; Mi et al., 2008; Sandri et al., 2010; Sandri et al., 2007). 
Further studies are required to understand this apparently deviant behaviour of conjugate 
nanoparticles. To summarise, chitosan and chitosan nanoparticles did not cause much 
difference in the permeability. The conjugate caused a slight, but significant enhancement 
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of the permeability, while the conjugate nanoparticles had the opposite effect. Thus, the 
rank order of the 4 samples in terms of associated transepithelial permeability was: 
conjugate>chitosan=chitosan nanoparticle>conjugate nanoparticles. 
It is evident that, with particulate chitosan and both the neat and particulate conjugate, the 
permeability effect at the concentration of 4 mg/mL deviated from the pattern shown by 
the lower concentrations of 0.5, 1 and 2 mg/mL (Fig. 7-2.3 b, c, d).  This apparent aberration 
could be related to the higher level of cell toxicity observed at such a high concentration (as 
already shown under the MTT assay results in Fig. 7-1.1 a, b, c and d), but further studies 
are required to elucidate the exact cause of this deviation. 
 
7.3.3 In Vitro Evaluation of Inflammatory Effect by Chemokine (IL-8) Release Study 
This experiment attempted to investigate in vitro the inflammatory potential of the novel 
chitosan-L-leucine conjugate synthesized under this project and its nanoparticles on 
pulmonary epithelium in comparison with parent chitosan and its nanoparticles. Release of 
the chemokine interleukin-8 (IL-8) was taken as an indicator of inflammatory response and 
was estimated by enzyme-linked immunosorbent assay (ELISA). As for the Na Flu transport 
assay described in the previous section, a series of concentrations, viz. 0.5, 1, 2 and 4 
mg/mL, of the samples were chosen for the experiments on the basis of MTT assay results.  
 
As shown in the Fig. 7-3, chitosan and its nanoparticles showed a mild, but significant 
induction of IL-8 release; however there was no significant increase in the effect with 
concentration (p>0.05). Statistical analysis also shows that there was no difference between 
the effects of neat and particulate chitosan (p>0.05). Previous studies with chitosan 
microparticles on calu-3 cell line reports contradictory outcomes in relation to IL-8 release.  
While Witschi & Mrsny (1999) reported induction of IL-8 by chitosan microparticles, other 
investigators did not find any significant difference compared to control (Sivadas et al., 
2008). Although the neat conjugate appeared to be less inflammatory than both the neat 
and particulate chitosan, conjugate nanoparticles showed a completely opposite trend. 
While the IL-8 release caused by conjugate nanoparticles at 0.05 mg/mL (917±50 pg/mL) 
was statistically indifferent from that of control (768±76 pg/mL), the IL-8 levels observed for 
1, 2 and 4 mg/mL concentration of the conjugate nanoparticles were 2230±251, 2957±150 
Chapter 7 In Vitro Evaluation of Toxicity and Inflammatory Activity  
  
 
149 
 
and 1959±64 pg/mL respectively, which were in the order of 3-4 times the IL-8 level induced 
by the control (Table A7-3 in Appendix 7-3). This is a concern in consideration of the large 
dose size of the model drug, DH that could zeopradize the pharmaceutical benefits offered 
by the conjugate nanoparticles. Further studies are required to minimize the dose size of 
conjugate nanoparticles required. Replacement of part of the conjugate by a bulking agent 
like lactose or mannitol, as suggested for increasing the drug loading and release in      
chapter 6, might prove beneficial in this context too. However, since there was no 
significant induction of IL-8 at 0.5 mg/mL, the material might still be sufficiently safe for 
potent drugs with small dose sizes (e.g. salbutamol sulphate, morphine).    
 
The tapering down of the effect of both the neat and particulate forms of the conjugate 
beyond 2 mg/mL concentration may be related to the high cytotoxicity and considerable cell 
death taking place at such a high concentration as evidenced by MTT assay. It is possible 
that due to high toxicity exerted by such a high concentration the cells fail to respond 
normally to the treatment applied.  
 
7.4 CONCLUSION 
The biosafety of chitosan, its L-leucine conjugate and their nanoparticles, made by 
emulsification solvent evaporation, have been studied in vitro in terms of cell viability, 
transepithelial permeability and the chemokine, IL-8 release using the bronchial epithelial 
cell line, BEAS-2B as an in vitro model. In accordance with previous literatures on other 
respiratory epithelial cell lines like calu-3 and A-549, chitosan and its nanoparticles showed 
a low toxicity on BEAS-2B cell line. Similarly, the synthesised L-leucine conjugate of chitosan 
also demonstrated a low toxicity. The conjugate nanoparticle appeared to be relatively 
more toxic and inflammatory. However, its IC50 did not fall below 2 mg/mL even at 48 h 
treatment duration. Besides, it did not cause any significant induction of IL-8 on 24 h 
treatment of BEAS-2B cell line at 0.5 mg/mL concentration.  So, it could still be considered 
to have an acceptable level of toxicity, particularly for respiratory delivery of potent, low-
dose drugs (such as salbutamol sulphate or morphine). Further, epithelial cells in vitro can 
be more sensitive to toxicological insult compared to the epithelium in situ. In this context, a 
low level of toxicity demonstrated in vitro by these substances is an encouraging indicator of 
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their safety for respiratory delivery. However, the large dose size of the model drug, DH 
would potentially require a large volume of lung deposition of the nanoparticle formulation 
and so further studies are required to minimize the required dose of the formulation if this 
is to be considered for pulmonary delivery of DH. Replacement of part of the polymer in the 
nanoparticle formulaion with a bulking agent like lactose or mannitol could be a useful ploy 
to be considered in this line.  
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8.1 Summary 
This study revealed new strategies for addressing the issues of controlling drug release and 
enhancing aerosolization — two major concerns of present-day research on DPI 
formulation. Because of many unique advantages of controlled release therapy leading to 
enhanced patient compliance and convenience and better therapeutic outcomes, 
formulation scientists are in constant endeavour of developing DPIs in a controlled release 
form, although no such formulation has yet been launched to the market. Since the natural 
polymer chitosan has many attractive features including low toxicity, biocompatibility, 
biodegradability and mucoadhesiveness, its micro-/ nanoparticles have drawn special 
attention for formulating controlled release DPIs. The poor dispersibility of DPIs stems from 
agglomeration of micronized particles (<5 µm) required for their deposition into the deeper 
regions of respiratory airways.  The commonly used approach to improve dispersion of 
micronized particles from a DPI is mixing with an interactive carrier (e.g. lactose, mannitol) 
that acts to diffuse the cohesive force between like particles. Another popular approach is 
addition of an agent like L-leucine, magnesium stearate or PEG 6000 in the formulation as 
aerosolization enhancer. Besides, many other techniques including addition of fines and 
multifarious engineering of drug or carrier particles have been employed. Of late, addition 
of L-leucine in the formulation as an aerosolization enhancer has been shown to greatly 
reduce particle agglomeration and improve dispersibility of chitosan-based DPI 
formulations. This study demonstrated that chemical conjugation of L-leucine to chitosan 
can also enhance dispersibility of particles from a DPI formulation. Using diltiazem 
hydrochloride — an antihypertensive agent undergoing extensive first-pass metabolism 
following oral administration — as the model drug, this work has further revealed that          
L-leucine conjugated chitosan nanoparticles can offer better controlled release profile 
compared to those prepared from the parent chitosan.  
 
The scientific basis of this work was the hypothesis that L-leucine conjugation to chitosan 
would create an amphiphilic environment around the chitosan backbone resulting in 
reduced inter-particle interaction and so enhanced dispersion of particles. Another 
consideration here was freedom of the pulmonary route from the drawback of hepatic first-
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pass metabolism that potentially could improve bioavailability of a drug like diltiazem 
hydrochloride. Based on these considerations, the first step in course of this work was 
synthesis of a chitosan-L-leucine conjugate. The next step to follow was preparation of 
nanoparticulate formulations of both chitosan and its conjugate and assessment of their 
suitability for lung deposition in terms of particle size, shape and surface characteristics. 
Then, the aerosolization property and drug release profiles of the two formulations were 
studied and compared. Finally, the nanoparticle formulations were also assessed for their 
safety for respiratory delivery. 
 
Forthcoming sections summarize the key findings of this research and their implications. 
This is followed by an account of the potential future research in this connection.  
 
8.1.1 Conjugation of L-leucine with Chitosan 
This study has demonstrated successful synthesis of a chitosan-L-leucine conjugate.  It was a 
new compound with improved aqueous solubility that allowed its prompt dissolution in 
water or PBS without the requirement of any acid as for chitosan. This higher solubility of 
the conjugate is attributable, at least in part, to the amphiphilic environment created by the 
conjugated L-leucine around the chitosan backbone. It is a great finding with potentially far-
reaching impact in view of the poor solubility of chitosan in both aqueous and organic 
solvents that restricted so far its utilization to the potential in pharmaceutical, biomedical 
and other fields. This discovery could be expected to open a new window in the effort of 
scientists for producing soluble derivatives of the polymer for its better exploitation. 
 
The structure of chitosan offers three possibilities for conjugation of L-leucine — at C-2, C-6 
or both. In consideration of the higher reactivity of the ─NH2 group, this study performed, as 
the first approach, selective conjugation at C-2. A protection-deprotection technique was 
employed to ensure regioselectivity. Initially, the C-2 was protected by N-phthaloylation and 
after tritylation at C-6 it was removed by hydrazinalysis. Then, L-leucine was conjugated at 
C-2 by reacting with Boc-L-leucine succinimide where the Boc was another protecting group 
for preventing polymerization of L-leucine. Finally, both trityl and Boc groups were 
deprotected simultaneously by 4M HCl in Dioxane. The intermediates and the final product, 
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Chitosan-N-L-leucine HCl were characterized by a combination of FT-IR, 1H and 13C NMR 
spectroscopy and elemental analysis. As the last two products in the pathway were new to 
the existing literature, they were further characterized by 2D 1H-13C HSQC spectroscopy.  
 
The FTIR spectra showed characteristic absorption for N-phthaloyl-chitosan (phthaloyl C=C 
1703 and 1774 cm-1, phthaloyl aromatic 718 cm-1), N-phthaloyl-6-O-trityl-chtiosan (trityl C=C 
1448 and 1490 cm-1, trityl aromatics 699, 746 and 764 cm-1 in addition to phthaloyl signals), 
6-O-trityl-chitosan-N-Boc-L-leucine (intensified amide-I signal at 1683 cm-1, Boc t-butyl/       
L-leucine isopropyl at 1367 and 1390 cm-1 in addition to trityl signals) and chitosan-N-L-
leucine.HCl (amide-1 1628 and 1672, L-leucine isopropyl 1372 and 1390 cm-1). The IR spectra 
of 6-O-trityl-chitosan confirmed disappearance of the phthaloyl signals (at 1712 and        
1776 cm-1) while still keeping the trityl signals in place. The spectrum of chitosan-                   
N-L-leucine.HCl also showed disappearance of trityl signals (at 702, 747 and 764 cm-1) and  
reduction in the intensity of the doublet at 1372 and 1390 cm-1 giving an indication that the 
Boc group has been removed and the signal arose from L-leucine isopropyl only. 
 
The solubility of N-phthaloyl-chitosan and N-phthaloyl-6-O-trityl-chitosan in common NMR 
solvents was not good enough for getting 1H and 13C NMR spectra in solution and they were 
acetylated to improve their solubility and get NMR spectrum in solution. The 1H and 13CNMR 
spectra of the peracetate derivatives in CDCl3 showed characteristic chemical shifts for the 
phthaloyl and trityl aromatic protons and carbons, respectively, in appropriate regions in 
addition to those of pyranose. The proton NMR spectrum of 6-O-trityl-chitosan in        
pyridine-d5 confirmed the removal of phthaloyl peaks while still retaining the trityl peaks. 
The compound failed to show enough solubility either as such or as peracetate derivative to 
get 13C NMR spectrum in solution. The 1H and 13C NMR spectra of 6-O-trityl-chitosan-Boc-    
N-L-leucine in pyridine-d5 showed characteristic signals at 1.44 and 28.9 ppm for Boc t-butyl 
in addition to the signals for trityl aromatics, pyranose and L-leucine protons and carbons at 
appropriate places, thereby confirming conjugation of Boc-L-leucine to 6-O-trityl-chitosan. 
On the other hand, the 1H and 13C NMR spectra of chitosan-N-L-leucine.HCl in D2O 
confirmed removal of the Boc and trityl peaks while still retaining the pyranose and              
L-leucine proton and carbon signals. As Boc t-butyl and L-leucine isopropyl had IR absorption 
at the same positions, the NMR spectra was important to definitively ascertain the 
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conjugation of L-leucine moiety and ultimate deprotection of the Boc group. The 2D spectra 
of 6-O-trityl-chitosan-N-Boc-L-leucine and chitosan-N-L-leucine.HCl showed clear-cut data 
points correlating the carbon signals to proton signals. The 2D spectrum of 6-O-trityl-
chitosan-N-Boc-L-leucine, however, missed the data points for the anomeric carbon, but the 
presence of corresponding data points in the 2D spectrum of the final product, chitosan-     
N-L-leucine.HCl (the next compound in the pathway) confirmed that their absence from the 
2D spectrum of the former was simply due to lack of enough solubility. Taken together, the 
IR and NMR data conclusively confirmed the identity of the intermediates and the final 
product. 
 
For further confirmation of conjugation of L-leucine to chitosan and having an insight into 
the phenomenon at the surface level, the final product chitosan-L-leucine.HCl was also 
investigated by XPS analysis. The high resolution XPS scan of N showed a reduction in the 
intensity of NNH signal and elevation in the intensity of NN+ and Namide, as was expected from 
conjugation of L-leucine to chitosan in consideration of the chemical structure of chitosan,  
L-leucine and the conjugate. Moreover, high resolution scan of C also showed expected 
elevation in C-C carbon signal, further confirming the conjugation. 
 
The elemental analysis of most intermediates and the final product provided satisfactory 
results allowing calculation of the degrees of substitution and elimination of the substituent 
groups. The DS values for the substitution of phthaloyl, trityl and Boc-L-leucine moieties in 
N-phthaloyl-chitosan, N-phthaloyl-6-O-trityl-chitosan and 6-O-trityl-chitosan-N-Boc-L-leucine 
were determined from the C/N ratios of elemental analysis to be 0.91, 1.06 and 0.74, 
respectively. The degree of elimination of Boc and trityl moieties from 6-O-trityl-chitosan-   
N-Boc-L-leucine to give chitosan-N-L-leucine.HCl was calculated to be 91%. However, the 
C/N ratio from the microanalytical data of 6-O-trityl-chitosan gave a value of 1.13 as the 
degree of elimination of phthaloyl groups from N-phthaloyl-6-O-trityl-chitosan, which was 
higher than the theoretical maximum of 0.91. This deviation was probably due to some 
detritylation taking place at the high temperature condition of ~110 °C at which the reaction 
was conducted. So, based on IR and NMR data, suggesting complete removal of phthaloyl 
groups, the degree of dephthaloylation was taken to be 0.91.  
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The yield of the reaction products were determined on the basis of their calculated degrees 
of substitution to be 94.70% for N-phthaloyl-chitosan, 80% for N-phthaloyl-6-O-trityl-
chitosan, 96% for 6-O-trityl-chitosan, 70% for 6-O-tityl-chitosan-N-Boc-L-Leucine and 66% for 
chitosan-N-L-leucine.HCl. This means that the reactions proceeded with reasonably good 
yields confirming their soundness from quantitative point of view too. 
 
8.1.2 Preparation and Characterization of Chitosan and Conjugate Nanoparticles 
and their Comparison in Terms of Aerosolization and Drug Release 
The study showed successful preparation of chitosan and conjugate nanoparticles with a 
particle size of less than 100 nm that indicated suitability of the particles for deposition into 
deeper regions of lungs. Of the two methods employed for nanoparticle preparation, 
however, the W/O emulsion- solvent evaporation method failed to load the model drug 
diltiazem hydrochloride into the particles, while the other method W/O emulsion- 
glutaraldehyde crosslinking was successful both in generating the particles of desired size 
and loading the drug into them. Although the emulsion- solvent evaporation method failed 
to load the drug, it was still a significant, novel outcome in the sense that it was the first 
report of its kind for generating chitosan nanoparticles by this method using paraffin oil as 
the external phase. The method might be useful for loading other drugs with different 
physicochemical properties. It could also be tried for loading diltiazem hydrochloride or 
other drugs by passive absorption from an aqueous solution. 
 
The study demonstrated superiority of conjugate nanoparticles over those of chitosan in 
terms of drug entrapment/loading, drug dispersion and controlled release. The conjugate 
nanoparticles showed an entrapment efficiency of 46±1%, which was significantly higher 
(p<0.05) than that of chitosan nanoparticles (38±1%). Similarly, the % loading of conjugate 
nanoparticles (20±1%) was significantly higher (p<0.05) than that of chitosan nanoparticles 
(16±1%). This higher entrapment efficiency and drug loading (%) can be taken as a sequel of 
the higher aqueous solubility of the conjugate that allowed better association of the drug 
molecules with the polymer.  
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The drug release studies in PBS (pH 7.3±0.2, 37 °C) showed twice as much higher (52%) and 
more prolonged (16 days) drug release from conjugate nanoparticles compared to that from 
chitosan nanoparticles (23%, 8 days). In both the cases, there was an initial burst release 
(chitosan 16%, conjugate 31%) within the first 30 min followed by a slow, controlled release 
over a prolonged period (chitosan 7%, conjugate 21%). Such a biphasic release can 
conveniently meet the requirements of a controlled release formulation, with the initial 
burst release offering the loading dose (DL) required for a prompt achievement of the 
desired blood level and the subsequent controlled release maintaining this level over time. 
The higher and more prolonged drug release from conjugate nanoparticles is again 
attributable to higher solubility of the conjugate that allowed for quicker hydration of the 
polymeric matrix promoting faster drug dissolution and release. On the other hand, the 
higher drug loading of conjugate nanoparticles, which is also attributed to higher solubility 
of the conjugate, produced a stronger driving force for drug release upon dissolution of the 
drug in the matrix. Kinetic analysis with different models demonstrated that the drug 
release occurred by Fickian diffusion (release exponent, n <0.45) and the release rate can 
best be described by square root of time kinetics (Higuchi model) with a release rate 
constant (kH) of 0.4709 × 10-2 and 1.1159 × 10-2  per hour for chitosan and conjugate 
nanoparticles, respectively. In consideration of the minimum effective concentration, Cd of 
0.05 μg/mL, apparent volume of distribution, Vd of 3.1 L/Kg and first order overall 
elimination rate constant, ke of 0.19/h for DH and assuming 100% absorption from the 
lungs, the required initial loading dose (DL) and the maintenance dose release rate (MDR) of 
DH stand out to be 10.85 mg and 2.06 mg/h, respectively.  It is estimated that, with 16 and 
20% drug loading and 16 and 31% burst release for chitosan and conjugate nanoparticles, 
respectively, a lung deposition of 423 and 175 mg of drug-loaded chitosan and conjugate 
nanoparticles, respectively, would be required to provide an initial DH loading dose of 10.85 
mg. With a release rate constant (kH) of 0.4709 × 10-2  and 1.1159 × 10-2 per hour for 
chitosan and conjugate nanoparticles, respectively, these doses can provide a release rate 
of 1.99 and 1.95 mg per hour, respectively. These values are close to the required 
maintenance dose release rate (MDR) of 2.06 mg/h for DH. This means that, although 
inhalation of such a bulky dose might be inconvenient for the patient, once inhaled the 
plasma concentration would be maintained close to the desired level over time for the 
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length of the estimated controlled release period (8 and 16 days for chitosan and conjugate 
nanoparticles, respectively). Further studies are required, however, to increase the drug 
loading and release so that the dose size could be reduced to a more convenient level. Use 
of bulking agents like lactose or mannitol to replace part of the polymer component might 
help in increasing drug loading and release and in turn minimizing the dose size. The present 
level of drug loading and pattern of drug release can still be useful for more potent drugs 
with small dose sizes (e.g. salbutamol sulphate, morphine). 
 
The aerosolization study of nanoparticle formulations with the in vitro lung model, Twin 
Stage Impinger (TSI) revealed that both the blank and drug-loaded nanoparticles of 
conjugate could produce significantly higher (p<0.05) fine particle fraction (FPF) than 
corresponding chitosan nanoparticles (Blank nanoparticles: chitosan 21±0.7%, conjugate 
24±0.8%; Drug-loaded nanoparticles: chitosan 15±1.5%, conjugate 19±1.01%).  This was an 
important finding that corroborated the hypothesis made in this regard as the background 
of this project. Although these FPF values do not appear to be very great in comparison with 
those available from currently available DPIs, they bear special significance from two 
perspectives: firstly, this finding opened a new window in current efforts for increasing 
dispersion from a DPI and secondly, this level of FPF cannot be expected with conventional 
DPIs containing drug particles without mixing with an interactive carrier like mannitol or 
lactose.     
 
8.1.3 Toxicity and Inflammatory Effect 
In the final part of this research, the polymers were assessed, both in neat and particulate 
forms, for their safety for pulmonary delivery using cytotoxicity, trans-epithelial 
permeability and chemokine release as the indicators of their toxicity and inflammatory 
effect. The bronchial epithelial cell line, BEAS-2B was chosen as the in vitro model in 
consideration of the fact that no study on the toxicity and inflammatory effect of chitosan or 
any of its derivatives has previously been reported for this cell line. Moreover, being a     
non-malignant respiratory epithelial cell line, investigation performed on this cell line was 
expected to complement previous reports on cell lines like calu-3 or A-549 which are 
malignant in nature.   
Chapter 8 Overall Conclusions and Further Directions 
  
 
158 
 
The results of MTT cell viability assay and the assessment of the chemokine, IL-8 induction 
indicated that particulate forms of the polymers were more cytotoxic and inflammatory 
than the neat polymers, where conjugate nanoparticles appeared to be the most cytotoxic 
and inflammatory. However, IC50 value of the conjugate nanoparticles for 48h exposure was 
determined to be 2 mg/mL, which indicted that, although more toxic than other samples, 
they still had a low level of toxicity. On the other hand, IL-8 release caused by conjugate 
nanoparticles were 2230±251 and 2957±150 pg/mL at 1 and 2 mg/mL concentrations which 
were 3 to 4 times higher than the basal level of IL-8 release (768±76 pg/mL) and so raises 
some concern about their safety for respiratory delivery. However, there was no significant 
induction of IL-8 at 0.5 mg/mL concentration. So, the nanoparticles could still be safe 
enough and useful for potent drugs with small dose sizes. For drugs like DH with bulky dose 
sizes, the idea of replacing part of the polymer with a bulking agent like lactose or mannitol 
is worth consideration.  
 
The trans-epithelial permeability study was performed using sodium fluorescein as a fluid 
phase marker. The results indicated that chitosan and its nanoparticles do not cause any 
significant change in the permeability, the conjugate showed mild but significant increase in 
the permeability while the conjugate nanoparticles rather caused a reduction in the 
permeability. 
8.2 Overall Conclusion 
This research showed successful conjugation of L-leucine to chitosan, giving a new 
compound with improved solubility and thus paving a way for better utilization of chitosan. 
The work established a methodology for preparing nanoparticles of both chitosan and its 
conjugate of sizes less than 100 nm indicating their suitability for deposition to the deeper 
regions of the respiratory airways. The conjugate nanoparticles showed higher drug loading, 
better controlled release profile and higher dispersibility suggesting their strong promise as 
a controlled release DPI formulation. However, they appeared to be more toxic and 
inflammatory than chitosan nanoparticles. So, in consideration of the large dose size of the 
model drug diltiazem hydrochloride, further studies are required to increase drug loading, 
release and dispersion from a DPI in order to reduce the required lung deposition of the 
nanoparticle formulation. However, the present level of drug loading, release and toxicity 
could still be fine for the delivery of potent drugs with small dose sizes. 
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8.3 Limitation of this Study 
One limitation of this work was that the conclusions drawn about the safety of the 
nanoparticle formulations for respiratory delivery were based on in vitro studies performed 
only on blank nanoparticles prepared by emulsion- solvent evaporation method. The 
responses could be different upon treating the cells with drug-loaded nanoparticles. 
Besides, the nanoparticles prepared by emulsion- glutaraldehyde technique may also 
behave differently. 
 
Secondly, the inferences drawn on the efficacy and safety of the prepared nanoparticle 
formulations of chitosan and its synthetic conjugate were all based on in vitro experiments. 
In vivo studies are required to prove their potential in a biological system. 
8.4 Future Directions 
The success of this effort to synthesize a chitosan-L-leucine conjugate and the promise 
shown by the derivative in terms of providing controlled release of drug and enhancing 
dispersion from a DPI warrants further studies to be carried out based on this research that 
could be expected to advance and enrich our current understanding and could result in an 
improved performance of the developed formulation. In particular, there is need of         
well-designed efforts for further increasing drug loading, release and aerosolization in order 
to reduce the amount of polymer needed in a given dose. Following are some suggestions in 
this line that might be worthy of endeavour and consideration. 
 
8.4.1 Synthesis of an L-Leucine Conjugate at C-6 of Chitosan or a Bis-Conjugate at 
C-2 and C-6 
This work reported selective conjugation of L-leucine at C-2 of chitosan. Conjugation of         
L-leucine selectively at C-6 or simultaneously both at C-2 and C-6 might come up with 
derivatives having relatively different physicochemical and biological attributes. This may 
open new opportunities to improve the solubility, dispersibility and drug release and toxicity 
profiles and minimize the limitations of the conjugate already synthesized.   
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Proposed below are two schemes (Figs. 8-1 & 8-2), based on this work and related literature 
reports (Li et al., 2003; Satoh et al., 2006), which could be taken as guidelines for performing 
L-leucine conjugation selectively at C-2 or simultaneously both at C-2 and C-6:   
 
8.4.2 Conjugation of Chitosan with other Amino Acids 
In addition to L-leucine, other amino acids have also been investigated by researchers for 
improving dispersion of micronized particles from a DPI with varying degrees of success 
(Chew et al., 2005; Li et al., 2005). In nature, there are more than 100 amino acids, all of 
which have the common structural features comprising amine (-NH2) and carboxylic acid       
(-COOH) functional groups, but they widely vary in the nature of the side chains giving each 
amino acid its own peculiarity in terms of physicochemical properties. Phenylalanine      
(non-polar aromatic side-chain), L-serine (polar uncharged side-chain), L-lysine (positively 
charged side-chain) and L-glutamate (negatively charged side-chain) are a few examples, for 
illustration (Fig. 8-3). It would be an interesting idea to conjugate a range of different types 
of amino acids to chitosan and assess their potential in increasing solubility, dispersibility 
and sustaining drug release from a controlled release DPI formulation.  
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Figure 8- 1: Selective Conjugation of L-Leucine to 6-OH of Chitosan 
 [Ac = ─COCH3, DMF = N,N-Dimethylformamide, NMP = N-methyl-2-pyrrolidone] 
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Figure 8- 2: Simultaneous conjugation of leucine on C-2 and C-6 of chitosan 
 [Ac = ─COCH3, NMP = N-methyl-2-pyrrolidone] 
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Figure 8- 3: A few amino acids with different types of side chains 
 
8.4.3 Loading the Drug into Blank Nanoparticles 
This study attempted to load the drug into the nanoparticles by mixing the drug with the 
polymer in the aqueous phase prior to emulsification. As noted before, the emulsion- 
solvent evaporation technique failed to load the model drug, DH due to precipitation of the 
drug out of the particles into the external phase as needle like crystals at the high 
temperature condition (60 °C) applied for hardening the particles. A number of investigators 
have previously reported loading of other drugs (e.g. hydroxyurea, rifampicin, centchroman, 
Bovine serum albumin (BSA), diphtheria toxoid (DT) and insulin) into chitosan particles by 
passive absorption from aqueous solution (Fig. 8-4) (Gupta & Jabrail, 2006, 2007a, 2007b; 
Jameela et al., 1994b; Ubaidulla et al., 2007). Considering the advantage of avoiding the use 
of a possibly irritant agent like glutaraldehyde offered by the solvent evaporation technique 
and the novelty of making the particles of nanometre size by this technique, the passive 
absorption approach is worth giving a try. Additionally, by applying this approach, the drug 
could be saved from exposure to elevated temperature that could be a source of instability 
for many drugs. Moreover, it also gives freedom of raising the temperature to a higher level 
that may help in more rapid solidification of the particles and may also add to their 
compactness. The possible destabilization of the model drug diltiazem hydrochloride was 
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the consideration behind not raising the temperature above 60 °C in this study. A 
comparative study could also be performed by loading diltiazem hydrochloride by passive 
absorption into blank particles made by glutaraldehyde crosslinking. This approach could 
also be attempted for loading other drugs, especially those susceptible to high temperature 
(such as peptides and proteins), into blank nanoparticles made by either method.  
 
 
 
 
Figure 8- 4: Loading drug into blank chitosan nanoparticles by passive absorption from an 
aqueous solution 
 
8.4.4 Emulsion- Solvent Evaporation Technique for Direct Loading of other Drugs 
Although the model drug (DH) precipitated out of the nanoparticles during the hardening 
phase in the emulsion- solvent evaporation method, the principles of this method might still 
be useful for generating chitosan nanoparticles loaded with other drugs (e.g. salbutamol 
sulphate, morphine etc.). Experiments with different drugs could also be expected to give a 
better understanding of the factors affecting drug loading into the particles by this method. 
 
8.4.5 Aerodynamic Particle Sizing of the Aerosol Plume 
Because of their extremely high surface area and associated surface free energy, it is not 
unusual that nanoparticles would fail to break their agglomerates when they are subjected 
to dispersive forces during aerosolization. Many of these agglomerates are ultimately 
deposited in the upper airways and in turn reduce the fraction of the delivered dose 
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reaching to the lungs. Zetasizer analysis of both the blank and drug-loaded chitosan and 
conjugate nanoparticles showed that the particles underwent agglomeration giving one or 
more additional peaks beyond the original size range (Fig. 6-2 in Chapter 6). The FPF 
obtained for the particles (15-24%) also indicated formation of particle agglomerates. 
Although zetasizer analysis gave a rough estimate of the agglomeration tendency of the 
nanoaparticles, a more conclusive idea of the extent of agglomeration of the particles could 
be obtained by aerodynamic particle sizing of the aerosol plume using instruments like 
Andersen cascade impactor, multi-stage liquid impinger (MSLI), time-of-flight (TOF) aerosol 
analysers or laser diffraction based aerosol spray particle sizer (e.g. Aerotrac or SprayTech). 
    
8.4.6 Mixing of Nanoparticles with Interactive Carrier Particles 
It is a common practice in DPI technology to mix the micronized drug particles with larger 
particles of a carrier substance such as lactose or mannitol to reduce the cohesive attraction 
between the drug particles that in turn reduce the agglomeration tendency of the particles 
and improve their dispersion. In this study, both chitosan and conjugate nanoparticles 
showed a higher dispersion when mixed with the lactose microcarrier (Inhalac® 120) at a 5% 
concentration of nanoparticles (Fig. 6-6.2(C). Mixing of the nanoparticles with large carriers 
at different ratios might come up with an appropriate combination with better lung 
deposition. In addition, other types of carriers including mannitol or sorbitol could also be 
investigated for searching out a better combination. 
 
8.4.7 Incorporation of Lactose, Mannitol or Similar Substances into the 
Nanoparticles as a Component of the Matrix 
In addition to adding lactose or mannitol in form of large interactive carrier particles to 
reduce inter-particle attraction of micronized particles, the literature also reports their 
incorporation into DPI micro-/ nanoparticles as a component of their matrix. Such 
incorporation can help to improve the particle characteristics in a number of ways. First, 
they can serve as a bulking agent and in turn can minimize the amount of total polymer to 
be used. Secondly, their incorporation into the particle matrix has also been shown to help 
increase the rate and extent of drug release from the particles by increasing their 
hydrophilicity (Abd El-Hameed & Kellaway, 1997; Jain et al., 2000; Li et al., 2009). Thirdly, 
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this increased hydrophilicity could be expected to increase in turn the loading of the model 
drug, DH which is a highly water soluble substance. Finally, Incorporation of mannitol into 
particles has also been reported to improve aerosolization of the particles from a DPI (Zhao 
et al., 2008). All these factors can combine together to ultimately reduce the dose size of 
the nanoparticle formulation. This is important in consideration of the toxicity profile of the 
conjugate nanoparticles observed in this study and the large dose size required for 
delivering the model drug, DH. So, it could be a good idea to investigate the impact of 
incorporation of these agents (in different percentages) as a component of the chitosan and 
conjugate nanoparticles on their drug loading, release and aerosolization. 
 
8.4.8 Incorporation of Antiadherents into the Nanoparticles 
Besides interactive carrier particles like lactose or mannitol, another popular approach for 
improving aerosolization of the prepared nanoparticles is incorporation of a small 
percentage of an antiadherent substance, such as L-leucine, PEG 6000 or magnesium 
stearate as a component of the particle formulations (Ely et al., 2007; Learoyd et al., 2009; 
Lim & Wan, 1998). This sort of agents has widely been reported to reduce inter-particle 
interaction and increase aerosolization of micronized particles from a DPI, often by 
depositing on the particle surface and in turn reducing the cohesive force between the 
particles. Therefore, it would make an interesting study to investigate the effect of mixing or 
incorporating these agents on the aerosolization of prepared chitosan and conjugate 
nanoparticles. 
 
8.4.9 Stability Study of the Nanoparticles 
It is important to ensure that the nanoparticle formulations would be able to maintain their 
physicochemical properties such as size and morphology, flowability and dispersibility, drug 
release behaviour during the storage period. It is also important to ensure the 
physicochemical stability of the incorporated drug. Besides, considerations also should be 
given to the fact that the formulations might be exposed to various extreme conditions of 
temperature and humidity during this period. A well designed stability study is therefore 
intended to predict stability of the formulations. Roughly, the formulations could be stored 
for a period of 3 to 6 months at different storage conditions such as room temperature      
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(25 °C), refrigerator (4-8 °C) and accelerated temperature and humidity (40 °C/ 75% RH) and 
samples could be assessed for various characteristics as noted above at intervals (say, 0, 1, 3 
and 6 months). 
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Appendix 5-1 
 
 
Figure A5-1. 1: FT-IR (ATR) Spectrum of N-Phthaloyl-Chitosan 
 
 
Figure A5-1. 2: FT-IR (ATR) Spectrum of N-Phthaloyl-3,6-Di-O-Acetyl-Chitosan 
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Figure A5-1. 3: FT-IR (ATR) Spectrum of N-Phthaloyl-6-O-Trityl-Chitosan 
 
 
Figure A5-1. 4: FT-IR (ATR) Spectrum of N-Phthaloyl-3-O-Acetyl-6-O-Trityl-Chitosan 
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Figure A5-1. 5: FT-IR (ATR) Spectrum of 6-O-Trityl-Chitosan 
 
 
Figure A5-1. 6: FT-IR (ATR) Spectrum of 6-O-Trityl-Chitosan [run with hydrazine hydrate 
solution (40-60%), diluted further with water (1:1)] 
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Figure A5-1. 7: FT-IR (ATR) Spectrum of 6-O-Trityl-Chitosan-N-Boc-L-Leucine 
 
 
Figure A5-1. 8: FT-IR (ATR) Spectrum of Chitosan-N-L-Leucine.HCl 
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Appendix 5-2 
 
 
Figure A5-2. 1: 1H NMR Spectrum of N-Phthaloyl-3,6-Di-O-Acetyl-Chitosan in CDCl3 
 
 
 
Figure A5-2. 2: 1H NMR Spectrum of N-Phthaloyl-3-O-Acetyl-6-O-Trityl-Chitosan in CDCl3 
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Figure A5-2. 3: 1H NMR Spectrum of 6-O-Trityl-Chitosan in Pyridine-d5 
 
 
Figure A5-2. 4: 1H NMR Spectrum of 6-O-Trityl-Chitosan-N-Boc-L-Leucine in Pyridine-d5 
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Figure A5-2. 5: 1H NMR spectrum of Chitosan-N-L-leucine.HCl in D2O 
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Appendix 5-3 
 
 
Figure A5-3. 1: 13C NMR Spectrum of N-Phthaloyl-3,6-Di-O-Acetyl-Chitosan in CDCl3 
 
Figure A5-3. 2: 13C NMR Spectrum of N-Phthaloyl-3-O-Acetyl-6-O-Trityl-Chitosan in CDCl3 
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Figure A5-3. 3: 13C NMR Spectrum of 6-O-Trityl-Chitosan-N-Boc-L-Leucine in Pyridine-d5 
 
 
Figure A5-3. 4: 13C NMR Spectrum of Chitosan-N-L-Leucine.HCl in D2O 
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Appendix 5-4 
 
Figure A5-4. 1: Determination of Degree of Substitution (DS) of N-Phthaloyl-3,6-Di-O-
Acetyl-Chitosan from C/N Ratio Obtained by Elemental Analysis 
 
 
Figure A5-4. 2: Determination of Degree of Trityl Substitution (DS) of N-Phthaloyl-6-O-
Trityl-Chitosan from C/N Ratio Obtained by Elemental Analysis 
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Figure A5-4. 3: Determination of Degree of Dephthaloylation of 6-O-Trityl-Chitosan from 
C/N Ratio Obtained by Elemental Analysis 
 
 
Figure A5-4. 4: Determination of Degree of Substitution of 6-O-Trityl-Chitosan-N-Boc-        
L-Leucine from C/N Ratio Obtained by Elemental Analysis 
 
 
Figure A5-4. 5: Determination of Degree of Trityl and Boc Deprotection in Chitosan-           
N-L-Leucine.HCl from C/N Ratio Obtained by Elemental Analysis 
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Appendix 5-5 
 
 
Figure A5-5. 1: XPS Survey spectra of Chitosan, L-Leucine and Chitosan-N-L-Leucine.HCl 
 
 
 
Figure A5-5. 2: XPS Multiplex spectra of Chitosan, L-Leucine and Chitosan-N-L-Leucine.HCl 
for Oxygen 
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Appendix 6 
 
Table A6- 1: Zetasizer Analysis of Blank and Drug-loaded Chitosan and Conjugate 
Nanoparticles 
Method of 
Preparation Formulations Peaks Size (r.nm) % Intensity Width (r.nm) Z-Average (r.nm) PDI 
Method-1 
Blank Chitosan 
Nanoparticles Peak-1 48.96±1.56 100.00±0.00 7.48±0.41 67.25±2.82 0.58±0.26 
Blank 
Conjugate 
Nanoparticles 
Peak-1 70.28±2.06 100.00±0.00 12.62±0.57 76.61±1.23 0.35±0.08 
Method-2 
Blank Chitosan 
Nanoparticles 
Peak-1 16.46±1.01 17.47±0.69 1.9±0.14 
70.34±3.99 1.00±0.00 
Peak-2 194.37±10.6 82.53±0.69 44.74±2.79 
Blank 
Conjugate 
Nanoparticles 
Peak-1 9.93±0.19 22.27±0.82 1.40±0.07 
21.17±0.52 1.00±0.00 
Peak 2 254.77±9.55 77.73±0.82 65.75±4.6 
Drug-loaded 
Chitosan 
Nanoparticles 
Peak-1 16.03±0.66 23.2±1.92 2.22±0.09 
32.23±1.29 1.00±0.00 
Peak 2 262.77±13.09 76.80±1.92 66.9±3.18 
Drug-loaded 
Conjugate 
Nanoparticles 
Peak-1 0.49±0.01 16.1±0.55 0.11±0.01 
9.26±0.99 1.00±0.00 Peak 2 15.02±0.93 9.83±0.43 3.28±0.38 
Peak 3 248.57±10.67 74.07±0.88 93.68±6.08 
 
Note: Data represent mean ± SE (n=3). The sizes are presented as r.nm (hydrodynamic radius in nm). 
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Table A6- 2:  In Vitro Release of Diltiazem HCl from Chitosan and Conjugate Nanoparticles 
in PBS at 37 °C 
Formulation Chitosan nanoparticle  Conjugate nanoparticle 
Time Points (h) Cumulative % Drug 
Released 
Cumulative % Drug 
Remaining 
Cumulative % Drug 
Released 
Cumulative % Drug 
Remaining 
0.5 16±0.32 84±0.55 31±1.98 69±3.42 
1 17±0.3 83±0.53 32±1.83 68±3.18 
2 17±0.33 83±0.58 33±2.05 67±3.55 
4 18±0.27 82±0.46 33±1.99 67±3.45 
6 18±0.3 82±0.53 34±1.91 66±3.31 
12 18±0.32 82±0.55 36±2.18 64±3.77 
24 19±0.3 81±0.52 38±1.73 62±3 
48 20±0.35 80±0.61 41±1.78 59±3.09 
72 21±0.35 79±0.61 43±1.74 57±3.02 
96 21±0.31 79±0.54 45±1.52 55±2.64 
120 22±0.31 78±0.54 46±1.78 54±3.09 
144 22±0.34 78±0.58 47±1.67 53±2.89 
168 22±0.3 78±0.53 48±1.67 52±2.89 
192 23±0.35 77±0.6 49±1.59 51±2.76 
216 23±0.32 77±0.56 50±1.67 50±2.89 
240 23±0.31 77±0.54 50±1.58 50±2.73 
264 23±0.38 77±0.66 51±1.56 49±2.71 
288 23±0.37 77±0.63 51±1.61 49±2.79 
312 23±0.38 77±0.65 51±1.49 49±2.57 
336 23±0.34 77±0.59 51±1.53 49±2.65 
360 23±0.35 77±0.6 51±1.4 49±2.43 
384 23±0.37 77±0.63 52±1.55 48±2.69 
408 23±0.28 77±0.49 52±1.53 48±2.65 
432 23±0.36 77±0.62 52±1.56 48±2.7 
456 23±0.32 77±0.56 52±1.53 48±2.66 
480 23±0.36 77±0.62 52±1.47 48±2.55 
504 23±0.32 77±0.56 52±1.34 48±2.33 
528 23±0.35 77±0.6 52±1.37 48±2.37 
552 23±0.33 77±0.57 52±1.42 48±2.46 
576 23±0.3 77±0.53 53±1.49 47±2.58 
600 23±0.29 77±0.49 52±1.49 48±2.59 
624 23±0.38 77±0.66 52±1.48 48±2.56 
648 23±0.29 77±0.5 52±1.41 48±2.44 
672 23±0.31 77±0.53 52±1.46 48±2.52 
696 23±0.34 77±0.59 52±1.45 48±2.5 
720 23±0.3 77±0.52 53±1.52 47±2.63 
Note: Data represent mean ± SE (n=3). 
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Table A6- 3: Aerosolization Study of Blank and Drug-Loaded Chitosan and Conjugate 
Nanoparticles Using Twin-Stage Impinger (TSI) 
Method Formulation 
% Deposition 
Recovered 
Dose (RD) 
(%) 
Emitted 
Dose (ED) 
(%) 
Fine 
Particle 
Fraction 
(FPF) Rotahaler 
(R) 
Stage-1 
(S1) 
Stage-2 
(S2) 
Gravimetric analysis 
Blank chitosan 
nanoparticle 
38±0.4 43±1.4 19±1.01 84±1.32 62±0.39 19±1.01 
Blank conjugate 
nanoparticle 
15±0.9 61±0.2 24±0.8 86±0.73 85±0.94 24±0.8 
Drug-loaded chitosan 
nanoparticle 
27±2 58±2 15±1.5 81±1.92 73±1.96 15±1.5 
Drug-loaded conjugate 
nanoparticle 
22±2.5 57±3.2 21±0.7 74±2.52 79±2.52 21±0.7 
Spectrophotometric 
analysis 
Drug-loaded chitosan 
nanoparticle 
28±2.2 56±2.2 16±1.6 81±1.66 72±2.15 16±1.6 
Drug-loaded conjugate 
nanoparticle 
21±2.4 58±3.1 21±0.7 87±2.97 79±2.39 21±0.7 
Note: Data represent mean ± SE (n=3). 
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Appendix 7-1 
 
Table A7-1.1 a: MTT Assay of Chitosan on BEAS-2B Cell Line 
Duration 
% Survival at different concentrations of the treatment (mean ± SE, n=3) 
0.125 mg/mL 0.25 mg/mL 0.375 mg/mL 0.5 mg/mL 1 mg/mL 2 mg/mL 4 mg/mL 8 mg/mL 12 mg/mL 16 mg/mL 
12 hour 99±0.36 94±0.58 96±0.03 91±2.05 93±1.77 88±3.74 85±1.81 85±2.50 82±1.97 83±3.58 
24 hour 99±1.09 94±0.88 85±5.13 84±6.00 78±5.39 81±2.58 70±1.21 77±2.51 71±6.38 66±2.91 
48 hour 97±0.62 85±0.29 84±1.79 82±4.22 84±1.80 84±2.38 70±3.52 68±3.49 64±2.30 53±1.54 
 
 
Table A7-1.1 b: MTT Assay of Chitosan Nanoparticles on BEAS-2B Cell Line 
Duration 
% Survival at different concentrations of the treatment (mean ± SE, n=3) 
0.125 mg/mL 0.25 mg/mL 0.375 mg/mL 0.5 mg/mL 1 mg/mL 2 mg/mL 4 mg/mL 8 mg/mL 12 mg/mL 16 mg/mL 
12 hour 98±8.66 93±1.39 101±6.57 90±9.37 88±10.36 77±6.61 60±2.41 10±6.06 1±3.03 -3±5.01 
24 hour 102±10.55 101±3.38 96±2.87 104±3.86 95±6.63 85±5.08 84±8.80 11±4.50 -4±0.41 -1±0.46 
48 hour 69±2.15 67±4.29 56±7.05 52±6.15 51±3.90 56±1.63 45±2.70 12±3.04 -1±1.29 -2±1.14 
 
 
Table A7-1.1 c: MTT Assay of Chitosan-L-Leucine Conjugate on BEAS-2B Cell Line 
Duration 
% Survival at different concentrations of the treatment (mean ± SE, n=3) 
0.125 mg/mL 0.25 mg/mL 0.375 mg/mL 0.5 mg/mL 1 mg/mL 2 mg/mL 4 mg/mL 8 mg/mL 12 mg/mL 16 mg/mL 
12 hour 82±1.62 79±0.38 78±2.48 83±2.81 78±1.18 77±2.59 59±2.64 32±2.25 5±0.78 6±0.56 
24 hour 69±2.74 73±1.56 72±0.55 69±1.49 69±3.00 60±2.34 36±1.44 7±2.52 3±0.64 5±0.68 
48 hour 80±2.82 72±0.48 73±1.21 69±0.57 64±4.98 54±1.50 23±2.99 5±2.81 2±1.11 2±0.90 
 
Table A7-1.1 d: MTT Assay of Chitosan-L-Leucine Conjugate Nanoparticles on BEAS-2B Cell 
Line 
Duration 
% Survival at different concentrations of the treatment (mean ± SE, n=3) 
0.125 mg/mL 0.25 mg/mL 0.375 mg/mL 0.5 mg/mL 1 mg/mL 2 mg/mL 4 mg/mL 8 mg/mL 12 mg/mL 16 mg/mL 
12 hour 72±3.51 71±2.91 66±4.97 63±4.44 53±7.01 56±4.03 50±4.64 39±1.62 9±0.48 8±0.91 
24 hour 80±5.90 76±2.85 74±0.92 68±1.92 59±2.66 49±1.75 36±0.90 21±0.72 5±0.35 5±0.97 
48 hour 66±1.06 64±3.36 57±3.19 53±0.11 43±3.59 38±2.80 25±2.63 5±1.50 2±0.75 2±0.60 
 
 
Table A7-1. 2: MTT Assay of Diltiazem HCl on BEAS-2B Cell Line 
Duration 
% Survival at different concentrations of the treatment (mean ± SE, n=3) 
0.125 mg/mL 0.25 mg/mL 0.375 mg/mL 0.5 mg/mL 1 mg/mL 2 mg/mL 4 mg/mL 8 mg/mL 12 mg/mL 16 mg/mL 
12 hour 124±17.30 139±9.90 112±3.23 29±2.54 5±0.19 5±0.40 5±0.40 5±0.19 5±0.26 6±0.71 
24 hour 122±3.01 119±5.54 89±2.54 10±0.12 7±0.29 6±0.81 4±0.22 4±0.09 4±0.17 4±0.21 
48 hour 93±3.89 81±0.58 63±2.94 0±1.45 0±1.19 0±1.19 0±1.30 0±1.19 1±1.20 2±1.03 
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Appendix 7-2 
 
Table A7-2. 1: TEER of BEAS-2B Cell Lines Grown on Transwell Inserts at Different Time 
Intervals 
Day 
TEER (ohm-cm2) 
1 2 3 Mean SE 
1 3.74 1.54 3.74 3.01 0.73 
2 4.07 3.52 6.27 4.62 0.84 
3 4.18 6.49 10.56 7.08 1.86 
4 12.65 16.83 10.23 13.24 1.93 
5 8.25 12.54 5.50 8.76 2.05 
6 9.24 8.91 1.87 6.67 2.40 
7 4.40 3.41 3.96 3.92 0.29 
8 3.08 3.63 4.73 3.81 0.49 
9 2.31 1.10 1.87 1.76 0.35 
10 0.66 1.10 2.20 1.32 0.46 
 
Table A7-2. 2: Permeability of Na Flu across a Blank Transwell and a Transwell Containig 
Confluent BEAS-2B Monolayer 
Type of Transwell 
Apparent Permeability Coefficient, Papp ( nm/s) 
1 2 3 Mean SE 
Blank Transwell 711 675 722 703 14 
Transwell containing polarized BEAS-2B 
monolayer 
108 107 115 110 2 
 
Table A7-2.3 a: Effect of Chitosan on Na Flu Transport across the BEAS-2B Monolayer 
Concentration Time interval → 0.5 h 1 h 2 h 4 h 6 h 12 h 24 h 48 h 
0 mg/mL 
Cumulative amount of Na Flu transported (mg)  0.0003±0 0.001±0 0.0016±0 0.0024±0 0.0037±0.0001 0.0053±0.0001 0.006±0 0.0059±0.0002 
Apparent permeability coefficient, Papp (nm/s)  33±2.37 45±2.2 33±0.44 25±0.58 26±1.29 18±0.68 10±0.16 5±0.19 
0.5 mg/mL 
Cumulative amount of Na Flu transported  (mg) 0.0003±0 0.0009±0 0.0016±0.0001 0.0023±0.0001 0.0033±0.0001 0.0054±0.0002 0.0063±0.0001 0.0067±0.0002 
Apparent permeability coefficient, Papp (nm/s)  33±1.9 40±1.68 33±2.22 24±1.32 23±1.16 19±0.73 11±0.33 5±0.19 
Papp,polymer/Papp,control 1.01±0.13 0.9±0.04 1±0.05 0.94±0.06 0.9±0.04 1.02±0.01 1.05±0.02 1.13±0.01 
1 mg/mL 
Cumulative amount of Na Flu transported (mg)  0.0004±0 0.0009±0 0.0015±0 0.0024±0.0001 0.0033±0.0001 0.0055±0.0001 0.0062±0.0002 0.0064±0.0002 
Apparent permeability coefficient, Papp (nm/s)  36±0.62 40±2.64 32±1.3 25±1.47 23±0.96 19±0.58 10±0.46 5±0.17 
Papp,polymer/Papp,control  1.1±0.08 0.89±0.02 0.95±0.05 1±0.03 0.9±0.04 1.04±0.04 1.04±0.03 1.1±0 
2 mg/mL 
Cumulative amount of Na Flu transported (mg) 0.0003±0 0.0009±0 0.0014±0 0.0022±0.0001 0.0032±0 0.0056±0.0001 0.006±0.0002 0.0064±0.0003 
Apparent permeability coefficient, Papp (nm/s) 28±6.54 40±1.33 30±0.6 24±1.36 22±0.49 19±0.64 10±0.36 5±0.26 
Papp,polymer/Papp,control  0.83±0.13 0.89±0.01 0.91±0.01 0.93±0.04 0.87±0.03 1.06±0.02 1.01±0.04 1.09±0.01 
4 mg/mL 
Cumulative amount of Na Flu transported (mg) 0.0003±0 0.0008±0 0.0013±0 0.0023±0 0.003±0.0001 0.0051±0 0.0061±0.0002 0.0066±0.0002 
Apparent permeability coefficient, Papp (nm/s) 27±4.46 36±1.59 28±0.69 24±0.41 21±1.28 17±0.25 10±0.4 5±0.18 
Papp,polymer/Papp,control  0.8±0.1 0.79±0 0.86±0.03 0.96±0.01 0.82±0.02 0.95±0.02 1.02±0.03 1.12±0.04 
Note: The values represent mean of 3 replicates ± SE 
 
Table A7-2.3 b: Effect of Chitosan Nanoparticles on Na Flu Transport across the BEAS-2B 
Monolayer 
Concentration Time interval→ 0.5 h 1 h 2 h 4 h 6 h 12 h 24 h 48 h 
0 mg/mL 
Cumulative amount of Na Flu transported (mg)  0.0057±0.0001 0.0073±0 0.0093±0.0001 0.0107±0 0.0155±0.0004 0.0212±0.0004 0.0255±0.0002 0.0241±0.0005 
Apparent permeability coefficient, Papp (nm/s)  483±13.48 310±3.92 197±3.72 113±0.88 109±3.47 74±1.62 44±0.41 21±0.46 
0 .5 mg/mL 
Cumulative amount of Na Flu transported  (mg) 0.0052±0 0.0072±0.0002 0.0092±0.0002 0.0108±0.0004 0.0159±0.0005 0.0225±0.0004 0.0258±0 0.0253±0.0004 
Apparent permeability coefficient, Papp (nm/s)  442±7.33 303±9.95 193±4.75 114±5.17 111±4.02 79±1.69 45±0 22±0.36 
Papp,polymer/Papp,control 0.91±0.01 0.97±0.03 0.98±0.04 1.01±0.04 1.02±0.02 1.06±0.02 1.01±0 1.05±0.01 
1 mg/mL 
Cumulative amount of Na Flu transported (mg)  0.0042±0.0001 0.0066±0.0003 0.0086±0.0004 0.0104±0.0004 0.0152±0.0005 0.0222±0.0003 0.0258±0 0.0257±0.0001 
Apparent permeability coefficient, Papp (nm/s)  356±10.91 281±14.52 181±8.94 110±4.84 106±3.62 77±1.34 45±0.05 22±0.13 
Papp,polymer/Papp,control  0.73±0.01 0.9±0.05 0.92±0.05 0.97±0.04 0.98±0.02 1.04±0.03 1±0.01 1.06±0.01 
2 mg/mL 
Cumulative amount of Na Flu transported (mg) 0.0034±0 0.0062±0.0002 0.0086±0.0003 0.0101±0.0004 0.0143±0.0006 0.0215±0.0006 0.0258±0 0.0258±0 
Apparent permeability coefficient, Papp (nm/s) 291±7.53 263±8.97 182±8.25 106±4.61 100±4.23 75±2.23 45±0.07 22±0 
Papp,polymer/Papp,control  0.6±0.01 0.84±0.03 0.92±0.03 0.94±0.04 0.92±0.02 1.01±0.04 1.01±0.01 1.07±0.02 
4 mg/mL 
Cumulative amount of Na Flu transported (mg) 0.003±0.0001 0.0055±0.0001 0.0074±0 0.009±0.0001 0.0117±0.0003 0.0205±0.0003 0.0256±0.0002 0.0255±0.0003 
Apparent permeability coefficient, Papp (nm/s) 258±13.97 234±4.81 157±0.75 95±1.14 82±2.11 72±1.2 44±0.4 22±0.29 
Papp,polymer/Papp,control  0.53±0.03 0.75±0.02 0.79±0.01 0.84±0.01 0.75±0.03 0.96±0.03 1±0 1.05±0.01 
Note: The values represent mean of 3 replicates ± SE 
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Table A7-2.3 c: Effect of Chitosan-L-Leucine Conjugate on Na Flu Transport across the 
BEAS-2B Monolayer 
Concentration Time interval→ 0.5 h 1 h 2 h 4 h 6 h 12 h 24 h 48 h 
0 mg/mL 
Cumulative amount of Na Flu transported (mg)  0.0008±0 0.0018±0 0.0024±0.0001 0.004±0 0.005±0.0001 0.0078±0.0001 0.0101±0.0001 0.011±0 
Apparent permeability coefficient, Papp (nm/s)  68±5.04 78±3.62 51±2.81 42±0.91 35±1.16 27±0.45 17±0.22 9±0.08 
0.5 mg/mL 
Cumulative amount of Na Flu transported  (mg) 0.0008±0 0.0019±0 0.0025±0.0001 0.004±0.0002 0.0051±0.0002 0.008±0.0002 0.0103±0.0001 0.011±0.0002 
Apparent permeability coefficient, Papp (nm/s)  74±6.98 81±0.9 54±2.78 42±2.32 35±2.01 28±0.86 18±0.24 9±0.24 
Papp,polymer/Papp,control 1.1±0.1 1.04±0.05 1.07±0.1 1±0.03 1±0.02 1.03±0.01 1.01±0.02 1±0.02 
1 mg/mL 
Cumulative amount of Na Flu transported (mg)  0.0008±0 0.0017±0 0.0023±0 0.004±0.0002 0.0047±0 0.0078±0.0001 0.0103±0.0003 0.011±0.0001 
Apparent permeability coefficient, Papp (nm/s)  71±5.66 74±0.11 50±1.9 42±2.34 33±0.34 27±0.46 18±0.54 9±0.1 
Papp,polymer/Papp,control  1.04±0.04 0.94±0.04 0.99±0.09 1.01±0.05 0.92±0.02 0.99±0.01 1.02±0.01 1±0 
2 mg/mL 
Cumulative amount of Na Flu transported (mg) 0.0008±0 0.0018±0.0001 0.0024±0.0001 0.0039±0 0.0048±0.0002 0.0078±0 0.0101±0.0001 0.0111±0.0001 
Apparent permeability coefficient, Papp (nm/s) 74±3.02 77±4.97 51±2.16 41±0.93 33±1.56 27±0.27 17±0.21 9±0.09 
Papp,polymer/Papp,control  1.1±0.04 0.98±0.01 1.01±0.03 0.97±0.03 0.94±0.01 1±0.02 1±0 1.01±0.01 
4 mg/mL 
Cumulative amount of Na Flu transported (mg) 0.0008±0 0.0019±0 0.0024±0.0001 0.0038±0.0002 0.0045±0.0001 0.0076±0.0002 0.0097±0.0003 0.0113±0.0002 
Apparent permeability coefficient, Papp (nm/s) 69±4.47 81±3.45 52±2.69 41±2.95 32±1.01 26±0.8 17±0.7 9±0.21 
Papp,polymer/Papp,control  1.01±0.03 1.04±0.08 1.03±0.1 0.96±0.04 0.89±0 0.97±0.01 0.96±0.04 1.02±0.02 
Note: The values represent mean of 3 replicates ± SE 
 
Table A7-2.3 d: Effect of Chitosan-L-Leucine Conjugate Nanoparticles on Na Flu Transport 
across the BEAS-2B Monolayer 
Concentration Time interval→ 0.5 h 1 h 2 h 4 h 6 h 12 h 24 h 48 h 
0 mg/mL 
Cumulative amount of Na Flu transported (mg)  0.0013±0 0.0028±0 0.0038±0.0001 0.0043±0 0.0059±0.0002 0.008±0.0001 0.0088±0 0.0088±0 
Apparent permeability coefficient, Papp (nm/s)  110±2.46 118±3.73 80±3.41 45±0.68 42±1.51 28±0.41 15±0.17 7±0.07 
0.5 mg/mL 
Cumulative amount of Na Flu transported  (mg) 0.0001±0 0.0002±0 0.0004±0 0.0005±0 0.0009±0 0.0018±0 0.0023±0 0.0024±0 
Apparent permeability coefficient, Papp (nm/s)  12±0.1 12±0.62 9±0.75 6±0.34 6±0.29 6±0.09 4±0.1 2±0.02 
Papp,polymer/Papp,control 0.11±0 0.1±0 0.12±0.01 0.13±0 0.16±0 0.23±0 0.26±0 0.27±0 
1 mg/mL 
Cumulative amount of Na Flu transported (mg)  0.0003±0 0.0006±0 0.0008±0 0.0011±0 0.0014±0 0.0031±0.0002 0.004±0 0.0041±0.0002 
Apparent permeability coefficient, Papp (nm/s)  26±1.58 27±1.08 18±0.8 12±0.1 10±0.4 11±0.7 7±0.1 3±0.2 
Papp,polymer/Papp,control  0.23±0.01 0.22±0 0.22±0 0.26±0 0.24±0.01 0.39±0.02 0.46±0 0.46±0.02 
2 mg/mL 
Cumulative amount of Na Flu transported (mg) 0.0006±0 0.0013±0 0.0017±0 0.0024±0 0.0036±0.0001 0.0056±0 0.0066±0.0001 0.0069±0.0001 
Apparent permeability coefficient, Papp (nm/s) 58±5.9 57±1.46 37±1.13 25±0.44 25±0.9 19±0.29 11±0.24 6±0.11 
Papp,polymer/Papp,control  0.53±0.06 0.48±0.02 0.46±0.03 0.55±0.01 0.6±0 0.7±0.01 0.75±0.02 0.79±0.01 
4 mg/mL 
Cumulative amount of Na Flu transported (mg) 0.0011±0 0.0025±0.0001 0.0032±0 0.0041±0 0.0048±0.0001 0.0067±0.0001 0.0086±0.0001 0.0089±0 
Apparent permeability coefficient, Papp (nm/s) 99±3.07 107±6.32 68±1.29 43±0.96 33±1.4 23±0.59 15±0.2 7±0.01 
Papp,polymer/Papp,control  0.89±0.02 0.9±0.06 0.84±0.02 0.95±0.03 0.8±0.04 0.84±0.03 0.98±0 1.01±0.01 
Note: The values represent mean of 3 replicates ± SE 
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Appendix 7-3 
 
Table A7-  3: ELISA for IL-8 Released by BEAS-2B Cells upon Treatment with Chitosan, its      
L-Leucine Conjugate and their Nanoparticles 
Concentration of 
Treatment (mg/mL) 
Concentration of IL-8 (pg/mL)  
Chitosan Chitosan nanoparticles Conjugate 
Conjugate 
nanoparticles 
0 557±64 451±96 444±100  
0.5 1105±86 1416±41 789±68 917±50 
1 1262±79 1380±9 861±90 2230±251 
2 1346±140 1136±61 1347±79 2957±150 
4 1518±98 1230±64 1070±54 1959±64 
N.B. The values represent mean of 3 replicates ± SE 
 
 
 
 
